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ABSTRACT OF DISSERTATION

EXPRESSION OF BORDERLINE PERSONALITY DISORDER SYMPTOMS
ACROSS THE OVULATORY CYCLE: A MULTILEVEL INVESTIGATION

Borderline Personality Disorder (BPD) is a disabling condition characterized by chronic
emotion dysregulation and behavioral impulsivity. Prospective studies that test proposed
mechanisms of within-person change in BPD hold the key to improving symptom
predictability and control in this disorder. A small body of evidence suggests that
fluctuations in estradiol such as those occurring naturally at ovulation during the monthly
female reproductive cycle may increase symptoms in women with BPD (DeSoto et al.,
2003). Furthermore, there is preliminary evidence that both self-esteem and feelings of
social rejection are highest at ovulation, when estradiol peaks (Durante and Hill, 2009;
Eisenlohr-Moul et al., under review). Such feelings have been reliably linked to increases
in BPD-related behavior in all individuals (e.g., Twenge et al., 2002). The purpose of this
dissertation was to test a cyclical vulnerability model for women with BPD in which
ovulatory estradiol shifts are associated with reductions in felt social acceptance, which
in turn are associated with increased BPD symptom expression. 40 women, sampled to
achieve a flat distribution of BPD symptoms, completed 28 daily diaries online, as well
as four 1-hour weekly visits to the laboratory to complete longer assessments and provide
saliva samples, which were assayed for estradiol. In addition, participants underwent the
Structured Clinical Interview for the Diagnosis of BPD at the end of the study.
Results of multilevel models revealed the opposite of the predicted effects of withinperson changes in estradiol and their interaction with trait BPD. The data suggest a
pattern in which women high in trait BPD show increases in felt acceptance and
reductions in BPD symptom expression at higher levels of conception probability and
higher-than-usual levels of estradiol. Women low in trait BPD show the opposite pattern
in some cases. Several alternative moderators were tested, and results suggest that some
risk factors for BPD (e.g., Neuroticism, Sexual Abuse) interact with high trait levels of
estradiol to predict greater symptoms. Both average levels of estradiol and monthly
fluctuations in estradiol may have relevance for women with BPD. It is recommended
that future studies utilize clinical samples and additional physiological measures to

	
  

further elucidate the mechanisms through which estradiol exerts clinically-relevant
change.
KEY WORDS: Borderline Personality Disorder, 17-Beta Estradiol, Menstrual Cycle,
Ovulation
Tory Anne Eisenlohr-Moul
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Chapter One: Introduction
Borderline Personality Disorder
Individuals with Borderline Personality Disorder (BPD) suffer from a distinctive
combination of particularly disabling psychological and behavioral symptoms (Skodol et
al., 2002). Extreme emotion dysregulation, harmful impulsive behaviors, identity
disturbance, chronic feelings of emptiness, repeated parasuicidal and suicidal behaviors,
and chaotic interpersonal relationships are all common features of BPD. Roughly 10% of
outpatients and 20% of inpatients meet criteria for BPD, and epidemiological studies
suggest that roughly 6% of the U.S. population will meet criteria for BPD at some point
in their lives (DSM-IV-TR, 2000; Swartz et al., 1990; Widiger & Weissman, 1991; Grant
et al., 2008). Though the disorder is equally prevalent in men and women, more women
than men receive the diagnosis, and BPD is associated with greater distress and
functional impairment in women (Grant et al., 2008).
For many years, BPD was considered untreatable by psychiatrists and
psychologists alike. Historically, individuals with BPD have been perceived by clinicians
as manipulative, hostile, and unable to benefit from treatment due to their erratically
shifting emotions, behavior, and attitudes—especially toward clinicians and therapy.
However, the recent development of cognitive and behavioral interventions such as
Dialectical Behavior Therapy (DBT; Linehan, 1993), which have shown promise in the
treatment of BPD, has led clinical scientists to rethink the assumption that individuals
with BPD either do not wish to change or are unable to change. This has led to an
increased interest in the study of potential mechanisms of treatment-related improvement
among those who suffer from this condition.
1

Though BPD and its response to treatment are better understood today than when
treatments such as DBT were initially developed, the nature and causes of natural day-today variability in BPD symptom expression remain poorly understood, especially on a
physiological level. A clearer understanding of the physiological underpinnings of
emotional, cognitive, and behavioral variability in BPD would be of great use to those
interested in improving and streamlining both psychosocial and physiological treatments
for the disorder. Existing treatments for BPD focus on the development of skills aimed at
understanding, acknowledging, and responding to emotions, thoughts, and physical
sensations in more helpful ways. Such cognitive behavioral treatments are effective for
reducing dysfunctional, harmful behavior patterns; they are also costly and more time
consuming than normal outpatient psychotherapy. A better understanding of the
physiological causes of symptom variability in BPD could aid in the development of
synergistic approaches that utilize both psychosocial and biological treatments. Therefore,
the present project sought to address this gap in the scientific literature by exploring
whether the female monthly reproductive cycle is a reliable source of variability in dayto-day and week-to-week expression of BPD symptoms.
The Reproductive Cycle and BPD Symptoms: Could Hormones Play a Role?
Given the higher rates of diagnosis and diagnosis-related distress and impairment
among women with BPD, it has been suggested that monthly fluctuations in reproductive
hormones associated with the reproductive (or ovulatory) cycle may play a role in
symptom expression. A small literature, reviewed below, specifically examines the links
between estradiol and BPD symptoms. Although progesterone and other hormones may
play important roles in predicting these outcomes, the present project focuses primarily
2

on the association of ovulation and associated changes in estradiol on symptom
expression.
Cyclical and Hormonal Effects on BPD Symptoms. A small body of research
links shifts in estradiol, a steroid reproductive hormone that rises before and falls after
ovulation, to increased expression of BPD symptoms. Across the female lifespan, BPD
symptoms are greatest during adolescence and perimenopause—developmental
transitions characterized by rapid changes in estradiol (Bardenstein & McGlashen, 1988;
Stone, 1992). Additionally, differential prevalence of BPD in men and women has been
identified during these same developmental transitions, suggesting that shifts in estradiol
may be associated with changes in BPD symptom expression (Bardenstein & McGlashen,
1988).
The most convincing evidence for a causal link between estradiol and BPD
symptoms comes from a series of three studies conducted by DeSoto, Geary, Hoard,
Sheldon, and Cooper (2003). In the first study, 226 undergraduate women completed the
Borderline subscale of the Personality Assessment Inventory (PAI-BOR; Morey, 1991)
and reported the number of days since the beginning of their most recent menstrual
period. Individuals assessed on days 5 through 10 of their cycle, when estradiol is rising,
reported higher levels of BPD symptoms. In the second study, 57 women provided four
weekly saliva samples and PAI-BOR assessments. Greater overall variability in estradiol
across the cycle was associated with higher overall PAI-BOR scores. In the third study,
24 women about to begin estrogen-containing hormonal contraceptives and 29 control
participants completed eight weekly PAI-BOR measurements (four measurements prior
to starting birth control and four measurements after starting birth control). Women with

3

above average levels of BPD symptoms prior to starting the pill evidenced a significant
increase in symptoms after starting the pill, whereas BPD symptoms did not change
significantly in women with low pre-existing symptoms or in women not starting the pill.
Additionally, results of a laboratory study of 52 women suggest that even short-term
changes in estradiol occurring during a laboratory session are associated with higher
scores on the PAI-BOR (Evardone, Alexander, & Morey, 2008). Taken together, these
results provide a groundwork of evidence that changes in estradiol at ovulation may have
implications for the expression of BPD symptoms. Furthermore, the finding that shifts in
estradiol may be problematic specifically for women with high trait levels of BPD
symptoms is consistent with recent evidence that women may differ in their emotional
and behavioral responses to hormones across the reproductive cycle (Kiesner, 2011).
Finally, no study has examined the effects of both average levels of estradiol (betweenperson effects on trait BPD symptoms) and fluctuations in estradiol (within-person
effects on state BPD symptoms).
Cyclical Effects on Felt Social Acceptance. Evidence from the social and
evolutionary psychological literature also indicates that ovulation—and, by extension,
fluctuations in estradiol—is associated with decreased self-esteem (Hill & Durante, 2009),
decreased felt acceptance (Eisenlohr-Moul et al., under review), and increased implicit
motivation to affiliate closely with others (Schultheiss, Dargel, & Rohde, 2003). Such
changes may indicate a downward shift in feelings of social acceptance at ovulation
(Leary, Haupt, Strausser, & Chokel, 1998). While such patterns may be benign or even
adaptive in normal women, fluctuations in levels of self-esteem, felt acceptance, and
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motivations to pursue relationships may play a role in within-person changes in BPD
symptoms across the reproductive cycle.
A New Cyclical Vulnerability Theory of BPD in Women
Sociometer theory (Leary et al., 1998) argues that self-esteem serves as an
indicator of social acceptance (i.e., a “sociometer”). Leary (2004) points out that the
“sociometer” can sometimes be miscalibrated; one type of miscalibration occurs when
the sociometer is “set low.” Individuals with a sociometer that is set low tend to perceive
less social acceptance than others are objectively communicating, thereby experiencing
chronically low self-esteem. If, in some women, ovulatory estradiol release leads to
exaggerated reductions in self-esteem (i.e., decreased felt acceptance), this may create
strong monthly patterns of change in attitudes towards oneself and others. This appears to
describe BPD symptoms quite well; individuals with BPD suffer from excessive
variability in attitudes toward themselves (self-esteem; Tolpin, Gunthert, Cohen, &
O’Neill, 2004) and others (Russell, Moskowitz, Zuroff, Sookman, & Paris, 2007) that
may be expected to arise when a sociometer is recalibrated drastically twice each month
(i.e., prior to and after ovulation).
I propose a new cyclical vulnerability theory of within-woman change in BPD
that predicts exaggerated downward shifts in sociometric calibration and increased
symptoms as a function of ovulatory increases in estradiol in women with high trait levels
of BPD symptoms. As stated before, some evidence suggests that feelings of self-esteem
and social acceptance decrease at ovulation in all women (Durante & Hill, 2009;
Eisenlohr-Moul et al., under review). Such feelings of low social acceptance are 1)
inherent in many of the symptoms of BPD and 2) a reliable risk factor for behavioral
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dysregulation of the kind typically seen in BPD (impulsivity and risk-taking: Twenge,
Catanese, & Baumeister, 2002; anger and aggression: Sampson & Laub, 1990; Twenge et
al., 2007; identity disturbance: Richman et al., under review; chronic feelings of
emptiness: Twenge, Catanese, & Baumeister, 2003). Also critically, no study has
simultaneously examined the impact of both trait levels of felt acceptance (e.g., rejection
sensitivity) and within-person changes in felt acceptance on expression of BPD
symptoms. The present study will seek to comprehensively test this full cyclical
vulnerability theory on multiple levels using multiple methods.
FFM Personality Abnormalities: Alternative Moderators of Cyclical Vulnerability
BPD is an extremely heterogeneous disorder; there are 256 ways to meet criteria
for BPD using the DSM-IV-TR diagnostic criteria (Ellis, Abrams, & Abrams, 2008).
Furthermore, BPD symptoms overlap strongly with a wide variety of other psychological
disorders such as anxiety disorders, other personality disorders, mood disorders, and
substance use disorders (Lenzenweger, Lane, Loranger, & Kessler, 2007). In an attempt
to more clearly capture the underlying personality extremity that characterizes BPD and
other personality disorders, recent models of personality disorders posit a dimensional
model of personality disorders based on the Five Factor Model (FFM) of Personality
(Widiger & Mullins-Sweatt, 2009). Of relevance for the present study, individuals with
BPD are characterized by extremely high levels of all aspects of Neuroticism, low levels
of some aspects of Agreeableness and Conscientiousness, and high levels of some aspects
of Openness to Experience. Such traits may be the “active ingredients” in moderating the
effect of cycle variables on BPD symptoms. If “trait” levels of BPD do indeed modulate
the impact of ovulatory estradiol shifts on BPD symptom expression, it would be
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theoretically important to determine which aspect(s) of extreme FFM personality
functioning are responsible for this reactivity to the cycle.
A Special Case of Linehan’s Biosocial Model of BPD: Aspects of Childhood
Maltreatment as Alternative Moderators of Cyclical Vulnerability
Linehan’s biosocial model of BPD (Linehan, 1993) is “a biological theory of
emotion regulation” positing that symptoms of BPD emerge as a result of a complex
interaction between (1) a physiological predisposition toward emotion dysregulation, and
(2) an invalidating childhood environment. The physiological predisposition is
conceptualized as whichever physiological conditions produce a pattern of extreme
emotional reactions, sensitivity to such emotional reactions, and abnormally prolonged
emotional reactions (i.e., slow return to baseline). The cyclical vulnerability model
proposed above assumes that, at least for some women, higher-than-usual estradiol may
temporarily increase one’s physiological predisposition toward emotion dysregulation. In
this way, the cyclical vulnerability model is a kind of special case of the biosocial theory
in which state levels of physiological variables (i.e., fertility, estradiol) are thought to
boost a physiological predisposition to emotion dysregulation, creating a greater
sensitivity to internal and external social rejection cues.
The second part of the biosocial model has to do with childhood environments
that invalidate and devalue the child’s desires and emotions rather than instructing the
child in or modeling useful skills for managing emotions, thoughts, and behavior.
Linehan argues that such invalidating environments teach the child to respond to their
own emotional responses in unhelpful ways (e.g., chronic emotional suppression) that
tend to have the paradoxical effects of further dysregulating emotions and behavior
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among these individuals. In discussing the myriad forms that such invalidating
environments can take, Linehan emphasizes both the subjectivity of the experience of
emotional invalidation and the idea that overt childhood emotional, physical, and sexual
abuse exemplify invalidating environments. It is possible that some aspects of childhood
maltreatment that interact with trait physiological vulnerability to emotion dysregulation
could also act as potent moderators of the transient ovulatory changes in physiologicallybased emotional vulnerability hypothesized here. In the present study, therefore, if “trait”
levels of BPD do indeed modulate responses to estradiol and other ovulatory processes, I
will explore the possibility that various aspects of childhood maltreatment serve as a
central predisposing factors that interact with ovulatory physiological changes to
produce changes in BPD symptoms.
Alternative Mechanisms of Cycle-Related Change in BPD Symptoms
The cyclical vulnerability theory presented here predicts that ovulatory effects on
the emotional and behavioral symptoms of BPD across the cycle occur due to decreases
in felt acceptance. More proximally, however, these changes may also be due to
ovulatory changes in various aspects of impulsivity or global self-control. In the context
of this theory, it may be helpful to determine whether cycle-related changes in BPD
symptoms are also mediated by ovulatory effects on one of these interrelated variables
with relevance for BPD: global self-regulatory ability, emotion-related urges, problems
with thinking ahead (or premeditation), problems persisting in the face of difficulty, or
desire to seek out new, potentially dangerous sensations. Therefore, in addition to testing
felt acceptance as the primary mediator in the cyclical vulnerability model, I will also
test these more proximal mediators of cyclical effects on BPD symptoms.
8

Global Self-Control as an Alternative Mediator
Self-control refers to the application of executive cognitive functions in the
service of long-term goals. Although some evidence suggests that self-control and the
executive functions that underlie self-control may be heterogeneous (Duckworth & Kern,
2011), questionnaires measuring a unitary construct of self-control perform quite well in
predicting a wide variety of BPD-related distress and functional outcomes (de Ridder,
Lensvelt-Mulders, Finkenauer, Stok, & Baumeister, 2012). Therefore, the present study
operationalizes self-control as successful application of executive functions that produce
adaptive behavioral responses consistent with long-term goals in a wide variety of
situations (Tangney, Baumeister, and Boone, 2004). This will also be the first study to
simultaneously examine both between-person and within-person effects of global selfcontrol on the expression of BPD symptoms.
Aspects of Impulsivity as Alternative Mediators
The UPPS-P model of impulsivity describes five aspects of impulsivity
(Whiteside and Lynam, 2001): Negative Urgency, or the tendency to experience
increased urges and to engage in related rash action under conditions of negative
emotion; Positive Urgency, or the tendency to experience increased urges and to engage
in related rash action under conditions of positive emotion; Lack of Premeditation, or the
tendency to fail to think over the consequences of an action before engaging in that
action; Lack of Perseverance, or difficulty persisting on tasks that may be difficult or
boring; and Sensation Seeking, or the tendency to seek out and be open to engaging in
stimulating, novel experiences that may or may not be dangerous. Previous evidence
links trait levels of BPD symptoms as measured using the Personality Assessment
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Inventory Borderline subscale (PAI-BOR; Morey, 1991) to higher trait levels of Negative
Urgency, Positive Urgency, and Lack of Premeditation (Tragesser & Robinson, 2009).
However, as with self-control, no study has examined the potentially unique roles of
between-person differences and within-person changes in the UPPS-P facets on BPD
symptoms.
The Present Study: Aims and Hypotheses
Since the establishment of tentative links between ovulatory estradiol shifts and
BPD symptoms a decade ago (DeSoto et al, 2003), little or no work has examined the
psychological mechanisms through which estradiol influences BPD symptoms.
Prospective studies that test proposed mechanisms of within-person change in BPD hold
the key to improving symptom predictability and control in this disorder. The present
study aimed to test a proposed cyclical vulnerability model of BPD: women, and
especially those with higher trait levels of BPD, respond to ovulatory estradiol shifts with
exaggerated downward shifts in the calibration of the sociometer (decreased feelings of
acceptance), which in turn leads to increases in BPD symptom expression. The present
study tested this model using a 2-pronged repeated measures design.
It was hypothesized that;
1. In all participants, ovulation (as measured by both deviations in estradiol at the
weekly level and conception probability at the daily level) would be associated with
greater expression of BPD symptoms as measured by daily and weekly measures of BPD
symptoms.
2. Trait levels of BPD symptoms (as measured by the average of weekly scores on
a measure of BPD symptoms and number of SCID-II items endorsed in a diagnostic
10

interview) would moderate the effect of ovulation (as measured using weekly deviations
in estradiol and daily conception probability) on expression of BPD symptoms. If these
results are significant, further models will replace the Trait BPD variable with each of the
five domains of the FFM and with aspects of childhood maltreatment in order to elucidate
the underlying factor(s) conferring risk for ovulatory changes in BPD.
3. All significant effects of both deviations in estradiol and conception probability
on symptoms of BPD would be mediated by decreases in felt acceptance at the same
measurement level. Specifically, on days or weeks when estradiol or conception
probability is high, felt social acceptance will be low and will mediate the association
between estradiol deviations or conception probability and symptoms of BPD. Decreased
feelings of social acceptance were also expected to mediate the interactive effect of
estradiol and trait BPD on daily BPD symptoms.
Further, weekly changes in aspects of impulsivity and self-control were expected
to mediate the association between weekly estradiol deviations and increased BPD
symptoms, and also to mediate the interactive effect of estradiol deviations and trait BPD
on weekly symptoms.
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Chapter Two: Method
Overview and Study Design
The present study consisted of a two-pronged repeated measures approach to
understanding within-woman change in BPD across the reproductive cycle. 40 women,
sampled to achieve a flat distribution of trait BPD scores, were invited and incentivized
to provide up to 28 days of online daily dairy reports of ovulatory cycle status, felt
acceptance, and BPD symptoms. Self-harm and suicidality items were omitted from daily
diary assessments in order to reduce the risk of participant distress. In addition, they
attended 4 weekly laboratory sessions at which they completed more comprehensive
repeated assessments of felt acceptance, BPD symptoms, impulsivity, and self-control.
During a fifth and final visit, participants underwent a structured clinical interview for
diagnosis of BPD and completed trait measures of FFM personality traits and aspects of
childhood maltreatment.
Participants
Participants were 40 naturally-cycling undergraduate women between the ages of
18 and 30 who were fulfilling research participation requirements for an introductory
undergraduate psychology course. Participants were recruited so as to achieve a “flat”
distribution; 10 participants had low average PAI-BOR scores (T<50), 10 had high
average scores (50<T<60), 10 had above average scores (60<T<70), and 10 will have
high scores (T>70). Participants were not allowed to participate if they reported 1)
currently using hormonal birth control, 2) currently using any “as needed” psychiatric
medication (e.g., benzodiazepines), 3) not speaking English fluently, 3) having
reproductive cycles typically lasting fewer than 25 days or greater than 35 days, or 4)
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having a history of psychosis other than brief periods of dissociation. Final demographic
characteristics of the sample can be found in Table 1.
Procedure
Screening and Recruitment
Initial screening was completed in introductory psychology classes. During a
department-wide screening session, women completed the PAI-BOR and a measure of
inclusion criteria. 10 eligible women were recruited via telephone from each of the four
symptom ranges. Interested participants were asked to schedule 4 repeating weekly
timeslots at the same day and time each week.
Because individuals with high levels of trait BPD symptoms were expected to
have greater-than-average difficulty complying with laboratory attendance expectations
and daily diary protocols, monetary incentives were offered to increase the rate of daily
diary and weekly session compliance. In addition to course credit for the completion of
laboratory visits, individuals were paid $25 if they completed at least 75% of the 28 daily
diaries. In addition, in order to improve retention, weekly laboratory visits lasted only 50
minutes, and daily diaries were pre-tested to ensure that the average time to complete the
diaries was roughly 5 minutes.
Weekly Laboratory Protocol
Participants came to the lab once a week for 5 weeks at the same day and time (4
assessments and 1 interview/debriefing session). Reminder emails were sent two days in
advance of each session, reminding the participant of the location, date, and time of their
next session as well as requesting that participants refrain from chewing gum, drinking
caffeine or alcohol, or taking nonprescription medications for 12 hours prior to sessions
13

Table 1
Demographic Sample Characteristics (N = 40)
Variable
Age
Body Mass Index (BMI)
Race
Caucasian
African American
Hispanic
Asian American
Other
Religion
Christian - Protestant
Christian - Catholic
Islam
Judaism
Other
None/Atheist/Agnostic
Note. SD = standard deviation.

Mean
18.66
23.20

SD
1.38
3.62

%

73.2
9.8
9.8
14.6
2.4
39
34.1
2.4
2.4
2.4
19.7
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on visit days (instructions related to saliva sample; see Estradiol section below). Nearly
all missed sessions were rescheduled and completed within 3 days of the missed
appointments; in the few cases where this was not possible (n = 6 sessions), the
participant returned to the lab for the next scheduled session and added an additional
week to their participation to compensate for the missed session.
Upon arrival in the laboratory for weekly sessions, the participant was met by
either the principal investigator or an undergraduate research assistant and taken to a
private room. At the first session, participants completed an informed consent form, were
reminded of the exclusion criteria, and were oriented to the online diary system. Next, at
each session, participants were reminded of the free mental health services available to
them as students at the university and reminded that they could always call emergency
services if they felt that they were not safe due to parasuicidal or suicidal symptoms.
Participants were then asked to turn off their cell phones. Next, they were instructed in
the provision of the saliva sample and entered information about any relevant control
information into the computer (e.g., use of caffeine, medication, etc.). After that,
participants were given 8 minutes to provide the saliva sample. Finally, after the
experimenter assured the individual that all answers were confidential, participants
completed all weekly measures on a computer in a randomized order. At the fifth session,
the principal investigator administered the SCID-II for BPD diagnosis and debriefed the
participant. Following the fifth session, participants were sent a check in the mail for $25
if they had completed at least 75% of the online diaries that they received.
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Follow-Up Risk Assessment Protocol
Weekly measurements included self-harm and suicidality items. Responses to
these items were screened daily by the principal investigator, and follow-up telephone
risk assessments were conducted where endorsement level indicated significant risk of
harm to the participant. Follow-up telephone risk assessments consisted of a call to the
participant in which the principal investigator briefly screened the participant for current
risk of life-threatening self-harm or suicidal behavior (n = 23). In each case, risk
assessments were carried out to ensure that the participant was not actively suicidal.
Though in some cases participants endorsed suicidal planning (n = 3), no participants
endorsed current intent to engage in self-injury or suicidal behavior. Each call consisted
of a brief screening followed by encouraging the client to (1) seek out the free mental
health care available to them as students at the university, and (2) go to the local
emergency room if necessary. Though some participants reported thoughts about suicidal
planning (n = 6; e.g., “I think about the fact that if I cut myself in the right way, I could
die), no participants reported current suicidal intent (e.g., “I think about how I could do it,
but I never would and I have no intent to die”). Therefore, these telephone risk
assessments did not result in any emergency hospitalization of clients. No clients reported
seeking out psychological or psychiatric services during the study; however, several
participants noted their intention to do so after completion of the study.
Daily Diary Protocol
As described above, participants were oriented to the online diary system during
the first laboratory session. They provided their email address, which was then added to
the mailing list to receive the daily diaries for 28 days. Participants received a daily

16

email with a link to the URL for that day’s online diary for the completion of deidentified daily assessments. During the first session, participants were instructed to fill
out the daily diary between 5pm-2am, and that diaries completed outside of this time
frame would not be accepted.
Weekly Measures
Items administered repeatedly at each of the four weekly sessions are discussed
below. Means, standard deviations, and aggregated internal consistencies for estradiol
and measures of BPD are discussed and compared in the descriptive analysis section of
the Results. Means, standard deviations, and aggregated internal consistencies for weekly
mediators are presented in the text below.
17β-Estradiol
Participants were instructed to salivate by passive drool into a polypropylene vial
(Salimetrics; State College, PA). During each session, participants recorded use of the
following in the past 24 hours: nicotine, caffeine, over-the-counter drugs, prescription
drugs, and illicit drugs. No participants reported prescription or illicit drug use. At some
assessment points, participants reported having smoked cigarettes (13 assessment points),
having more than 1 caffeinated beverage (2 assessment points), or having used over-thecounter drugs (7 assessment points) in the past 12 hours.1 Participants passively drooled
into a prolyprolyene vial through a straw until 1.8 mL of saliva had been collected.
Samples were immediately frozen at -20° C in a locked room. Later, they were
	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  
1
All hypotheses concerning estradiol were originally tested controlling for the use of
these substances; however, use of these substances did not significantly impact estradiol
or any outcome, and inclusion of these controls in models did not change model
outcomes in any substantive way. Therefore, they were not included in models presented
in the results section.
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transferred to the University of Kentucky General Clinical Research Center for 17ßEstradiol assay using ELISA kits (Salimetrics). Intra-assay coefficient of variation for
estradiol was 1.6%; inter-assay coefficient of variation was 2.2%. The standard curves
were of expected shape and slope for 17ß-Estradiol.
Weekly BPD Symptoms
Personality Assessment Inventory - Borderline Subscale (PAI-BOR; Morey, 1991).
The PAI-BOR is a 24-item measure of BPD symptoms, including 4 subscales measuring
affective instability (example item: “my mood could shift quite suddenly”), identity
problems (example item: “my attitude about myself changed a lot”), negative
relationships (example item: “my relationships have been stormy”), and self-harm
(example item: “I was a reckless person). Notably, the self-harm subscale actually
measures tendency toward impulsive behaviors rather than physical self-harm. The PAIBOR is the most well-studied measure of borderline personality disorder symptoms, and
has been used widely in both research and clinical settings to predict BPD diagnosis
(Morey, 1991; Stein, Pinsker-Aspen, & Hilsenroth, 2007). Participants were asked to rate
the extent to which each statement described them in the past week on a scale from 0
(False, Not True at All) to 4 (Very True).
Borderline Symptom List - 23 (BSL-23; Bohus et al., 2007). The BSL-23 is a 23item shortened version of a 95-item measure of BPD symptoms based on the SCID-II
DSM-IV diagnosis of BPD. In the initial validation sample, scores on the full and
shortened versions of the BSL were significantly greater among individuals with a SCIDII diagnosis of BPD than among those with Axis I diagnosis (e.g., mood or anxiety
disorders) and among healthy controls. In another validation sample of individuals with a
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diagnosis of BPD, scores the BSL reduced significantly in response to Dialectical
Behavior Therapy; this evidence that BSL scores change with treatment makes it a
particularly appropriate measure of change for the present study. Example items include
“I felt helpless”, “my mood rapidly cycled in terms of anxiety, anger, and depression”, “I
was afraid of losing control”, and “I didn’t believe in my right to live.” Participants were
asked to rate the extent to which each statement described them in the past week on a
scale from 0 (Not at all) to 4 (Very much). A simple comparison of the face validity of
the items on this scale to items on the PAI-BOR led to the conclusion that the items on
this scale may be more appropriate for measuring the upper, more extreme range of BPD
symptoms. Distributions of the two scales confirmed this; scores on the BSL-23
appeared more positively skewed than scores on the PAI-BOR, suggesting that the BSL23 may be capturing rarer, more extreme symptoms of BPD. In further support of this
hypothesis, the correlations of number of SCID-II criteria met in the present study with
the PAI-BOR and the BSL-23 revealed a significantly stronger correlation of SCID-II
number of criteria with the BSL-23 than with the PAI-BOR or the MSI-BPD (see
descriptive section of the Results).
McLean Screening Instrument for BPD (MSI-BPD; Zanarini et al., 2003). The
MSI-BPD uses 10 dichotomous (yes or no) items to measure the nine DSM-IV BPD
criteria. Example items include, “Have you been distrustful of other people?”, “Have you
been extremely moody?”, and “Have you deliberately hurt yourself physically (e.g.,
punched yourself, cut yourself, burned yourself)? How about made a suicide attempt?” In
several studies, scores on the MSI-BPD were positively associated with other measures
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of BPD symptoms (Gardner & Qualter, 2009), and predicted actual SCID-II diagnosis of
BPD (Zanarini et al., 2003).
Weekly Feelings of Social Acceptance
Weekly feelings of social acceptance were measured using the Social Evaluation
scale of the State Self-Esteem Scale (SSES; Heatherton & Polivy, 1991). The Social
Evaluation subscale uses 7 items to measure the degree to which an individual feels that
they a valued highly by the members of their social group. Social stress tasks and social
shame inductions reliably produce temporary reductions in scores on this subscale of the
SSES, suggesting that it taps into relatively temporary levels of felt acceptance
(Gruenewald, Kemeny, Aziz, & Fahey, 2004). Example items include, “I feel inferior to
others at this moment” (reverse scored) and “I feel that others respect and admire me.”
Participants rated the extent to which they felt each item described their thoughts in the
past week on a scale from 1 (Not at all) to 5 (Extremely). In the present study, individuals’
average scores on this scale functioned adequately with a mean of 5.37, a standard
deviation of .88, and an internal consistency of α = .87.
Weekly Self-Control
Self-control was measured using the Brief Self-Control Scale (BSCS; Tangney,
Baumeister, & Boone, 2004). The BSCS is a 13-item questionnaire designed to measure
one’s trait capacity for self-control. Example items include, “I am good at resisting
temptation”, “I am lazy” (reverse-scored), and “People would say that I have iron selfdiscipline.” Participants were asked to rate the extent to which each item had been true of
them in the past week on a scale from 1 (“Not at All”) to 5 (“Very Much). Higher scores
on the self-control scale are associated with higher grade point average and positive
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psychological adjustment (Tagney, Baumeister, & Boone, 2004). In the present study,
individuals’ average scores on the SCS functioned adequately, with a mean of 3.42, a
standard deviation of .05, and an internal consistency of α = .87.
Weekly Impulsivity
Weekly impulsivity was measured using the UPPS-P Impulsivity Scale
(Whiteside and Lynam, 2001). The UPPS-P impulsivity scale measures five distinct
pathways to impulsive behavior: negative urgency, or the tendency to act rashly in the
face of negative emotion, positive urgency, or the tendency to act rashly in the presence
of positive emotion, lack of perseverance, or the lack of ability to persist in the face of
boredom, lack of premeditation, or the tendency not to think through actions, and
sensation seeking, or the tendency to engage in novel, high-sensation behaviors. Example
items include, “This week, it was hard for me to resist acting on my feelings” (Negative
Urgency), “This week when I was happy, I tended to do things that could cause problems
in my life” (Positive Urgency), “This week, my thinking was careful and purposeful”
(Lack of Premeditation), “This week, I finished what I started” (Lack of Perseverance,
and “This week, I sought out new experiences and sensations” (Sensation Seeking).
Participants were asked to rate the extent to which each item had been true for them in
the past week on a scale from 1 (Not at All) to 4 (Very much). In a variety of studies,
facets of the UPPS-P have predicted a variety of impulsivity-related outcomes such as
substance use and abuse (Verdejo-Garcia, Bechara, Recknor, & Perez-Garcia, 2007),
problem gambling (Cyders & Smith, 2008), eating disorder symptoms (Fischer,
Anderson, & Smith, 2004), and aggression (Derefinko, DeWall, Metze, Walsh, & Lynam,
2011). In the present study, individuals’ average scores on the UPPS-P functioned
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adequately, including Negative Urgency (Mean: 3.30, SD: .05, α = .83), Positive Urgency
(Mean: 3.15, SD: .04, α = .73), Lack of Premeditation (Mean: 3.15, SD: .06, α = .85),
Lack of Perseverance (Mean: 3.13, SD: .05, α = .84), and Sensation Seeking (Mean: 2.76,
SD: .06, α = .78).
Daily Measures
Conception Probability
Daily, participants reported the start date of their most recent menstrual period.
This allowed for the calculation of cycle day and associated conception probabilities
(Wilcox et al., 2001) for estimating fertility/ovulation.
Daily BPD Symptoms
Daily symptoms of BPD were measured using a modified version of the
Personality Assessment Inventory - Borderline Subscale (see weekly measures above;
PAI-BOR; Morey, 1991) in which the one item referencing physical self-harm (“When I
was upset, I typically did something to hurt myself”) was omitted. This item was omitted
to reduce the risk of daily priming and distress. Participants were asked to rate the extent
to which each statement described them in the past 24 hours on a scale from 0 (False, not
true at all) to 4 (Very true). Descriptive statistics and internal consistencies on the PAIBOR at the daily level were as follows: Affective Instability (Mean: .59, SD: .02, α = .84),
Identity Instability (Mean: .65, SD: .02, α = .70), Negative Relationships (Mean: .73,
SD: .02, α = .74), and Self-Harm (Mean: .38, SD: .01, α = .73).
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Daily Felt Acceptance
Daily levels of felt acceptance were measured using a scale created for this study.
Participants were asked to rate the following items indicating the extent to which she had
experienced each item in the past 24 hours: “Accepted”, “Included”, “Rejected”,
“Excluded”, “Lonely”, and “Abandoned” (last four items reverse-scored). Response
options ranged from 1 (“Very Slightly or Not at All”) to 5 (“Extremely”). Descriptive
statistics and internal consistency for the average of daily felt acceptance are as follows:
Mean = 4.05, SD = 1.10, α = .91. In addition, person averages of this composite variable
were negatively associated with person averages of weekly measures of Social
Evaluation subscale of the State Self-Esteem Scale (r = .84, p < .0001).
Between-Person Measures
Five Factor Model (FFM) Personality
The Five Factor Model Rating Form (FFMRF) is a 30-item instrument that asks
participants to rate themselves on the 30 facets of the Five Factor Model of personality
(FFM; Mullins-Sweatt, Jamerson, Samuel, Olson, & Widiger, 2006). Each item is rated
on a scale from 1 (“Extremely Low”) and 5 (“Extremely High”). Individual facets were
combined to construct the FFM domains: Neuroticism, Extraversion, Openness to
Experience, Agreeableness, and Conscientiousness. This short measure of the five factor
model of personality has been validated for use in student samples, and correlates well
with longer measures of FFM personality such as the NEO-PI-R (Costa & McCrae, 1992;
Mullins-Sweatt et al., 2006).
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Childhood Maltreatment
The Childhood Trauma Questionnaire (CTQ) is a 28-item retrospective measure
of various types of maltreatment in childhood, and includes subscales measuring
Emotional Abuse (example item: “Someone in my family yelled and screamed at me”,
Emotional Neglect “I felt like there was someone in my family who wanted me to be a
success”—reverse-scored), Physical Abuse (“Someone in my family hit me so hard that it
left me with bruises or marks”), Physical Neglect (“I had to wear dirty clothes”), and
Sexual Abuse (“Someone threatened to hurt me or tell lies about me unless I did
something sexual with them”) (Bernstein et al., 2003). Each item begins with the phrase,
“When I was growing up,” and is rated on a scale from 1 (“Never True”) to 5 (“Rarely
True”). The CTQ also includes a 3-item validity scale designed to detect underreporting
of maltreatment; subscale scores from individuals scoring above the cutoff on this
validity scale are invalid and not included in analyses (n = 0 in the present study). In
diverse samples, the CTQ correlates well with therapist and peer reports of an
individual’s childhood maltreatment, as well as independent evidence of childhood
maltreatment in the domain specified (Bernstein et al., 2003).
DSM-IV Diagnosis of BPD
The BPD module of the Structured Clinical Interview for Diagnosis—II (SCID-II;
First, 1997) was administered to determine diagnostic status and the number of DSM-IV
BPD criteria met. During the final session, the principal investigator (n = 30) and another
master’s level clinician with experience completing the SCID-II (n = 10) led each
participant through the BPD module of the SCID-II. After completion of the study,
transcripts of participant responses to interview prompts were independently scored
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(without knowledge of the original clinician’s ratings) by the clinician who did not
complete the interview. Agreement was perfect for all items.
Data Analytic Plan
Power Analysis
The current study is powered on the results of the post-hoc moderation analyses
from a preliminary study (Eisenlohr-Moul et al., under review). Power was estimated by
(1) using formulae provided by Snijders and Bosker (1999) to determine design effects
due to the intraclass correlation (ICC) and the resulting effective N, and (2) calculating
smallest detectable effect size based upon the effective N, 80% power, and an alpha level
of .05. Results indicated that the current study would have 80% power to detect small
effects (r = .10) with 711 lower-level units, yielding an effective N of 515 after
accounting for average ICCs for daily felt acceptance and BPD-related outcomes found in
the original study. In order to obtain an effective N of this size in the current study, I
would need only 25 women (i.e., 25 multiplied by 28 is equal to 728 daily measurements).
However, in order to allow for missed diaries and to ensure that the sample size will be
large enough to detect week-level effects, data will be collected from 40 women (i.e., 40
multiplied by 4 weekly visits is equal to 160 weekly measurements; effective N estimated
to be 115). This results in 80% power to detect medium (r = .25) effects of estradiol at
the weekly level, and small effects (r = .12) of conception probability (ovulation) at the
daily level.
Multilevel Models
Data were analyzed using multilevel models in SAS PROC MIXED and SAS
PROC GLIMMIX with daily diaries or laboratory visits at Level 1 and people at Level 2.
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Multilevel models utilize all available data with no listwise deletion. In daily and weekly
models, level 1 predictors were centered to isolate the within-person component. For
example, each person at each laboratory visit had two estradiol variables: (1) the person’s
mean levels of estradiol across all visits (the same across all visits within an individual), and
(2) the person’s deviation from their own mean score at the current laboratory visit. The latter
deviation reflects fluctuations in estradiol relative to the person’s own mean level and was
the relevant, visit-level predictor. Prior to conducting analyses, all variables were screened
for distributional normality; in most cases, the distribution was positively skewed to such an
extent that linear transformations were not successful in approximating normality. Given the
relatively low base rate of BPD in the general population, such distributional characteristics
are unsurprising. Preliminary inspection of the properties of these distributions suggested that
most followed a Poisson or zero-inflated Poisson distribution. Furthermore, comparisons of
the model fit for various alternative multilevel models (zero-inflated Poisson, negative
binomial, and Poisson) suggested that a Poisson distribution resulted in the best fit. In these
cases, therefore, multilevel Poisson models were utilized. All continuous between-person
predictors were standardized.
Model Fitting and Random Effects
For each model, I tested the significance of changes in -2 log likelihood (or, in the
case of Poisson models, -2 restricted log pseudo-likelihood) in a stepwise manner,
comparing: (1) a model with no predictors and a random intercept, (2) a model adding all
relevant predictors for testing hypotheses as fixed effects, and (3) a model adding random
effects for the relevant within-person predictor (e.g., deviations in estradiol). Significant
differences between each model and the best-fitting previous model are clearly labeled in
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each table. Random effects were only retained in further (e.g., mediation/moderation)
models where the improvement in model fit was significant with their inclusion. When
moderation hypotheses were tested, results of best-fitting models up to that point were
transposed to new tables for ease of model comparison.
Specific Hypothesis Tests
The primary hypothesis was that increases in conception probability and estradiol
would be associated with increased expression of BPD symptoms. At the daily level, this
hypothesis was tested in multilevel Poisson regression models with daily assessments at
level one and women at level two; daily scores on the PAI-BOR were regressed on
conception probability. At the weekly level, the hypothesis was tested in multilevel
Poisson regression models with weekly assessments at level one and women at level two;
weekly scores on the PAI-BOR, the BSL-23, and the MSI-BPD were regressed on
average estradiol and weekly deviation in estradiol.
Moderation by Trait BPD Symptoms. The second hypothesis concerned the
moderation of these effects by trait levels of BPD symptoms as measured by (1) the
average of weekly PAI-BOR total score and (2) the number of SCID-II criteria met in the
diagnostic interview. At the daily level, I tested this hypothesis in two multilevel Poisson
regression models: (1) regressing daily PAI-BOR scores on conception probability,
average weekly PAI-BOR total score, and their interaction, and (2) regressing daily PAIBOR scores on conception probability, number of SCID-II criteria met during the
diagnostic interview, and their interaction. At the weekly level, I tested this hypothesis in
two multilevel Poisson regression models for each of the three measures of BPD
symptoms (PAI-BOR, BSL-23, and MSI-BPD): (1) regressing weekly symptoms on
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average estradiol and weekly deviation in estradiol, average weekly PAI-BOR total score,
and the interactions of average weekly PAI-BOR total score with both average estradiol
and weekly deviation in estradiol, and (2) regressing weekly symptoms on average
estradiol and weekly deviation in estradiol, number of SCID-II criteria met during the
diagnostic interview, and the interactions of number of SCID-II criteria with both average
estradiol and weekly deviation in estradiol. Because trait BPD as defined here is a
heterogeneous construct, further moderation analyses were also conducted in which
aspects of FFM personality and different types of childhood maltreatment were
substituted as moderators of the effects of estradiol.
Mediation by Felt Acceptance, Impulsivity, and Self-Control. The third hypothesis
concerned the mediation of conception probability and estradiol effects on symptoms by
felt acceptance, multiple facets of impulsivity, and self-control. A primary step in testing
mediation is to test for effects of the focal predictors on outcomes of interest; this was
accomplished during tests of hypothesis 1 and 2. A second step is to test the effects of
these focal predictors on the mediators. A third step is to test the impact of the mediator
on the outcomes of interest. Finally, given significant findings in these three tests, a final
test used estimates and standard errors for the A and B paths to generate a 95%
confidence interval for the indirect effect of the focal predictor (e.g., weekly deviations in
estradiol) on the outcome of interest (e.g., BPD symptoms) via the mediator (e.g., felt
acceptance) using the RMediation program (Tofighi & MacKinnon, 2011). Where
moderation hypotheses were supported, mediational analyses were also conducted to
determine whether felt acceptance, UPPS impulsivity, or self-control mediated these
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moderation effects. Models included in testing the second and third steps discussed above
will now be described in detail for each of the three proposed mediators.
The first proposed mediator was felt acceptance. At the daily level, this was tested
in two models: (1) regressing daily felt acceptance on conception probability, and (2)
regressing daily PAI-BOR scores on average levels of felt acceptance and daily
deviations in felt acceptance. At the weekly level, this was tested in similar models: (1)
regressing weekly scores on the Social Evaluation subscale of the SSE scale on average
estradiol and weekly deviations in estradiol, and (2) regressing weekly BPD symptoms
(on the PAI-BOR, the BSL-23, and the MSI) on average scores on the Social Evaluation
subscale of the SSE scale and weekly deviations in scores on the Social Evaluation
subscale of the SSE scale. Where moderation models were significant, tests of mediated
moderation were also carried out. The second proposed mediator was impulsivity. At the
weekly level, this was tested in the following models: (1) regressing weekly scores on
each subscale of the UPPS-P on average estradiol and weekly deviations in estradiol, and
(2) regressing weekly BPD symptoms (on the PAI-BOR, the BSL-23, and the MSI-BPD)
on average scores on each subscale of the UPPS-P and weekly deviations in scores on
each subscale of the UPPS-P. The third proposed mediator was self-control. At the
weekly level, this was tested in the following models: (1) regressing weekly scores on the
BSCS on average estradiol and weekly deviations in estradiol, and (2) regressing weekly
BPD symptoms (on the PAI-BOR, the BSL-23, and the MSI) on average of all weekly
scores on the BSCS and weekly deviations in scores on the BSCS.

Copyright © Tory Eisenlohr-Moul 2013
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Chapter Three: Results
Observations at the Daily and Weekly Level
At the daily level, there were 729 observations, indicating an average of 18.22
diaries completed per participant. At the weekly level, there were no missed lab sessions
that were unable to be rescheduled; therefore, the maximum number of 160 data points
were collected. This means that all 40 participants provided data at exactly four lab visits.
Descriptive and Correlational Analyses
Before carrying out hypothesis tests, I examined the zero-order correlations
between a woman’s average levels of estradiol, a woman’s average scores on daily and
weekly BPD measures, and between-person variables (e.g., SCID criteria met, FFM
personality domains, and types of childhood maltreatment). Zero-order correlations,
means, standard deviations, and internal consistencies for these variables can be found in
Table 2. Unexpectedly, higher average levels of estradiol were significantly negatively
correlated with Extraversion. Additional post-hoc correlations of average estradiol with
the five facet items for Extraversion on the FFM-RF revealed that this significant
association was accounted for by significant negative correlations between average
estradiol and the warmth (r = -.36, p = .01) and positive emotions (r = -.32, p = .02)
facets. In addition, average levels of estradiol were associated with higher levels of both
physical and emotional abuse; these correlations were also not anticipated, and the
reasons for these associations are unclear. Average levels of estradiol were uncorrelated
with any measure of BPD.
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Table 2
Zero-order correlations among between-person measures, average estradiol, and average daily and weekly measures of BPD
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Variable
1
2
1 Average Estradiol
2 Neuroticism
.12
3 Agreeableness
-.02
-.24
4 Conscientiousness
.11
-.19
5 Extraversion
-.30*
-.23
6 Openness
.03
.12
7 Emotional Abuse
.25*
.27*
8 Emotional Neglect
.02
.32*
9 Physical Abuse
.26*
.22
10 Physical Neglect
.13
.34*
11 Sexual Abuse
.04
.18
12 SCID-II Criteria Met -.13
.41*
13 Avg PAI-BOR (D)
-.08
.59*
14 Avg PAI-BOR (W)
-.002
.59*
15 Avg BSL-23 (W)
.07
.59*
16 Avg MSI (W)
-.10
.49*
Mean
3.39
2.40
(SD)
(.08)
(.12)
Cronbach’s α
.75
Note. *p < .05. Estradiol units are pg/mL.

3

4

5

6

7

8

9

10

11

12

13

14

15

.07
.21
.33*
-.14
-.21
-.17
-.09
-.26*
-.10
-.29*
-.31*
-.34*
-.31*
3.55
(.11)
.75

.21
-.05
.05
-.13
.10
-.10
.11
-.18
-.29*
-.26*
-.10
-.19
3.57
(.09)
.71

.27*
-.02
-.07
-.14
-.04
.0001
.06
-.04
-.08
-.09
-.03
3.71
(.12)
.77

.14
.15
.09
.28*
.01
.15
.21
.17
.13
.23
3.90
(.10)
.81

.83*
.81*
.70*
.52*
.38*
.21
.33*
.54*
.22
.13
(.37)
.85

.70*
.78*
.39*
.42*
.34*
.38*
.62*
.40*
1.55
(.15)
.93

.78*
.55*
.18
.06
.17
.42*
.15
1.26
(.11)
.86

.61*
.26*
.19
.26*
.47*
.25*
1.22
(.09)
.81

.13
.006
.25*
.26*
.03
1.28
(.14)
.95

.64*
.66*
.78*
.67*
1.32
(.33)
-

.95*
.82*
.88*
.59
(.06)
.89

.88*
.87*
.70
(.04)
.91

.87*
.48
(.47)
.93

	
  

1

16

2.08
(2.26)
.77

	
  
Consistent with dimensional FFM personality models of BPD (Widiger &
Mullins-Sweatt, 2009), Neuroticism was positively correlated with all measures of BPD.
Agreeableness was negatively correlated with all measures of BPD except the SCID-II
interview, and Conscientiousness was negatively associated with two of the five
measures of BPD; however, Openness was not associated with any measure of BPD.
Neuroticism was also positively correlated with higher scores on some facets of the CTQ
(Emotional Abuse, Emotional Neglect, and Physical Neglect). Consistent with Linehan’s
biosocial theory of BPD, subscales of the CTQ were generally but inconsistently
associated with higher BPD features; Emotional Abuse, Emotional Neglect, Physical
Neglect, and Sexual Abuse showed the most consistent positive associations with BPD
scores. Notably, scores on the Sexual Abuse subscale were both positively associated
with higher average scores on the weekly PAI-BOR and BSL-23 and negatively
correlated with Agreeableness. Intercorrelations among average daily, average weekly,
and number of SCID-II criteria met were all significant in expected directions, suggesting
good convergent validity among these various ways of measuring BPD (all r’s
between .69 and .95). All subscales of the CTQ were also highly intercorrelated in
expected directions. Internal consistencies were all acceptable to excellent.
Examination of the SCID-II criteria met variable revealed that, on average,
individuals endorsed a low number (1.33) of BPD criteria during the interview. Notably,
though all of the other measures of BPD were significantly correlated with number of
SCID-II criteria met, significance testing for the differences between correlations
revealed that the correlation between the BSL-23 and number of SCID-II criteria met (r
= .78) was significantly greater than the correlations between number of SCID-II criteria
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met and average weekly PAI-BOR (t(37) = -2.38, p = .002), average daily PAI-BOR
(t(37) = -2.25, p =.03), and the MSI-BPD (t(37) = -2.09, p =.04). Therefore, although all
of the self-report measures were highly positively correlated with BPD symptoms as
measured using the SCID-II diagnostic interview, the BSL-23 may be considered a
stronger indicator of interview-confirmed BPD symptoms in the present sample.
Testing Hypothesis 1: Ovulation, Estradiol, and BPD Symptom Expression
Daily Analyses. It was predicted that higher levels of conception probability
would predict greater expression of BPD symptoms at the daily level. Results of
multilevel Poisson regression models predicting each of the four PAI-BOR subscales and
the PAI-BOR total scale from conception probability are presented in Table 3.
Results of these models do not support Hypothesis 1; conception probability did
not significantly predict any PAI-BOR subscale or the total scale. However, comparing
Model 2 (a model with a fixed effect of conception probability) to Model 3 (a model with
a random effect specified for conception probability) revealed significant improvement in
model fit when predicting each of the PAI-BOR subscales and the total. This indicates
that the influence of conception probability (ovulation) on BPD symptoms differs
between individuals (i.e., there is a moderator).
Weekly Analyses. It was also predicted that increases in estradiol (which are
typically associated with ovulation) would predict greater expression of BPD symptoms
at the weekly level. Results of models predicting each of the four PAI-BOR subscales
and total score, the MSI-BPD, and BSL-23 from average estradiol and weekly deviations
in estradiol are presented in Table 4.
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Table 3
Multilevel Poisson Regression Models Predicting Daily PAI-BOR Scores from Daily
Conception Probability Values
Parameter

Model 1
(null)
Dependent Variable: PAI-BOR Total Score

Model 2
(fixed CP slope)

Model 3
(random CP slope)

Intercept
Conception Probability

-.62* (.10)

Intercept
Conception Probability
Residual

.38* (.09)

Fixed Effects
-.62* (.10)
.17 (.59)
Random Parameters
.37* (.09)

.13* (.006)

.13* (.007)

.39* (.09)
18.25* (7.30)
.12* (.006)

1224.61†

1185.02†

-2 Restricted Log Pseudo1348.35
likelihood
Dependent Variable: PAI-BOR Affective Instability Subscale

-.62* (.10)
.20 (.98)

Intercept
Conception Probability

-.68* (.12)

Intercept
Conception Probability
Residual

.59* (.15)

Fixed Effects
-.68* (.13)
.13 (.93)
Random Parameters
.60* (.15)

.33* (.01)

.13* (.93)

.60* (.15)
20.71* (12.12)
.31* (.01)

1915.66†

1903.81†

-2 Restricted Log Pseudo2117.42
likelihood
Dependent Variable: PAI-BOR Identity Disturbance Subscale

-.67* (.13)
-.24 (1.29)

Intercept
Conception Probability

-.55* (.10)

Intercept
Conception Probability
Residual

.42* (.10)

Fixed Effects
-.53* (.10)
-.56 (.65)
Random Parameters
.43* (.10)

.17* (.009)

.17* (.009)

.45* (.11)
15.48* (7.39)
.16* (.009)

1521.40

1376.87†

1357.97†

-2 Restricted Log Pseudolikelihood
Table Continued on Next Page
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Dependent Variable: PAI-BOR Negative Relationships Subscale
Fixed Effects
Intercept
-.48* (.10)
-.49* (.11)
Conception Probability
.60 (.68)
Random Parameters
Intercept
.44* (.10)
.44* (.11)
Conception Probability
Residual
.22* (.01)
.23* (.01)
-2 Restricted Log Pseudo1622.09
likelihood
Dependent Variable: PAI-BOR Self-Harm Subscale

1487.02†

Intercept
Conception Probability

-1.13* (.15)

Intercept
Conception Probability
Residual

.87* (.24)

Fixed Effects
-1.11* (.15)
.70 (1.17)
Random Parameters
.77* (.22)

.34* (.01)

.34* (.01)

-.50* (.11)
.73 (1.04)
.45* (.11)
16.59* (8.81)
.21* (.01)
1472.61†

-1.10* (.15)
.36 (.83)
.77* (.23)
48.07* (23.80)
.31* (.01)

-2 Restricted Log Pseudo2551.02
2264.19†
2242.93†
likelihood
Note. Standard errors are in parentheses. CP = Daily Conception Probability.
*p < .05.
†Change in -2 Restricted Log Pseudo-likelihood over the previous model is significant at p < .05.
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Table 4
Multilevel Poisson Regression Models Predicting Weekly BPD Symptoms from Average
Levels of Estradiol and Weekly Deviations in Estradiol
Parameter

Model 1
(null)

Model 2
Model 3
(fixed deviation slope) (random deviation
slope)

Dependent Variable: PAI-BOR Total Score
Intercept
Average Weekly Estradiol
Deviations in Estradiol

-.50* (.10)

Intercept
Deviations in Estradiol
Residual

.39* (.09)

Fixed Effects
-.50* (.10)
-.02 (.10)
.001 (.04)
Random Parameters
.40* (.10)

.08* (.01)

-2 Restricted Log Pseudo240.55
likelihood
Dependent Variable: PAI-BOR Affective Instability Subscale
Intercept
Average Weekly Estradiol
Deviations in Estradiol

-.60* (.15)

Intercept
Deviations in Estradiol
Residual

.83* (.23)

-2 Restricted Log Pseudo370.17
likelihood
Dependent Variable: PAI-BOR Identity Disturbance Subscale
Intercept
Average Weekly Estradiol
Deviations in Estradiol

-.30* (.11)

Intercept
Deviations in Estradiol
Residual

.45* (.11)

-2 Restricted Log Pseudolikelihood
Table Continued on Next Page

	
  

.08* (.01)

.40* (.10)
.03 (.06)
.08* (.02)

239.27

240.27

Fixed Effects
-.61* (.15)
-.10 (.15)
-.05 (.06)
Random Parameters
.85* (.23)

.16* (.02)

-.50* (.10)
-.02 (.09)
.001 (.05)

-.61* (.15)
-.10 (.14)
-.05 (.06)

.16* (.02)

.85* (.23)
.04 (.03)
.16* (.02)

370.09

369.89

Fixed Effects
-.30* (.11)
-.03 (.11)
-.00069 (.05)
Random Parameters
.46* (.11)

-.30* (.11)
-.04 (.11)
.01 (.06)

.12* (.01)

.12* (.01)

.47* (.11)
.02 (.04)
.11* (.01)

274.93

273.58

273.18
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Dependent Variable: PAI-BOR Negative Relationships Subscale
Intercept
Average Weekly Estradiol
Deviations in Estradiol

-.41* (.12)

Intercept
Deviations in Estradiol
Residual

.53* (.14)
.16* (.02)

-2 Restricted Log Pseudo332.16
likelihood
Dependent Variable: PAI-BOR Self-Harm Subscale
Intercept
Average Weekly Estradiol
Deviations in Estradiol
Intercept
Deviations in Estradiol
Residual

-1.03* (.11)

.35* (.12)
.18* (.02)

Fixed Effects
-.42 (.12)
-.01 (.10)
.03 (.15)
Random Parameters
.55* (.16)
.17* (.02)

.55* (.16)
.01 (.07)
.17* (.02)

332.10

330.77

Fixed Effects
-1.03* (.11)
.01 (.11)
.02 (.09)
Random Parameters
.37* (.12)
.18* (.02)

-2 Restricted Log Pseudo407.23
411.88
likelihood
Dependent Variable: Borderline Symptom Checklist—23 (BSL-23)
Fixed Effects
Intercept
2.05* (.16)
2.04* (.17)
Average Weekly Estradiol
.003 (.17)
Deviations in Estradiol
-.11* (.03)
Random Parameters
Intercept
1.06* (.29)
1.11* (.30)
Deviations in Estradiol
Residual
2.34* (.31)
2.26* (.30)
-2 Restricted Log Pseudolikelihood
Table Continued on Next Page

379.72
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-.42 (.12)
-.01 (.10)
.03 (.15)

371.22

-1.04* (.11)
.01 (.11)
.02 (.09)
.37* (.12)
.002 (.05)
.18* (.02)
411.86

2.04* (.18)
.003 (.16)
-.11* (.02)
1.11* (.30)
.004 (.06)
2.26* (.30)
378.22

	
  
Dependent Variable: McLean Screening Instrument for BPD (MSI-BPD)
Fixed Effects
Intercept
.17 (.22)
.17 (.22)
Average Weekly Estradiol
-.03 (.22)
Deviations in Estradiol
-.08 (.07)
Random Parameters
Intercept
1.80* (.54)
1.86* (.56)
Deviations in Estradiol
Residual
.68* (.09)
.69* (.09)

.17 (.22)
-.03 (.22)
-.08 (.07)
1.87* (.56)
-.03 (.22)
-.08 (.07)

-2 Restricted Log Pseudo481.04
480.91
480.02
likelihood
Note. Standard errors are in parentheses. A dashed line indicates that the model did not converge, likely due
to nonsignificance of random effects included.
*p < .05.
†Change in -2 Restricted Log Pseudo-likelihood over the previous model is significant at p < .05.
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For each of the models except the one predicting the BSL-23, were no significant
fixed or random effects of either average levels of estradiol or weekly deviations in
estradiol. There was a significant fixed effect of deviations in estradiol such that higherthan-usual levels of estradiol were associated with lower scores on the BSL-23.
Testing Hypothesis 2: Moderation of Cycle Effects by Trait BPD
Daily Analyses. It was predicted that the effect of daily conception probability
values on expression of BPD symptoms as measured by the PAI-BOR would be
moderated by (1) average weekly values of the total PAI-BOR scale and (2) number of
BPD criteria met during the SCID-II diagnostic interview. Specifically, it was
hypothesized that women with generally higher levels of BPD symptoms (as measured by
average of the four extended weekly assessments or number of BPD criteria met during
the SCID-II interview) would show a stronger positive association between daily
conception probability values and BPD symptoms. Results of models predicting each of
the four PAI-BOR subscales and total scale from conception probability, average of
weekly PAI-BOR total score assessments, and their interaction are presented in Table 5.
In each case, Model 3 information was transplanted from Table 3 for ease of comparing
Model 3 (in which a random effect of conception probability was identified) to Model 4,
in which the moderator is included.
Though models including the moderator provided significantly better model fit
than a model including only a random effect of conception probability, only one of these
models provided evidence that trait BPD moderates the impact of daily conception
probability values on daily BPD symptoms. There was a significant interactive effect of
average daily total PAI-BOR scores and conception probability in the opposite of the
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Table 5
Multilevel Poisson Regression Models Predicting Daily PAI-BOR Scores from the
Interaction of Daily Conception Probability Values and Average of Weekly PAI-BOR
Assessments (Trait BPD)
Parameter

Model 3
(random CP slope)

Model 4
(with moderator)

Dependent Variable: Daily PAI-BOR Total Score
Fixed Effects
Intercept
Conception Probability
Avg of Weekly PAI-BOR
Avg of Weekly PAI-BOR*CP

-.62* (.10)
.20 (.98)

-.65* (.04)
.49 (.64)
.56* (.03)
-.89* (.07)

Random Parameters
.39* (.09)
.03* (.01)
18.25* (7.30)
16.48* (6.67)
.12* (.006)
.13* (.007)

Intercept
Conception Probability
Residual

-2 Restricted Log Pseudo-likelihood
1185.02
Dependent Variable: Daily PAI-BOR Affective Instability Subscale

1146.20†
Fixed Effects

Intercept
Conception Probability
Avg of Weekly PAI-BOR
Avg of Weekly PAI-BOR*CP

-.67* (.13)
-.24* (1.29)

-.70* (.07)
-.43 (1.33)
.62* (.18)
-.17 (.88)

Random Parameters
.60* (.15)
.15* (.05)
20.71* (12.12)
19.12* (11.02)
.31* (.01)
.31* (.01)

Intercept
Conception Probability
Residual

-2 Restricted Log Pseudo-likelihood
1903.81
Dependent Variable: Daily PAI-BOR Identity Disturbance Subscale

1849.49†
Fixed Effects

Intercept
Conception Probability
Avg of Weekly PAI-BOR
Avg of Weekly PAI-BOR*CP

-.53* (.11)
-.71 (.99)

-.56* (.06)
-.54 (.99)
.57* (.05)
-1.11 (.89)

Random Parameters
.45* (.11)
.10* (.03)
15.48* (7.39)
13.93* (6.82)
.16* (.009)
.16* (.009)

Intercept
Conception Probability
Residual
-2 Restricted Log Pseudo-likelihood
Table Continued on Next Page
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Dependent Variable: Daily PAI-BOR Negative Relationships Subscale
Fixed Effects
Intercept
-.50* (.11)
-.52* (.06)
Conception Probability
.73 (1.04)
.97 (1.00)
Avg of Weekly PAI-BOR
.57* (.06)
Avg of Weekly PAI-BOR*CP
-1.16 (.91)
Random Parameters
Intercept
.45* (.11)
.11* (.03)
Conception Probability
16.59* (8.81)
12.79* (7.38)
Residual
.21* (.01)
.21* (.01)
-2 Restricted Log Pseudo-likelihood
1472.61
Dependent Variable: Daily PAI-BOR Self-Harm Subscale

1424.62†
Fixed Effects

Intercept
Conception Probability
Avg of Weekly PAI-BOR
Avg of Weekly PAI-BOR*CP

-.62* (.10)
.20 (.98)

-1.12* (.12)
.14 (1.77)
.55* (.11)
-.25 (.87)

Random Parameters
.77* (.23)
.43* (.13)
48.07* (23.80)
46.84* (23.18)
.31* (.01)
.31* (.01)

Intercept
Conception Probability
Residual

-2 Restricted Log Pseudo-likelihood
2242.93
2216.45†
Note. Standard errors are in parentheses. CP = Daily Conception Probability.
*p < .05.
†Change in -2 Restricted Log Pseudo-likelihood over the previous model is significant at p < .05.
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predicted direction: women with lower (-1 standard deviation) trait BPD symptoms
showed increased daily BPD symptoms on days when conception probability was higher
(γLOWTRAITBPD*CP = .58, SE = .44, t(697) = 3.53, p = .0004), whereas there was no effect
of conception probability in women with higher (+1 standard deviation) trait levels of
BPD (γHIGHTRAITBPD*CP = -.05, SE = .26, t(697) = -.19, p = .84). A graph depicting the
interaction can be found in Figure 1.
Next, models were executed in which number of SCID-II criteria met was
substituted for Average Weekly PAI-BOR scores as an alternative measure of trait BPD
symptoms. Results of these models are presented in Table 6. The results from the
random slope models (Model 3) were again transplanted from Table 3 for ease of model
comparison. As with the majority of the PAI-BOR moderation models, the SCID-II
criteria moderation models provided significantly better model fit than a model including
only a random effect of conception probability; however, these models provided no
evidence that trait BPD influences the impact of daily conception probability values on
daily BPD symptoms.
Weekly Analyses. It was also predicted that the effect of weekly deviations in
estradiol on BPD symptoms as measured by the PAI-BOR, the BSL-23, and the MSIBPD would be moderated by (1) average weekly values of the total PAI-BOR scale and
(2) number of criteria met on the SCID-II BPD module. Again, it was hypothesized that
women with generally higher levels of BPD symptoms (as measured by average of the
four extended weekly assessments and number of BPD criteria met during the SCID-II
interview) would show stronger positive associations between weekly fluctuations in
estradiol and BPD symptoms. Results of models predicting each of the four PAI-BOR
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Figure 1. A graph of the interaction between trait BPD symptoms and daily conception
probability predicting daily PAI-BOR total score.
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Table 6
Multilevel Poisson Regression Models Predicting Daily PAI-BOR Scores from the
Interaction of Daily Conception Probability Values and Number of SCID-II BPD Criteria
Met (Trait BPD)
Parameter

Model 3
(random CP slope)

Model 4
(with moderator)

Dependent Variable: PAI-BOR Total Score
Fixed Effects
Intercept
Conception Probability
SCID-II BPD Criteria Met
SCID-II BPD Criteria Met*CP

-.62* (.10)
.20 (.98)

-.65*(.08)
.24 (99)
.39* (.08)
-.56 (.89)

Random Parameters
.39* (.09)
.24* (.06)
18.25* (7.30)
18.23* (.7.22)
.12* (.006)
.12* (.006)

Intercept
Conception Probability
Residual

-2 Restricted Log Pseudo-likelihood
1185.02
Dependent Variable: PAI-BOR Affective Instability Subscale

1164.11†
Fixed Effects

Intercept
Conception Probability
SCID-II BPD Criteria Met
SCID-II BPD Criteria Met*CP

-.67* (.13)
-.24 (1.29)

-.70* (.11)
-.47 (1.34)
.46* (.10)
.10 (1.17)

Random Parameters
.60* (.15)
.38* (.10)
20.71* (12.12)
21.46* (12.34)
.31* (.01)
.31* (.01)

Intercept
Conception Probability
Residual

-2 Restricted Log Pseudo-likelihood
1903.81
Dependent Variable: PAI-BOR Identity Disturbance Subscale

1883.70†
Fixed Effects

Intercept
Conception Probability
SCID-II BPD Criteria Met
SCID-II BPD Criteria Met*CP

-.53* (.11)
-.71 (.99)

-.56* (.09)
-.54 (1.01)
.40* (.09)
-.51 (.91)

Random Parameters
.45* (.11)
.30* (.07)
15.48* (7.39)
15.86* (7.34)
.16* (.009)
.16* (.009)

Intercept
Conception Probability
Residual
-2 Restricted Log Pseudo-likelihood
Table Continued on Next Page
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Dependent Variable: Negative Relationships Subscale
Fixed Effects
Intercept
Conception Probability
SCID-II BPD Criteria Met
SCID-II BPD Criteria Met*CP

-.50* (.11)
.73 (1.04)

-.52* (.09)
.77 (1.06)
.39* (.09)
-.53 (.95)

Random Parameters
.45* (.11)
.31* (.08)
16.59* (8.81)
16.88* (8.85)
.21* (.01)
.21* (.01)

Intercept
Conception Probability
Residual
-2 Restricted Log Pseudo-likelihood
Dependent Variable: Self-Harm Subscale

1472.61

1457.30†
Fixed Effects

Intercept
Conception Probability
SCID-II BPD Criteria Met
SCID-II BPD Criteria Met*CP

-.62* (.10)
.20 (.98)

-1.14* (.14)
.40 (1.75)
.33* (.14)
-1.32 (1.60)

Random Parameters
.77* (.23)
.71* (.21)
48.07* (23.80)
47.84* (23.67)
.31* (.01)
.31* (.01)

Intercept
Conception Probability
Residual

-2 Restricted Log Pseudo-likelihood
2242.93
2234.05†
Note. Standard errors are in parentheses. CP = Daily Conception Probability.
*p < .05.
†Change in -2 Restricted Log Pseudo-likelihood over the previous model is significant at p < .05.
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subscales and the PAI-BOR total scale, the BSL-23, and the MSI-BPD from average
estradiol, deviations in estradiol, average of weekly PAI-BOR total score assessments,
and the interactions of trait BPD and each estradiol variable are presented in Table 7. In
each case, the null model (Model 1) was transplanted from Table 4 for ease of
comparison with Model 4, in which the trait BPD moderator is included.
For each outcome, model fit was significantly improved with the inclusion of the
fixed effects. Results presented in Table 7 reveal several significant interactive effects of
trait BPD and fluctuations in estradiol, though the interactive effects are in the opposite
of the predicted direction. In the model predicting the total score of the PAI-BOR,
women with lower levels of trait BPD showed a positive association between higherthan-usual levels of estradiol and BPD symptoms (γLOWTRAITBPD*ESTRADIOLDEVIATION = .14,
SE = .08, t(117) = 2.70, p = .007), while higher-than-usual levels in estradiol were
associated with lower BPD symptoms among women with higher levels of trait BPD
(γHIGHTRAITBPD*ESTRADIOLDEVIATION = -.13, SE = .03, t(117) = 4.33, p < .0001). A graph of
the interaction can be found in Figure 2.
Results for several of the other scales tended to follow a similar pattern of results
in which BPD symptoms tended to be reduced at higher-than-usual estradiol among those
with high trait levels of BPD but tended to be increased with higher-than-usual estradiol
among those with low trait levels of BPD symptoms (see Figure 3-5 for graphs depicting
significant interactions). In the model predicting Identity Disturbance, there was a
significant association between higher-than-usual estradiol and decreased symptoms
among women high in trait BPD (γHIGHTRAITBPD*ESTRADIOLDEVIATION = -.18, SE = .06,
t(117) = 1.99, p = .04), but there was not a significant association between fluctuations in
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Table 7
Multilevel Poisson Regression Models Predicting Weekly BPD Symptoms from the
Interaction of Average of Weekly PAI-BOR Assessments (Trait BPD) with Average
Estradiol and Weekly Deviations in Estradiol
Parameter

Model 1
(null)

Model 4
(with moderator)

Dependent Variable: PAI-BOR Total Score
Fixed Effects
Intercept
Avg Estradiol
Weekly Deviation in Estradiol
Avg of Weekly PAI-BOR
Avg of Weekly PAI-BOR*Avg Estradiol
Avg of Weekly PAI-BOR*Estradiol Deviation

-.50* (.10)

-.51* (.03)
-.01 (.03)
.03 (.05)
.53* (.02)
.003 (.02)
-.10* (.05)
Random Parameters
.39* (.09)
.001 (.007)

Intercept
Weekly Deviation in Estradiol
Residual

.08* (.01)

.08* (.01)

-2 Restricted Log Pseudo-likelihood
240.55
Dependent Variable: PAI-BOR Affective Instability Subscale

161.70†
Fixed Effects

Intercept
Avg Estradiol
Weekly Deviation in Estradiol
Avg of Weekly PAI-BOR
Avg of Weekly PAI-BOR*Avg Estradiol
Avg of Weekly PAI-BOR*Estradiol Deviation

-.60* (.15)

-.62* (.08)
-.09 (.08)
.001 (.07)
.69* (.07)
.02 (.07)
-.13* (.03)
Random Parameters
.83* (.23)
.16* (.06)

Intercept
Weekly Deviation in Estradiol
Residual
-2 Restricted Log Pseudo-likelihood
Table Continued on Next Page
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Dependent Variable: PAI-BOR Identity Disturbance Subscale
Fixed Effects
Intercept
Avg Estradiol
Weekly Deviation in Estradiol
Avg of Weekly PAI-BOR
Avg of Weekly PAI-BOR*Avg Estradiol
Avg of Weekly PAI-BOR*Estradiol Deviation

-.30* (.11)

-.33* (.05)
-.03 (.05)
.04 (.05)
.58* (.04)
.01 (.04)
-.13* (.05)
Random Parameters
.45* (.11)
.05* (.02)

Intercept
Weekly Deviation in Estradiol
Residual

.12* (.01)

.12* (.01)

-2 Restricted Log Pseudo-likelihood
274.93
Dependent Variable: PAI-BOR Negative Relationships Subscale

223.86†
Fixed Effects

Intercept
Avg Estradiol
Weekly Deviation in Estradiol
Avg of Weekly PAI-BOR
Avg of Weekly PAI-BOR*Avg Estradiol
Avg of Weekly PAI-BOR*Estradiol Deviation

-.41* (.12)

-.42* (.06)
-.01 (.06)
.06 (.06)
.57* (.05)
.04 (.05)
-.07 (.07)
Random Parameters
.53* (.14)
.07* (.03)

Intercept
Weekly Deviation in Estradiol
Residual
-2 Restricted Log Pseudo-likelihood
Dependent Variable: PAI-BOR Self-Harm Subscale

.16* (.02)

.16* (.02)

332.16

288.91†

Fixed Effects
-1.03* (.11)
-1.05* (.09)
.06 (.09)
.04 (.09)
.39* (.08)
-.15* (.06)
-.10 (.10)
Random Parameters
.35* (.12)
.17* (.08)

Intercept
Avg Estradiol
Weekly Deviation in Estradiol
Avg of Weekly PAI-BOR
Avg of Weekly PAI-BOR*Avg Estradiol
Avg of Weekly PAI-BOR*Estradiol Deviation
Intercept
Weekly Deviation in Estradiol
Residual
-2 Restricted Log Pseudo-likelihood
Table Continued on Next Page

48
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Dependent Variable: Borderline Symptom Checklist—23 (BSL-23)
Fixed Effects
Intercept
Avg Estradiol
Weekly Deviation in Estradiol
Avg of Weekly PAI-BOR
Avg of Weekly PAI-BOR*Avg Estradiol
Avg of Weekly PAI-BOR*Estradiol Deviation

2.05* (.16)

2.02* (.10)
.03 (.10)
-.07 (.06)
.77* (.09)
-.03 (.09)
-.13* (.05)
Random Parameters
1.06* (.29)
.32* (.10)

Intercept
Weekly Deviation in Estradiol
Residual

2.34* (.31)

2.24* (.30)

-2 Restricted Log Pseudo-likelihood
379.72
342.77†
Dependent Variable: McLean Screening Instrument for BPD (MSI-BPD)
Fixed Effects
Intercept
.17 (.22)
.17 (.14)
Avg Estradiol
-.02 (.14)
Weekly Deviation in Estradiol
-.05 (.09)
Avg of Weekly PAI-BOR
.96* (.13)
Avg of Weekly PAI-BOR*Avg Estradiol
-.11 (.12)
Avg of Weekly PAI-BOR*Estradiol Deviation
-.06 (.10)
Random Parameters
Intercept
1.80* (.54)
.56* (.20)
Weekly Deviation in Estradiol
Residual
.68* (.09)
.72* (.09)
-2 Restricted Log Pseudo-likelihood
481.04
450.59†
Note. Standard errors are in parentheses.
*p < .05.
†Change in -2 Restricted Log Pseudo-likelihood over the previous model is significant at p < .05.

49

	
  
3	
  

Low Trait BPD (-1 SD)
High Trait BPD (+1 SD)
Very High Trait BPD (+2 SD)

Weekly PAI-BOR Total

2.5	
  

2	
  

1.5	
  

1	
  

0.5	
  

0	
  
Lower-than-usual Estradiol

Higher-than-usual Estradiol

Figure 2. A graph of the interaction between trait BPD symptoms and deviation in
estradiol predicting weekly PAI-BOR total score.
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Figure 3. A graph of the interaction between trait BPD symptoms and deviation in
estradiol predicting weekly PAI-BOR Identity Disturbance subscale score.
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Figure 4. A graph of the interaction between trait BPD symptoms and deviation in
estradiol predicting weekly PAI-BOR Affective Instability subscale score.
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Figure 5. A graph of the interaction between trait BPD symptoms and deviation in
estradiol predicting weekly BSL-23 score.
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estradiol and symptom expression among women low in trait BPD symptoms
(γLOWTRAITBPD*ESTRADIOLDEVIATION = .08, SE = .06, t(117) = 1.39, p = .16). In the model
predicting the Affective Instability subscale, there was a significant effect of higher-thanusual estradiol predicting lower Affective Instability among women higher in trait BPD
(γHIGHTRAITBPD*ESTRADIOLDEVIATION = -.13, SE = .04, t(117) = -3.25, p = .0007), but there
was no significant effect of higher-than-usual estradiol on Affective Instability among
women with lower trait BPD (γLOWTRAITBPD*ESTRADIOLDEVIATION = .13, SE = .11, t(117) =
1.18, p = .29). There was also a significant interaction between average scores on the
PAI-BOR total and fluctuations in estradiol predicting scores on the BSL-23. Among
women higher in trait BPD, higher-than-usual levels of estradiol were associated with
decreased BPD symptoms (γHIGHTRAITBPD*ESTRADIOLDEVIATION = -.21, SE = .07, t(117) = 2.72, p = .003). However, among women lower in trait BPD, higher-than-usual estradiol
was not associated with BPD symptom expression (γLOWTRAITBPD*ESTRADIOLDEVIATION = .06,
SE = .11, t(117) = .54, p = .58). Finally, in the model predicting the Self-Harm subscale,
there was no significant interaction between trait BPD and fluctuations in estradiol;
however, there was a significant interaction between trait BPD and average levels of
estradiol such that higher average levels of estradiol were associated with greater
symptoms among women with lower trait BPD (γLOWTRAITBPD*HIGHAVGESTRADIOL = .21, SE
= .10, t(117) = 2.10, p = .01), but was not significant among women with higher trait
BPD (γHIGHTRAITBPD*HIGHAVGESTRADIOL = -.09, SE = .11, t(117) = -.81, p = .40). A graph of
the interaction predicting Self-Harm can be found in Figure 6.
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Figure 6. A graph of the interaction between trait BPD symptoms and average estradiol
predicting weekly PAI-BOR Self-Harm subscale score.
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Results of models substituting number of SCID-II criteria met for average weekly
scores on the PAI-BOR total scale are presented in Table 8. None of the interactions of
trait BPD with average estradiol or fluctuations in estradiol were statistically significant.
Testing Hypothesis 3a: Mediation by Felt Social Acceptance
It was predicted that increases in daily conception probability would be associated
with lower daily felt acceptance, and that these effects would be stronger among women
high in trait BPD features. Previous analyses suggest that conception probability and
estradiol may not exert robust main effects on BPD features (i.e., the C path of the
mediation model may not be significant); however, tests of whether increases in
conception probability and estradiol are associated with decreased felt acceptance (Path
A in the mediation model) and whether changes in felt acceptance were associated with
daily BPD symptom expression (Path B in the mediation model) were nevertheless
carried out. In addition, because the interactive effect of weekly deviations in estradiol
and trait levels of BPD features on weekly BPD features were in some cases significant,
similar models predicting felt acceptance (in addition to full mediation testing) were be
carried out as well using averages of weekly PAI-BOR as the moderator.
Path A at the Daily Level: Does daily conception probability exert a main or
moderated effect on daily felt acceptance? Results of multilevel models regressing daily
felt acceptance on conception probability are presented in Table 9. Because the
distribution of daily felt rejection followed the inverse of a Poisson distribution (i.e., most
people reported feeling high levels of acceptance on most days) and could not be
transformed to normality using a linear transformation, Poisson models predicting
reverse-scored acceptance (i.e., rejection), were utilized; however, the signs (i.e., -/+)
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Table 8
Multilevel Poisson Regression Models Predicting Weekly BPD Symptoms from the
Interaction of Number of SCID-II Criteria Met (Trait BPD) with Average Estradiol and
Weekly Deviations in Estradiol
Parameter

Model 1
(null)

Model 4
(with moderator)

Dependent Variable: PAI-BOR Total Score
Fixed Effects
Intercept
Avg Estradiol
Weekly Deviation in Estradiol
Number of SCID-II Criteria Met
Number of SCID-II Criteria Met*Avg Estradiol
Number of SCID-II Criteria Met*Estradiol
Deviation

-.50* (.10)

-.52* (.07)
-.02 (.08)
.001 (.04)
.42* (.07)
.09 (.06)
.03 (.05)

Random Parameters
.39* (.09)
.20* (.05)

Intercept
Weekly Deviation in Estradiol
Residual

.08* (.01)

.08* (.01)

-2 Restricted Log Pseudo-likelihood
240.55
Dependent Variable: PAI-BOR Affective Instability Subscale

232.89†
Fixed Effects

Intercept
Avg Estradiol
Weekly Deviation in Estradiol
Number of SCID-II Criteria Met
Number of SCID-II Criteria Met*Avg Estradiol
Number of SCID-II Criteria Met*Estradiol
Deviation

-.60* (.15)

-.61* (.12)
-.11 (.12)
-.05 (.06)
.55* (.12)
.16 (.12)
.03 (.07)

Random Parameters
.83* (.23)
.49* (.15)

Intercept
Weekly Deviation in Estradiol
Residual
-2 Restricted Log Pseudo-likelihood
Table Continued on Next Page
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.16* (.02)

.16* (.02)

370.17

361.50†

	
  
Dependent Variable: PAI-BOR Identity Disturbance Subscale
Fixed Effects
Intercept
Avg Estradiol
Weekly Deviation in Estradiol
Number of SCID-II Criteria Met
Number of SCID-II Criteria Met*Avg Estradiol
Number of SCID-II Criteria Met*Estradiol
Deviation

-.30* (.11)

-.32 (.08)
-.03 (.08)
.001 (.05)
.48 (.08)
.08 (.06)
-.01 (.05)

Random Parameters
.45* (.11)
.20* (.06)

Intercept
Weekly Deviation in Estradiol
Residual

.12* (.01)

.12* (.01)

-2 Restricted Log Pseudo-likelihood
274.93
Dependent Variable: PAI-BOR Negative Relationships Subscale

261.14†
Fixed Effects

Intercept
Avg Estradiol
Weekly Deviation in Estradiol
Number of SCID-II Criteria Met
Number of SCID-II Criteria Met*Avg Estradiol
Number of SCID-II Criteria Met*Estradiol
Deviation

-.41* (.12)

-.29* (.09)
-.03 (.10)
.04 (.15)
.33* (.08)
.11 (.08)
.005 (.18)

Random Parameters
.53* (.14)
.37* (.11)

Intercept
Weekly Deviation in Estradiol
Residual
-2 Restricted Log Pseudo-likelihood
Dependent Variable: PAI-BOR Self-Harm Subscale

.16* (.02)

.16* (.02)

332.16

329.44†

Fixed Effects
-1.03* (.11)
-1.04* (.11)
.05 (.11)
.04 (.11)
.22* (.11)
.02 (.09)
.11 (.10)

Intercept
Avg Estradiol
Weekly Deviation in Estradiol
Number of SCID-II Criteria Met
Number of SCID-II Criteria Met*Avg Estradiol
Number of SCID-II Criteria Met*Estradiol
Deviation

Random Parameters
.35* (.12)
.35* (.12)

Intercept
Weekly Deviation in Estradiol
Residual
-2 Restricted Log Pseudo-likelihood
Table Continued on Next Page
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Dependent Variable: Borderline Symptom Checklist—23 (BSL-23)
Fixed Effects
Intercept
Avg Estradiol
Weekly Deviation in Estradiol
Number of SCID-II Criteria Met
Number of SCID-II Criteria Met*Avg Estradiol
Number of SCID-II Criteria Met*Estradiol
Deviation

2.05* (.16)

2.02* (.14)
.03 (.14)
-.11* (.05)
.62* (.14)
.09 (.11)
-.05 (.07)

Random Parameters
1.06* (.29)
.68* (.20)

Intercept
Weekly Deviation in Estradiol
Residual

2.34* (.31)

2.26* (.30)

-2 Restricted Log Pseudo-likelihood
379.72
366.35†
Dependent Variable: McLean Screening Instrument for BPD (MSI-BPD)
Fixed Effects
Intercept
.17 (.22)
.13 (.19)
Avg Estradiol
.007 (.20)
Weekly Deviation in Estradiol
-.08 (.07)
Number of SCID-II Criteria Met
.76* (.19)
Number of SCID-II Criteria Met*Avg Estradiol
.02 (.15)
Number of SCID-II Criteria Met*Estradiol
.04 (.08)
Deviation
Random Parameters
Intercept
1.80* (.54)
1.26* (.41)
Weekly Deviation in Estradiol
Residual
.68* (.09)
.70* (.09)
-2 Restricted Log Pseudo-likelihood
481.04
473.71†
Note. Standard errors are in parentheses.
*p < .05.
†Change in -2 Restricted Log Pseudo-likelihood over the previous model is significant at p < .05.
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Table 9
Multilevel Poisson Regression Models Predicting Daily Felt Acceptance from Daily
Conception Probability Values
Parameter

Model 1
(null)
Dependent Variable: Daily Felt Acceptance

Model 2
(fixed CP slope)

Intercept
Conception Probability

-.13* (.05)

Intercept
Conception Probability
Residual

-.13* (.03)

Fixed Effects
-.53* (.06)
.27 (.40)
Random Parameters
-.13* (.03)

-.17* (.009)

-.18* (.09)

Model 3
(random CP slope)
-.54* (.06)
.65 (.73)
-.14* (.03
-11.98* (4.33)
-.16* (.008)

-2 Restricted Log Pseudo652.33
603.67†
548.99†
likelihood
Note. Standard errors are in parentheses. CP = Daily Conception Probability.
*p < .05.
†Change in -2 Restricted Log Pseudo-likelihood over the previous model is significant at p < .05.
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were reversed so that the estimates presented in Table 9 reflect the prediction of daily felt
acceptance rather than felt rejection.
Results presented in Table 9 indicate that, though the fixed effect of conception
probability was not significant for daily felt acceptance, there was a significant random
effect of conception probability on daily felt acceptance. This indicates that the influence
of conception probability values on daily felt acceptance differed between individuals.
Therefore, I next carried out moderation analyses to determine whether the average of
weekly PAI-BOR total score assessments or (2) the number of SCID-II BPD criteria met
moderated the effect of conception probability. Results of those models are presented in
Table 10 and Table 11. As before, estimates from previous best-fitting models were
transposed into these tables for ease of model comparison.
Results revealed a significant interactive effect of trait BPD and conception
probability predicting daily felt acceptance in the opposite of the direction predicted.
Women with higher levels of trait BPD showed increases in daily felt acceptance when
conception probability was higher (γHIGHTRAITBPD*CP = .70, SE = .20, t(686) = 3.50, p
= .0006), while women with lower levels of trait BPD showed no association between
conception probability and felt acceptance (γLOWTRAITBPD*CP = .41, SE = .63, t(686) = .65,
p = .51). A graph depicting the interaction can be found in Figure 7. In contrast, number
of SCID-II BPD criteria met was not a significant moderator of the effect of conception
probability.
Path A at the Weekly Level: Do changes in weekly felt acceptance impact
weekly BPD symptom expression? Next, I tested the same hypothesis at the weekly level.
Results of models regressing weekly scores on the Social Evaluation subscale of the State
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Table 10
Multilevel Poisson Regression Models Predicting Daily Felt Acceptance from the
Interaction of Daily Conception Probability Values and Average of Weekly PAI-BOR
Assessments (Trait BPD)
Parameter

Model 3
(random CP slope)

Model 4
(with moderator)

Dependent Variable: Daily Felt Acceptance
Fixed Effects
Intercept
Conception Probability
Avg of Weekly PAI-BOR
Avg of Weekly PAI-BOR*CP

-.54* (.06)
.65 (.73)

-.52* (.04)
.61 (.73)
-.29* (.04)
1.02* (.10)

Random Parameters
-.14* (.03
-.05* (.01)
-11.98* (4.33)
-12.21* (.4.47)
-.16* (.008)
-.15* (.008)

Intercept
Conception Probability
Residual

-2 Restricted Log Pseudo-likelihood
548.99
517.22†
Note. Standard errors are in parentheses. CP = Daily Conception Probability.
*p < .05.
†Change in -2 Restricted Log Pseudo-likelihood over the previous model is significant at p < .05.
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Table 11
Multilevel Poisson Regression Models Predicting Daily Felt Acceptance from the
Interaction of Daily Conception Probability Values and Number of SCID-II BPD Criteria
Met (Trait BPD)
Parameter

Model 3
(random CP slope)

Model 4
(with moderator)

Dependent Variable: Daily Felt Acceptance
Fixed Effects
Intercept
Conception Probability
SCID-II BPD Criteria Met
SCID-II BPD Criteria Met*CP

.54* (.06)
-.65 (.73)

-.52* (.05)
.52 (.74)
-.20* (.05)
.61 (.70)

Random Parameters
.14* (.03
.10* (.02)
11.98* (4.33)
12.40* (4.42)
.16* (.008)
.15* (.008)

Intercept
Conception Probability
Residual

-2 Restricted Log Pseudo-likelihood
548.99
531.54†
Note. Standard errors are in parentheses. CP = Daily Conception Probability.
*p < .05.
†Change in -2 Restricted Log Pseudo-likelihood over the previous model is significant at p < .05.
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Figure 7. A graph of the interaction between trait BPD symptoms and daily conception
probability predicting daily felt acceptance.
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Self-Esteem Scale on average estradiol and weekly deviations in estradiol are presented
in Table 12. There were no significant effects of deviations in estradiol on felt acceptance.
However, there was a significant improvement in model fit with the inclusion of a
random effect of deviations in estradiol, indicating that the effect of deviations in
estradiol on felt social acceptance differed between individuals.
Therefore, I next examined whether the effect of deviations in estradiol on weekly
felt acceptance was moderated by trait BPD symptoms as measured using the average of
weekly PAI-BOR total assessments. Results of this model can be found in Table 13.
Inclusion of the moderator significantly improved model fit, and the interaction was
significant in the opposite of the predicted direction. Among women higher in trait BPD,
higher-than-usual levels of estradiol were associated with higher felt acceptance
(γHIGHTRAITBPD*ESTRADIOLDEVIATION = .21, SE = .08, t(117) = 2.71, p = .007). Among
women lower in trait BPD, higher-than-usual levels of estradiol were associated with
lower felt acceptance (γLOWTRAITBPD*ESTRADIOLDEVIATION = -.17, SE = .08, t(117) = -2.12, p
= .03). A graph depicting this interaction can be found in Figure 8.
Path B at the Daily Level: Do changes in daily felt acceptance impact daily
BPD symptom expression? Next, I tested whether average levels of and daily changes in
felt acceptance impact expression of BPD symptoms. Results of models regressing
average levels of daily felt acceptance and daily deviations from one’s own average
levels of felt acceptance on each subscale and the total score of the daily PAI-BOR are
presented in Table 14.
For each subscale and the PAI-BOR total score, model fit was significantly
improved with the addition of the felt acceptance predictors as fixed effects. Model fit
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Table 12
Multilevel Regression Models Predicting Weekly Felt Acceptance from Average Estradiol
and Weekly Deviations in Estradiol
Parameter

Model 1
(null)

Model 2
(fixed deviation slope)

Dependent Variable: Weekly Felt Acceptance (Social Evaluation subscale of the SSES)
Fixed Effects
Intercept
5.37* (.12)
5.37* (.12)
Average Estradiol
.06 (.13)
Weekly Deviations in Estradiol
.02 (.05)
Random Parameters
Intercept
.58* (.14)
.58* (.13)
Weekly Deviations in Estradiol
Residual
.18* (.02)
.18* (.02)
-2 log likelihood
292.9
292.1
Note. Standard errors are in parentheses.
*p < .05.
†Change in -2 log likelihood over the previous model is significant at p < .05.
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(random
deviation slope)
5.37* (.12)
.09 (.13)
.0002 (.05)
.58* (.14)
.001 (.09)
.18* (.02)
289.4†

	
  
Table 13
Multilevel Regression Models Predicting Weekly Felt Acceptance from the Interaction of
Average Weekly PAI-BOR Total Score with Average Estradiol and Deviations in
Estradiol
Parameter

Model 1
Model 4
(null)
(with moderator)
Dependent Variable: Weekly Felt Acceptance (Social Evaluation subscale of the SSES)
Fixed Effects
Intercept
5.37* (.12)
5.39* (.10)
Average Estradiol
.04 (.11)
Weekly Deviations in Estradiol
.03 (.05)
Avg Weekly PAI-BOR Total
-.40* (.09)
Avg PAI-BOR*Avg Estradiol
.15 (.10)
Avg PAI-BOR*Estradiol Deviation
.16* (.05)
Random Parameters
Intercept
.58* (.14)
.40* (.09)
Weekly Deviations in Estradiol
Residual
.18* (.02)
.18* (.02)
-2 log likelihood
292.9
Note. Standard errors are in parentheses.
*p < .05.
†Change in -2 log likelihood over the previous model is significant at p < .05.
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Table 14
Multilevel Poisson Regression Models Predicting Daily PAI-BOR Scores from Average
Levels of Daily Felt Acceptance and Daily Deviations in Felt Acceptance
Parameter

Model 1
(null)

Model 2
(fixed deviation slope)

Model 3
(random
deviation slope)

Dependent Variable: PAI-BOR Total Score
Intercept
Average Daily Felt Acceptance
Deviations in Felt Acceptance

-.62* (.10)

Intercept
Deviations in Felt Acceptance
Residual

.38* (.09)

Fixed Effects
.70* (.06)
-.45* (.06)
-.34* (.01)
Random Parameters
.15* (.03)

.13* (.006)

.08* (.004)

.15* (.03)
.01 (.01)
.08* (.004)

1015.14†

1009.87†

-2 Restricted Log Pseudo1348.35
likelihood
Dependent Variable: PAI-BOR Affective Instability Subscale

.70* (.06)
-.45* (.06)
-.36* (.03)

Intercept
Average Daily Felt Acceptance
Deviations in Felt Acceptance

-.68* (.12)

Intercept
Deviations in Felt Acceptance
Residual

.59* (.15)

Fixed Effects
.70* (.09)
-.49* (.06)
-.41* (.04)
Random Parameters
.31* (.08)

.33* (.01)

.01* (.01)

.31* (.08)
.01 (.01)
.25* (.01)

2048.48†

1938.95†

-2 Restricted Log Pseudo2117.42
likelihood
Dependent Variable: PAI-BOR Identity Disturbance Subscale

.78* (.09)
-.50* (.08)
-.45* (.04)

Intercept
Average Daily Felt Acceptance
Deviations in Felt Acceptance

-.55* (.10)

Intercept
Deviations in Felt Acceptance
Residual

.42* (.10)

Fixed Effects
.62* (.07)
-.47* (.06)
-.30* (.02)
Random Parameters
.17* (.04)

.17* (.009)

.13* (.007)

.17* (.04)
.01 (.02)
.13* (.007)

1521.40

1322.46†

1324.32

-2 Restricted Log Pseudolikelihood
Table Continued on Next Page
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Dependent Variable: PAI-BOR Negative Relationships Subscale
Fixed Effects
Intercept
-.48* (.10)
.55* (.07)
Average Daily Felt Acceptance
-.47* (.07)
Deviations in Felt Acceptance
-.31* (.02)
Random Parameters
Intercept
.44* (.10)
.19* (.04)
Deviations in Felt Acceptance
Residual
.22* (.01)
.18* (.009)
-2 Restricted Log Pseudo1622.09
likelihood
Dependent Variable: PAI-BOR Self-Harm Subscale

1450.27†

Intercept
Average Daily Felt Acceptance
Deviations in Felt Acceptance

-1.13* (.15)

Intercept
Deviations in Felt Acceptance
Residual

.87* (.24)

Fixed Effects
1.21* (.14)
-.38* (.13)
-.31* (.04)
Random Parameters
.74* (.21)

.34* (.01)

.32* (.01)

.55* (.07)
-.47* (.07)
-.35* (.05)
.19* (.04)
.04 (.03)
.17* (.009)
1447.83†

1.20* (.14)
-.38* (.13)
-.29* (.05)
.74* (.21)
.01 (.01)
.32* (.01)

-2 Restricted Log Pseudo2551.02
2521.59†
2520.04
likelihood
Note. Standard errors are in parentheses. CP = Daily Conception Probability.
*p < .05.
†Change in -2 Restricted Log Pseudo-likelihood over the previous model is significant at p < .05.
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Figure 8. A graph of the interaction between trait BPD symptoms and deviation in
estradiol predicting weekly felt acceptance.
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improved significantly with the addition of random effects of daily deviations in felt
acceptance in all cases except the Self-Harm subscale and the Identity Disturbance
subscale; however, the random effect of deviations in felt acceptance was not significant
for any of the subscales or the total, suggesting that the effects of changes in felt
acceptance may be relatively similar across women. Results indicate that, for each daily
PAI-BOR subscale and the total score, both average levels of daily felt acceptance and
higher-than-usual daily levels of felt acceptance were associated with lower expression of
BPD symptoms.
Path B at the Weekly Level: Do changes in weekly felt acceptance impact
weekly BPD symptom expression? Next, I tested whether average levels of and daily
changes in felt acceptance impact expression of BPD symptoms at the weekly level.
Results of models regressing average levels of weekly felt acceptance (measured using
the Social Evaluation subscale of the State Self-Esteem Scale) and weekly deviations in
felt acceptance on each subscale and the total score of the daily PAI-BOR, the BSL-23,
and the MSI-BPD are presented in Table 15. For each dependent variable, model fit was
significantly improved with the inclusion of fixed effects of average weekly levels of felt
acceptance and weekly fluctuations in felt acceptance; however, model fit was not
improved significantly with the inclusion of random effect of weekly fluctuations in felt
acceptance, suggesting once again that the impact of felt acceptance on BPD symptoms is
similar across individuals. In every case, both higher average levels of felt acceptance
and higher-than-usual weekly felt acceptance were associated with lower levels of BPD
symptoms.
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Table 15
Multilevel Poisson Regression Models Predicting Weekly BPD Symptoms from Average
Levels of Weekly Felt Acceptance and Weekly Deviations in Felt Acceptance
Parameter

Model 1
(null)

Model 2
(fixed deviation slope)

Model 3
(random
deviation slope)

Dependent Variable: PAI-BOR Total Score
Intercept
Average Weekly Felt Acceptance
Deviations in Felt Acceptance

-.50 (.10)

Intercept
Deviations in Felt Acceptance
Residual

.39* (.09)

Fixed Effects
-.51* (.08)
-.36* (.08)
-.27* (.06)
Random Parameters
.27* (.07)

.08* (.01)

.07* (.009)

.27* (.07)
.04 (.04)
.06* (.009)

220.48†

218.38

-2 Restricted Log Pseudo240.55
likelihood
Dependent Variable: PAI-BOR Affective Instability Subscale

-.51* (.08)
-.36* (.08)
-.26* (.08)

Intercept
Average Weekly Felt Acceptance
Deviations in Felt Acceptance

-.60 (.15)

Intercept
Deviations in Felt Acceptance
Residual

.83* (.23)

Fixed Effects
-.63* (.14)
-.42* (.14)
-.38* (.08)
Random Parameters
.70* (.20)

.16* (.02)

.14* (.01)

.72* (.20)
.07 (.07)
.13* (.01)

358.78†

358.85

-2 Restricted Log Pseudo370.17
likelihood
Dependent Variable: PAI-BOR Identity Disturbance Subscale

-.64* (.14)
-.42* (.14)
-.39* (.11)

Intercept
Average Weekly Felt Acceptance
Deviations in Felt Acceptance

-.30 (.11)

Intercept
Deviations in Felt Acceptance
Residual

.45* (.11)

Fixed Effects
-.31* (.09)
-.42* (.09)
-.24* (.06)
Random Parameters
.29* (.07)

.12* (.01)

.11* (.01)

.29* (.07)
.02 (.03)
.11* (.01)

-2 Restricted Log Pseudolikelihood
Table Continued on Next Page

274.93

258.58†

256.62
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Dependent Variable: PAI-BOR Negative Relationships Subscale
Intercept
Average Weekly Felt Acceptance
Deviations in Felt Acceptance

-.41* (.12)

Intercept
Deviations in Felt Acceptance
Residual

.53* (.14)

Fixed Effects
-.42* (.10)
-.42* (.10)
-.22* (.08)
Random Parameters
.36* (.10)

.16* (.02)

.16* (.02)

.36* (.11)
.001 (.10)
.16* (.02)

320.31†

322.34

-2 Restricted Log Pseudo332.16
likelihood
Dependent Variable: PAI-BOR Self-Harm Subscale
Intercept
Average Weekly Felt Acceptance
Deviations in Felt Acceptance

-1.03 (.11)

Intercept
Deviations in Felt Acceptance
Residual

.35* (.12)
.18* (.02)

Fixed Effects
-1.04* (.10)
-.19* (.06)
-.23* (.13)
Random Parameters
.33* (.11)
.18* (.02)

-2 Restricted Log Pseudo407.23
405.74†
likelihood
Dependent Variable: McLean Screening Instrument for BPD (MSI-BPD)
Fixed Effects
Intercept
.17 (.22)
.15 (.18)
Average Weekly Felt Acceptance
-.85* (.19)
Deviations in Felt Acceptance
-.30* (.10)
Random Parameters
Intercept
1.80* (.54)
1.16* (.36)
Deviations in Felt Acceptance
Residual
.68* (.09)
.67* (.09)
-2 Restricted Log Pseudo481.04
470.40†
likelihood
Dependent Variable: Borderline Symptom Checklist—23 (BSL-23)
Fixed Effects
Intercept
2.05 (.16)
1.97*
Average Weekly Felt Acceptance
-.85* (.13)
Deviations in Felt Acceptance
-.48* (.11)
Random Parameters
Intercept
1.06* (.29)
.54* (.14)
Deviations in Felt Acceptance
.15* (.08)
Residual
2.34* (.31)
1.36* (.19)

-.42* (.10)
-.42* (.12)
-.23* (.08)

-1.06* (.10)
-.18* (.06)
-.23* (.13)
.35* (.12)
.24* (.23)
.16* (.02)
406.88

.12 (.19)
-.87* (.20)
-.27* (.14)
1.22* (.38)
.12 (.11)
.61* (.08)
471.91

1.97*
-.85* (.13)
-.48* (.11)
.56* (.15)
.15* (.08)
1.35* (.19)

-2 Restricted Log Pseudo379.72
322.00†
336.62
likelihood
Note. Standard errors are in parentheses.
*p < .05.
†Change in -2 Restricted Log Pseudo-likelihood over the previous model is significant at p < .05.
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Tests of Indirect Effects. Figures 9-12 depict mediation models with felt
acceptance as the mediator. First, I used the RMediation program (Tofighi & MacKinnon,
2011) to estimate 95% confidence intervals for the indirect effects of the interaction of
trait BPD and deviations in estradiol on weekly BPD symptoms through weekly felt
acceptance. The 95% confidence intervals did not include zero for the indirect effects of
Trait BPD x Deviations in Estradiol on the total score of the PAI-BOR (95% CI: -.01 to .08), the Affective Instability subscale of the PAI-BOR (95% CI: -.03 to -.12), the
Identity Disturbance subscale of the PAI-BOR (95% CI: -.02 to -.07), or the BSL-23
(95% CI: -.03 to -.14) via weekly felt acceptance. Furthermore, when average and weekly
deviations in felt acceptance were included in the models predicting BPD symptoms from
the interaction of Trait BPD with deviations in estradiol, none of the interactive effects of
Trait BPD X Deviations in Estradiol remained significant (Predicting the PAI-BOR total
score: γTRAITBPD*ESTRADIOLDEVIATION = -.05, SE = .05, t(117) = -1.05, p = .29; Predicting
the PAI-BOR Affective Instability subscale: γTRAITBPD*ESTRADIOLDEVIATION = -.05, SE = .07,
t(117) = -.70, p = .48; Predicting the PAI-BOR Identity Disturbance subscale:
γTRAITBPD*ESTRADIOLDEVIATION = -.08, SE = .05, t(117) = -1.49, p = .13; Predicting the BSL23: γTRAITBPD*ESTRADIOLDEVIATION = -.03, SE = .05, t(117) = -.59, p = .55). These results
indicate that the interactive effects of Trait BPD and deviations in estradiol on BPD
symptom expression are partially attributable to changes in felt acceptance.
Testing Hypothesis 3b and 3c: Mediation by Impulsivity and Self-Control
It was hypothesized that increases in estradiol would be associated with greater
impulsivity and poorer self-control, that these effects would be stronger among women
high in trait BPD features, and that such effects would mediate the main or moderated
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Weekly Felt Acceptance

γ = .16*, SE = .05

Trait BPD
X
Weekly Deviation in
Estradiol

γ = -.26*, SE = .08

γ = -.10*, SE = .05
Weekly PAI-BOR Total

(γ = -.05, SE = .05)
95% CI for Indirect Effect: -.01 to -.08

Figure 9. A depiction of the indirect effect of the interactive effect of trait BPD and
weekly deviation in estradiol on weekly PAI-BOR total score via weekly felt acceptance.
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Weekly Felt Acceptance

γ = .16*, SE = .05

Trait BPD
X
Weekly Deviation in
Estradiol

γ = -.39*, SE = .11

γ = -.13*, SE = .03
Weekly PAI-BOR
Affective Instability

(γ = -.05, SE = .07)
95% CI for Indirect Effect: -.03 to -.12

Figure 10. A depiction of the indirect effect of the interactive effect of trait BPD and
weekly deviation in estradiol on weekly PAI-BOR Affective Instability scores via weekly
felt acceptance.

76

	
  

Weekly Felt Acceptance

γ = .16*, SE = .05

Trait BPD
X
Weekly Deviation in
Estradiol

γ = -.23*, SE = .07

γ = -.13*, SE = .05
Weekly PAI-BOR Identity
Disturbance

(γ = -.08, SE = .05)
95% CI for Indirect Effect: -.02 to -.07

Figure 11. A depiction of the indirect effect of the interactive effect of trait BPD and
weekly deviation in estradiol on weekly PAI-BOR Identity Disturbance scores via
weekly felt acceptance.
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X
Weekly Deviation in
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(γ = -.03, SE = .05)
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95% CI for Indirect Effect: -.03 to -.14
Figure 12. A depiction of the indirect effect of the interactive effect of trait BPD and
weekly deviation in estradiol on weekly BSL-23 scores via weekly felt acceptance.
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effects of deviations in estradiol on weekly BPD features. Previous analyses suggest that
weekly deviations in estradiol do not exert a main effect on BPD features (i.e., there is
not a significant C path in the mediation model); however, tests of whether increases in
estradiol are associated with poorer self-control and greater impulsivity (Path A in the
mediation model) and whether changes in self-control and impulsivity are associated with
weekly BPD symptom expression (Path B in the mediation model) were nevertheless
carried out. In addition, because the interactive effect of weekly deviations in estradiol
and trait levels of BPD features on weekly BPD features were in some cases significant,
similar models predicting impulsivity and self-control (in addition to full mediation
testing) will be carried out as well using averages of weekly PAI-BOR as the moderator.
Because self-control and impulsivity were measured only at the weekly level, this
hypothesis was tested only at that level.
Path A at the Weekly Level: Do changes in weekly self-control impact weekly
BPD symptom expression? First, I regressed weekly scores on self-control and
impulsivity on average estradiol and weekly deviations in estradiol are presented in Table
16. Higher-than-usual levels of estradiol were associated with higher Self-Control, lower
Negative Urgency, lower Positive Urgency, and lower Lack of Perseverance. In each case,
model fit was significantly improved with the inclusion of a random effect of deviations
in estradiol, indicating the presence of a moderator. Therefore, I next examined models
predicting self-control and aspects of impulsivity from the interaction of the average of
weekly PAI-BOR total scores and deviations in estradiol. Results of these models can be
found in Table 17. The results of Model 3 (including a random effect of deviations in
estradiol) were transferred into the table for ease of model comparison.
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Table 16
Multilevel Regression Models Predicting Weekly Self-Control and Impulsivity from
Average Estradiol and Weekly Deviations in Estradiol
Parameter

Model 1
(null)

Model 2
(fixed deviation slope)

Model 3
(random
deviation slope)

Dependent Variable: Weekly Self-Control
Intercept
Average Estradiol
Weekly Deviations in Estradiol

3.42* (.10)

Intercept
Weekly Deviations in Estradiol
Residual

.37* (.09)

Fixed Effects
3.41* (.09)
.07 (.09)
.09+ (.06)
Random Parameters
.36* (.09)

.14* (.01)

.14* (.01)

-2 log likelihood
246.7
242.6†
Dependent Variable: Weekly UPPS-P Negative Urgency (Poisson model)
Fixed Effects
Intercept
.48* (.05)
.48* (.05)
Average Estradiol
-.05 (.05)
Weekly Deviations in Estradiol
-.05* (.01)
Random Parameters
Intercept
.10* (.02)
.10* (.02)
Weekly Deviations in Estradiol
Residual
.07* (.009)
.07* (.009)
-2 log likelihood
57.05
Dependent Variable: Weekly UPPS-P Positive Urgency

55.34†

3.41* (.09)
.06 (.09)
.09* (.03)
.37* (.09)
.02+ (.01)
.13* (.01)
238.8†
.48* (.05)
-.05 (.05)
-.05* (.01)
.10* (.02)
.002* (.001)
.07* (.01)
50.24†

Intercept
Average Estradiol
Weekly Deviations in Estradiol

1.84* (.07)

Intercept
Weekly Deviations in Estradiol
Residual

.20* (.05)

Fixed Effects
1.84* (.07)
-.15* (.06)
-.10* (.02)
Random Parameters
.17* (.04)

.13* (.01)

.12* (.01)

.17* (.04)
.01 (.02)
.12* (.01)

201.70†

191.23†

-2 log likelihood
210.1
Dependent Variable: Weekly UPPS-P Lack of Premeditation

1.84* (.07)
-.14* (.06)
-.11* (.03)

Intercept
Average Estradiol
Weekly Deviations in Estradiol

1.84* (.08)

Intercept
Weekly Deviations in Estradiol
Residual

.26* (.06)

Fixed Effects
1.84* (.08)
-.08 (.08)
-.02 (.03)
Random Parameters
.26* (.06)

.14* (.01)

.14* (.01)

.28* (.07)
.001 (.10)
.14* (.01)

-2 log likelihood
Table Continued on Next Page

231.20

227.3†

220.4†
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Dependent Variable: Weekly UPPS-P Lack of Perseverance
Intercept
Average Estradiol
Weekly Deviations in Estradiol

1.85* (.08)

Intercept
Weekly Deviations in Estradiol
Residual

.23* (.06)

Fixed Effects
1.85* (.08)
-.03 (.08)
-.14* (.06)
Random Parameters
.23* (.06)

.17* (.02)

.16* (.02)

.23* (.06)
.03 (.03)
.14* (.02)

242.4†

235.10†

-2 log likelihood
250
Dependent Variable: Weekly Sensation Seeking
Intercept
Average Estradiol
Weekly Deviations in Estradiol

2.24* (.10)

Intercept
Weekly Deviations in Estradiol
Residual

.36* (.09)

Fixed Effects
2.24* (.10)
-.03 (.10)
-.07 (.07)
Random Parameters
.36* (.09)

.17* (.02)

.17* (.02)

-2 log likelihood
269
266.1†
Note. Standard errors are in parentheses.
*p < .05.
+p < .15.
†Change in -2 log likelihood over the previous model is significant at p < .05.

81

1.85* (.08)
-.04 (.07)
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Table 17
Multilevel Regression Models Predicting Weekly Self-Control and Impulsivity from the
Interaction of Average Weekly PAI-BOR Total Score with Average Estradiol and Weekly
Deviations in Estradiol
Parameter

Model 3
(random deviation slope)

Model 4
(with moderator)

Dependent Variable: Weekly Self-Control
Fixed Effects
Intercept
Average Estradiol
Weekly Deviations in Estradiol
Avg Weekly PAI-BOR Total
Avg PAI-BOR* Avg Estradiol
Avg PAI-BOR* Estradiol Deviation

3.41* (.09)
.06 (.09)
.09+ (.05)

3.43* (.06)
.06 (.05)
.09+ (.05)
-.44* (.05)
.13* (.04)
.18* (.06)

Random Parameters
.37* (.09)
.02+ (.01)
.13* (.01)

Intercept
Weekly Deviations in Estradiol
Residual
-2 log likelihood
Dependent Variable: Weekly UPPS-P Negative Urgency

239.8

.16* (.04)
.01 (.02)
.13* (.01)
202.9†

Fixed Effects
Intercept
Average Estradiol
Weekly Deviations in Estradiol
Avg Weekly PAI-BOR Total
Avg PAI-BOR* Avg Estradiol
Avg PAI-BOR* Estradiol Deviation

.48* (.05)
-.05 (.05)
-.05* (.02)

.47* (.02)
-.04+ (.02)
-.05* (.02)
.27* (.02)
-.03* (.01)
-.06* (.03)

Random Parameters
.10* (.02)
.02* (.008)
.002* (.009)
.0001 (.09)
.07* (.01)
.07* (.009)

Intercept
Weekly Deviations in Estradiol
Residual
-2 log likelihood
Dependent Variable: Weekly UPPS-P Positive Urgency

62.51

27.70†
Fixed Effects

Intercept
Average Estradiol
Weekly Deviations in Estradiol
Avg Weekly PAI-BOR Total
Avg PAI-BOR* Avg Estradiol
Avg PAI-BOR* Estradiol Deviation

1.84* (.07)
-.14* (.06)
-.11* (.03)

1.84* (.06)
-.15* (.05)
-.10* (.03)
.21* (.05)
-.03 (.03)
-.11* (.04)

Random Parameters
.17* (.04)
.13* (.03)
.001 (.10)
.0001 (.11)
.12* (.01)
.12* (.01)

Intercept
Weekly Deviations in Estradiol
Residual
-2 log likelihood
Table Continued on Next Page
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Dependent Variable: Weekly UPPS-P Lack of Premeditation
Fixed Effects
Intercept
Average Estradiol
Weekly Deviations in Estradiol
Avg Weekly PAI-BOR Total
Avg PAI-BOR* Avg Estradiol
Avg PAI-BOR* Estradiol Deviation

1.84* (.08)
-.06 (.07)
-.02 (.03)

1.83* (.07)
-.07 (.06)
-.04 (.03)
.25* (.06)
-.12* (.05)
-.09* (.04)

Random Parameters
.28* (.07)
.18* (.05)
.001 (.10)
.0001 (.10)
.14* (.01)
.13* (.01)

Intercept
Weekly Deviations in Estradiol
Residual
-2 log likelihood
Dependent Variable: Weekly Lack of Perseverance

220.4

208.1†
Fixed Effects

Intercept
Average Estradiol
Weekly Deviations in Estradiol
Avg Weekly PAI-BOR Total
Avg PAI-BOR* Avg Estradiol
Avg PAI-BOR* Estradiol Deviation

1.85* (.08)
-.04 (.07)
-.15* (.06)

1.85* (.07)
-.03 (.07)
-.16* (.04)
.23* (.07)
-.04 (.08)
-.22* (.05)

Random Parameters
.23* (.06)
.18* (.04)
.03 (.03)
.0001 (.09)
.14* (.02)
.14* (.01)

Intercept
Weekly Deviations in Estradiol
Residual
-2 log likelihood
Dependent Variable: Weekly Sensation Seeking

235.10

218.01†
Fixed Effects

Intercept
Average Estradiol
Weekly Deviations in Estradiol
Avg Weekly PAI-BOR Total
Avg PAI-BOR* Avg Estradiol
Avg PAI-BOR* Estradiol Deviation

2.24* (.10)
-.05 (.10)
-.07 (.06)

Random Parameters
.36* (.09)
.03+ (.03)
.15* (.02)

Intercept
Weekly Deviations in Estradiol
Residual

-2 log likelihood
262.1
Note. Standard errors are in parentheses.
*p < .05.
+p < .15.
†Change in -2 log likelihood over the previous model is significant at p < .05.
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In the model predicting self-control, there was a significant interaction between
trait BPD and deviations in estradiol such that higher-than-usual levels of estradiol were
associated with higher self-control among women higher (+1 standard deviation) in trait
BPD (γHIGHTRAITBPD*ESTRADIOLDEVIATION = .28, SE = .09, t(117) = 2.96, p = .003) but were
not associated with self-control among women lower (-1 standard deviation) in trait BPD
(γLOWTRAITBPD*ESTRADIOLDEVIATION = -.09, SE = .07, t(117) = -1.21, p = .23). A graph of
this interaction can be found in Figure 13. Unexpectedly, there was also a significant
interaction between trait BPD and average levels of estradiol such that higher average
levels of estradiol were associated with higher levels of self-control among women
higher in trait BPD (γHIGHTRAITBPD*ESTRADIOLDEVIATION = .19, SE = .05, t(37) = 3.34, p
= .001), but was not associated with self-control among women lower in trait BPD
(γLOWTRAITBPD*ESTRADIOLDEVIATION = -.06, SE = .07, t(37) = -.88, p = .38). A graph of this
interaction can be found in Figure 14.
In the model predicting Negative Urgency, there was a significant interaction
between trait BPD and deviations in estradiol such that higher-than-usual levels of
estradiol were associated with lower Negative Urgency among women higher in trait
BPD (γHIGHTRAITBPD*ESTRADIOLDEVIATION = -.11, SE = .04, t(117) = -2.75, p = .006) but
were not associated with Negative Urgency among women lower in trait BPD
(γLOWTRAITBPD*ESTRADIOLDEVIATION = .01, SE = .04, t(117) = .24, p = .80). A graph of this
interaction can be found in Figure 15. Once again, there was also an unexpected
interaction between trait BPD and average levels of estradiol such that higher average
levels of estradiol were associated with lower levels of Negative Urgency among women
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5

Weekly Self-Control

4
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Low Trait BPD (-1 SD)

1

High Trait BPD (+1 SD)
Very High Trait BPD (+2 SD)
0
Lower-than-usual Estradiol

Higher-than-usual Estradiol

Figure 13. A graph of the interaction between trait BPD symptoms and deviation in
estradiol predicting weekly self-control.
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Weekly Self-Control
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Low Trait BPD (-1 SD)
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Figure 14. A graph of the interaction between trait BPD symptoms and Average estradiol
predicting weekly self-control.
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Low Trait BPD (-1 SD)
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High Trait BPD (+1 SD)
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Figure 15. A graph of the interaction between trait BPD symptoms and deviation in
estradiol predicting weekly UPPS-P negative urgency.
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higher in trait BPD (γHIGHTRAITBPD*AVERAGEESTRADIOL = -.07, SE = .03, t(37) = -2.10, p
= .04) but were not associated with levels of Negative Urgency among women lower in
trait BPD (γLOWTRAITBPD* AVERAGEESTRADIOL = -.003, SE = .04, t(37) = -.09, p = .93). A
graph of this interaction can be found in Figure 16.
In the model predicting Positive Urgency, there was a significant interaction
between trait BPD and deviations in estradiol such that higher-than-usual levels of
estradiol were associated with lower weekly levels of Positive Urgency among women
higher in trait BPD (γHIGHTRAITBPD*ESTRADIOLDEVIATION = -.20, SE = .07, t(117) = -2.90, p
= .004) but were not associated with Positive Urgency among women lower in trait BPD
(γLOWTRAITBPD*ESTRADIOLDEVIATION = .01, SE = .04, t(117) = .22, p = .82). A graph of the
interaction can be found in Figure 17.
In the model predicting Lack of Perseverance, there was a significant interaction
between trait BPD and deviations in estradiol such that higher-than-usual levels of
estradiol were associated with lower weekly Lack of Perseverance among women higher
in trait BPD (γHIGHTRAITBPD*ESTRADIOLDEVIATION = -.39, SE = .06, t(117) = -6.45, p < .0001)
but was not significantly associated with Lack of Perseverance among women lower in
trait BPD (γLOWTRAITBPD*ESTRADIOLDEVIATION = .06, SE = .07, t(117) = .88, p = .38). The
interaction is depicted in Figure 18.
Finally, in the model predicting Lack of Premeditation, there was a significant
interaction between trait BPD and deviations in estradiol such that higher-than-usual
levels of estradiol were associated with lower weekly Lack of Premeditation among
women higher in trait BPD (γHIGHRAITBPD*ESTRADIOLDEVIATION = -.14, SE = .06, t(117) = 1.99, p = .04) but was not significantly associated with Lack of Premeditation among
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Figure 16. A graph of the interaction between trait BPD symptoms and average estradiol
predicting weekly UPPS-P negative urgency.
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Figure 17. A graph of the interaction between trait BPD symptoms and deviation in
estradiol predicting weekly UPPS-P positive urgency.
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Figure 18. A graph of the interaction between trait BPD symptoms and deviation in
estradiol predicting weekly UPPS-P lack of perseverance.
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women lower in trait BPD (γLOWTRAITBPD*ESTRADIOLDEVIATION = .05, SE = .05, t(117) = .96,
p = .33). See Figure 19 for a graph of the interaction. Once again, there was a significant
unexpected interaction between average levels of estradiol and trait BPD such that higher
average levels of estradiol were associated with lower Lack of Premeditation among
women with higher levels of trait BPD (γHIGHTRAITBPD*AVERAGEESTRADIOL = -.19, SE = .06,
t(37) = -2.87, p = .006) but were not associated with Lack of Premeditation among
women with lower levels of trait BPD (γLOWTRAITBPD* AVERAGEESTRADIOL = .05, SE = .10,
t(37) = .49, p = .62). See Figure 20 for a graph of this interaction.
Path B at the Weekly Level: Do changes in weekly self-control and impulsivity
impact weekly BPD symptom expression? Next, I tested whether average levels of and
weekly changes in self-control and impulsivity impact expression of BPD symptoms.
Results of models regressing BPD symptoms on average levels of and deviations in selfcontrol and UPPS-P impulsivity on BPD symptom expression are presented in Tables 1823 and discussed in the following sections.
Self-Control. In models predicting BPD symptoms from average and weekly
deviations in self-control, models including fixed effects of deviations in self-control
significantly improved model fit. However, models including random effects of
deviations in self-control did not significantly improve model fit, suggesting that the
impact of changes in self-control on BPD symptoms is similar across individuals. In each
case, both average levels of self-control and higher-than-usual levels of self-control were
associated with lower BPD symptom expression.
Negative Urgency. In models predicting BPD symptoms from average and weekly
deviations in Negative Urgency, model fit improved significantly with the inclusion of
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Figure 19. A graph of the interaction between trait BPD symptoms and deviation in
estradiol predicting weekly UPPS-P lack of premeditation.
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Figure 20. A graph of the interaction between trait BPD symptoms and average estradiol
predicting weekly UPPS-P lack of premeditation.
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Table 18
Multilevel Poisson Regression Models Predicting Weekly BPD Symptoms from Average
Levels of Weekly Self-Control and Weekly Deviations in Self-Control
Parameter

Model 1
(null)

Model 2
(fixed deviation slope)

Model 3
(random
deviation slope)

Dependent Variable: PAI-BOR Total Score
Intercept
Average Self-Control
Deviations in Self-Control

-.50 (.10)

Intercept
Deviations in Self-Control
Residual

.39* (.09)

Fixed Effects
-.51* (.07)
-.45* (.07)
-.30* (.06)
Random Parameters
.18* (.05)

.08* (.01)

.06* (.009)

.18* (.05)
.001 (.01)
.06* (.009)

202.85†

203.59

-2 Restricted Log Pseudo240.55
likelihood
Dependent Variable: PAI-BOR Affective Instability Subscale

-.52* (.07)
-.45* (.07)
-.30* (.06)

Intercept
Average Self-Control
Deviations in Self-Control

-.60 (.15)

Intercept
Deviations in Self-Control
Residual

.83* (.23)

Fixed Effects
-.62* (.11)
-.62* (.11)
-.36* (.09)
Random Parameters
.43* (.13)

.16* (.02)

.15* (.02)

.42* (.13)
.0001 (.03)
.15* (.02)

342.56†

342.24

-2 Restricted Log Pseudo370.17
likelihood
Dependent Variable: PAI-BOR Identity Disturbance Subscale

-.62* (.11)
-.62* (.11)
-.36* (.09)

Intercept
Average Self-Control
Deviations in Self-Control

-.30 (.11)

Intercept
Deviations in Self-Control
Residual

.45* (.11)

Fixed Effects
-.31* (.09)
-.40* (.09)
-.25* (.07)
Random Parameters
.29* (.07)

.12* (.01)

.11* (.01)

.29* (.07)
.02 (.03)
.10* (.01)

274.93

254.46†

254.59

-2 Restricted Log Pseudolikelihood
Table Continued on Next Page
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Dependent Variable: PAI-BOR Negative Relationships Subscale
Intercept
Average Self-Control
Deviations in Self-Control

-.41* (.12)

Intercept
Deviations in Self-Control
Residual

.53* (.14)

Fixed Effects
-.42* (.09)
-.45* (.09)
-.25* (.09)
Random Parameters
.32* (.09)

.16* (.02)

.16* (.09)

.32* (.09)
.0001 (.04)
.16* (.02)

316.38†

315.89

-2 Restricted Log Pseudo332.16
likelihood
Dependent Variable: PAI-BOR Self-Harm Subscale
Intercept
Average Self-Control
Deviations in Self-Control

-1.03* (.11)

Intercept
Deviations in Self-Control
Residual

.35* (.12)
.18* (.02)

Fixed Effects
-1.05* (.09)
-.39* (.09)
-.41* (.14)
Random Parameters
.20* (.08)
.17* (.02)

-2 Restricted Log Pseudo407.23
391.96†
likelihood
Dependent Variable: McLean Screening Instrument for BPD (MSI-BPD)
Fixed Effects
Intercept
.17 (.22)
.14 (.18)
Average Self-Control
-.85* (.18)
Deviations in Self-Control
-.40* (.11)
Random Parameters
Intercept
1.80* (.54)
1.09* (.34)
Deviations in Self-Control
Residual
.68* (.09)
.64* (.08)
-2 Restricted Log Pseudo481.04
462.90†
likelihood
Dependent Variable: Borderline Symptom Checklist—23 (BSL-23)
Fixed Effects
Intercept
2.05 (.16)
2.01* (.14)
Average Self-Control
-.63* (.14)
Deviations in Self-Control
-.40* (.08)
Random Parameters
Intercept
1.06* (.29)
.75* (.20)
Deviations in Self-Control
Residual
2.34* (.31)
1.91* (.25)

-.42* (.09)
-.45* (.10)
-.25* (.09)

-1.05* (.09)
-.39* (.09)
-.41* (.14)
.20* (.08)
.0001 (.04)
.17* (.02)
391.01

.13 (.18)
-.86* (.18)
-.45* (.11)
1.12* (.35)
.02 (.03)
.62* (.08)
462.42

2.00* (.14)
-.63* (.14)
-.41* (.08)
.75* (.20)
.009 (.03)
1.86* (.30)

-2 Restricted Log Pseudo379.72
350.31†
350.41
likelihood
Note. Standard errors are in parentheses.
*p < .05.
†Change in -2 Restricted Log Pseudo-likelihood over the previous model is significant at p < .05.
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Table 19
Multilevel Poisson Regression Models Predicting Weekly BPD Symptoms from Average
Levels of Weekly UPPS-P Negative Urgency and Weekly Deviations in UPPS-P Negative
Urgency
Parameter

Model 1
(null)

Model 2
(fixed deviation slope)

Model 3
(random
deviation slope)

Dependent Variable: PAI-BOR Total Score
Intercept
Average Negative Urgency
Deviations in Negative Urgency

-.50 (.10)

Intercept
Deviations in Negative Urgency
Residual

.39* (.09)

Fixed Effects
-.52* (.06)
.49* (.06)
.36* (.06)
Random Parameters
.13* (.03)

.08* (.01)

.06* (.008)

.13* (.03)
.03 (.02)
.05* (.007)

180.48†

172.80†

-2 Restricted Log Pseudo-likelihood
240.55
Dependent Variable: PAI-BOR Affective Instability Subscale
Intercept
Average Negative Urgency
Deviations in Negative Urgency

-.60 (.15)

Intercept
Deviations in Negative Urgency
Residual

.83* (.23)

Fixed Effects
-.63* (.10)
.64* (.10)
.51* (.09)
Random Parameters
.37* (.11)

.16* (.02)

-2 Restricted Log Pseudo-likelihood
370.17
Dependent Variable: PAI-BOR Identity Disturbance Subscale
Intercept
Average Negative Urgency
Deviations in Negative Urgency

-.30 (.11)

Intercept
Deviations in Negative Urgency
Residual

.45* (.11)

-2 Restricted Log Pseudo-likelihood
274.93
Dependent Variable: PAI-BOR Negative Relationships Subscale
Intercept
Average Negative Urgency
Deviations in Negative Urgency

-.41* (.12)

Intercept
Deviations in Negative Urgency
Residual

.53* (.14)

-2 Restricted Log Pseudo-likelihood
Table Continued on Next Page

-.65* (.10)
.65* (.10)
.58* (.12)

.13* (.01)

.40* (.12)
.09 (.07)
.12* (.01)

322.53†

322.48

Fixed Effects
-.32* (.07)
.52* (.06)
.31* (.06)
Random Parameters
.16* (.04)

.12* (.01)

-.52* (.06)
.50* (.06)
.40* (.08)

-.32* (.07)
.53* (.07)
.39* (.08)

.10* (.01)

.16* (.04)
.03 (.03)
.09* (.01)

226.11†

222.81†

Fixed Effects
-.43* (.08)
.50* (.08)
.36* (.09)
Random Parameters
.26* (.08)

-.43* (.09)
.50* (.08)
.39* (.11)

.16* (.02)

.15* (.02)

.26* (.08)
.03 (.07)
.14* (.02)

332.16

302.14†

303.40
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Dependent Variable: PAI-BOR Self-Harm Subscale
Intercept
Average Negative Urgency
Deviations in Negative Urgency

-1.03* (.11)

Intercept
Deviations in Negative Urgency
Residual

.35* (.12)
.18* (.02)

Fixed Effects
-1.04* (.09)
.29* (.09)
.20* (.10)
Random Parameters
.26* (.10)
.18* (.02)

-2 Restricted Log Pseudo-likelihood
407.23
403.45†
Dependent Variable: McLean Screening Instrument for BPD (MSI-BPD)
Fixed Effects
Intercept
.17 (.22)
.10 (.17)
Average Negative Urgency
.93* (.17)
Deviations in Negative Urgency
.59* (.10)
Random Parameters
Intercept
1.80* (.54)
1.01* (.32)
Deviations in Negative Urgency
Residual
.68* (.09)
.55* (.07)
-2 Restricted Log Pseudo-likelihood
481.04
444.98†
Dependent Variable: Borderline Symptom Checklist—23 (BSL-23)
Fixed Effects
Intercept
2.05 (.16)
2.00* (.13)
Average Negative Urgency
.70* (.13)
Deviations in Negative Urgency
.47* (.07)
Random Parameters
Intercept
1.06* (.29)
.61* (.17)
Deviations in Negative Urgency
Residual
2.34* (.31)
1.74* (.23)

-1.04* (.09)
.29* (.09)
.20* (.10)
.26* (.10)
.01 (.08)
.18* (.02)
403.59
.06* (.18)
.95* (.17)
.70* (.16)
1.11* (.35)
.24 (.20)
.48* (.16)
451
1.99* (.13)
.71* (.13)
.53* (.11)
.64* (.18)
.09+ (.06)
1.53* (.21)

-2 Restricted Log Pseudo-likelihood
379.72
332.24†
329.89†
Note. Standard errors are in parentheses. CP = Daily Conception Probability.
*p < .05.
+p < .15.
†Change in -2 Restricted Log Pseudo-likelihood over the previous model is significant at p < .05.
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Table 20
Multilevel Poisson Regression Models Predicting Weekly BPD Symptoms from Average
Levels of Weekly UPPS-P Positive Urgency and Weekly Deviations in UPPS-P Positive
Urgency
Parameter

Model 1
(null)

Model 2
(fixed deviation slope)

Model 3
(random
deviation slope)

Dependent Variable: PAI-BOR Total Score
Intercept
Average Positive Urgency
Deviations in Positive Urgency

-.50 (.10)

Intercept
Deviations in Positive Urgency
Residual

.39* (.09)

Fixed Effects
-.51* (.09)
.29* (.09)
.14* (.07)
Random Parameters
.31* (.08)

.08* (.01)

-2 Restricted Log Pseudo-likelihood
240.55
Dependent Variable: PAI-BOR Affective Instability Subscale
Intercept
Average Positive Urgency
Deviations in Positive Urgency

-.60 (.15)

Intercept
Deviations in Positive Urgency
Residual

.83* (.23)

-2 Restricted Log Pseudo-likelihood
370.17
Dependent Variable: PAI-BOR Identity Disturbance Subscale
Intercept
Average Positive Urgency
Deviations in Positive Urgency

-.30 (.11)

Intercept
Deviations in Positive Urgency
Residual

.45* (.11)

-2 Restricted Log Pseudo-likelihood
274.93
Dependent Variable: PAI-BOR Negative Relationships Subscale
-.41* (.12)

Intercept
Deviations in Positive Urgency
Residual

.53* (.14)

-2 Restricted Log Pseudo-likelihood
Table Continued on Next Page

235†

235.19
-.61* (.14)
.36* (.14)
.13 (.11)

.16* (.02)

.71* (.20)
.0001 (.08)
.16* (.02)

367.28†

367.28

Fixed Effects
-.30* (.10)
.25* (.10)
.12 (.09)
Random Parameters
.39* (.10)

.12* (.01)

Intercept
Average Positive Urgency
Deviations in Positive Urgency

.07* (.01)

.31* (.08)
.03 (.08)
.07* (.01)

Fixed Effects
-.61* (.15)
.36* (.14)
.13 (.11)
Random Parameters
.71* (.20)

.16* (.02)

-.51* (.09)
.29* (.09)
.15+ (.10)

-.31* (.10)
.25* (.10)
.15 (.11)

.12* (.01)

.40* (.10)
.11 (.13)
.11 (.01)

271.76†

273.56

Fixed Effects
-.42* (.11)
.31* (.11)
.17* (.09)
Random Parameters
.45* (.12)

-.42* (.11)
.31* (.11)
.17* (.09)

.16* (.02)

.16* (.02)

.45* (.13)
.0001 (.07)
.16* (.02)

332.16

328.31†

328.31
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Dependent Variable: PAI-BOR Self-Harm Subscale
Intercept
Average Positive Urgency
Deviations in Positive Urgency

-1.03* (.11)

Intercept
Deviations in Positive Urgency
Residual

.35* (.12)
.18* (.02)

Fixed Effects
-1.03* (.10)
.26* (.10)
.17 (.25)
Random Parameters
.27* (.10)
.18* (.02)

-2 Restricted Log Pseudo-likelihood
407.23
405.26†
Dependent Variable: McLean Screening Instrument for BPD (MSI-BPD)
Fixed Effects
Intercept
.17 (.22)
.15 (.21)
Average Positive Urgency
.54* (.21)
Deviations in Positive Urgency
.29* (.13)
Random Parameters
Intercept
1.80* (.54)
1.58* (.48)
Deviations in Positive Urgency
Residual
.68* (.09)
.67* (.09)
-2 Restricted Log Pseudo-likelihood
481.04
478.24†
Dependent Variable: Borderline Symptom Checklist—23 (BSL-23)
Fixed Effects
Intercept
2.05 (.16)
2.02* (.16)
Average Positive Urgency
.38* (.16)
Deviations in Positive Urgency
.23* (.10)
Random Parameters
Intercept
1.06* (.29)
.99* (.22)
Deviations in Positive Urgency
Residual
2.34* (.31)
2.24* (.29)

-1.05* (.10)
.26* (.10)
.20 (.19)
.29* (.11)
.25 (.29)
.17* (.02)
406.49
.15 (.21)
.54* (.21)
.29* (.12)
1.58* (.48)
.0001 (.04)
.67* (.10)
478.20
2.00* (.16)
.39* (.16)
.23 (.17)
1.05* (.28)
.39 (.22)
1.80* (.27)

-2 Restricted Log Pseudo-likelihood
379.72
354.81†
375.27
Note. Standard errors are in parentheses.
*p < .05.
+p < .15.
†Change in -2 Restricted Log Pseudo-likelihood over the previous model is significant at p < .05.
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Table 21
Multilevel Poisson Regression Models Predicting Weekly BPD Symptoms from Average
Levels of Weekly UPPS-P Lack of Premeditation and Weekly Deviations in UPPS-P Lack
of Premeditation
Parameter

Model 1
(null)

Model 2
(fixed deviation slope)

Model 3
(random
deviation slope)

Dependent Variable: PAI-BOR Total Score
Intercept
Average Lack of Premeditation
Deviations in Lack of Premeditation

-.50 (.10)

Intercept
Deviations in Lack of Premeditation
Residual

.39* (.09)

Fixed Effects
-.52* (.09)
.25* (.09)
.34* (.06)
Random Parameters
.33* (.08)

.08* (.01)

.06* (.008)

.34* (.08)
.01 (.03)
.06* (.008)

216.89†

216.50

-2 Restricted Log Pseudo-likelihood
240.55
Dependent Variable: PAI-BOR Affective Instability Subscale
Intercept
Average Lack of Premeditation
Deviations in Lack of Premeditation

-.60* (.15)

Intercept
Deviations in Lack of Premeditation
Residual

.83* (.23)

Fixed Effects
-.64* (.14)
.32* (.14)
.52* (.09)
Random Parameters
.78 (.22)

.16* (.02)

-2 Restricted Log Pseudo-likelihood
370.17
Dependent Variable: PAI-BOR Identity Disturbance Subscale
Intercept
Average Lack of Premeditation
Deviations in Lack of Premeditation

-.30 (.11)

Intercept
Deviations in Lack of Premeditation
Residual

.45* (.11)

-2 Restricted Log Pseudo-likelihood
274.93
Dependent Variable: PAI-BOR Negative Relationships Subscale

-.65* (.14)
.32* (.14)
.54* (.13)

.13* (.01)

.81* (.23)
.15 (.14)
.12* (.01)

351.33†

353.86

Fixed Effects
-.31* (.10)
.21* (.10)
.24* (.07)
Random Parameters
.41* (.10)

.12* (.01)

-.52* (.09)
.25* (.09)
.35* (.07)

-.31* (.10)
.21* (.10)
.26* (.08)

.11* (.01)

.41* (.10)
.01 (.03)
.11* (.01)

267.26†

267.11

Fixed Effects
-.42* (.11)
.22* (.11)
.29* (.09)
Random Parameters
.49* (.13)

Intercept
Average Lack of Premeditation
Deviations in Lack of Premeditation

-.41* (.12)

Intercept
Deviations in Lack of Premeditation
Residual

.53* (.14)
.16* (.02)

.15* (.02)

.15* (.01)

-2 Restricted Log Pseudo-likelihood
Table Continued on Next Page

332.16

327.50†

326.70
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Dependent Variable: PAI-BOR Self-Harm Subscale
Intercept
Average Lack of Premeditation
Deviations in Lack of Premeditation

-1.03* (.11)

Intercept
Deviations in Lack of Premeditation
Residual

.35* (.12)
.18* (.02)

Fixed Effects
-1.04* (.09)
.32* (.09)
.39* (.14)
Random Parameters
.23* (.09)
.18* (.02)

-2 Restricted Log Pseudo-likelihood
407.23
399.10†
Dependent Variable: McLean Screening Instrument for BPD (MSI-BPD)
Fixed Effects
Intercept
.17 (.22)
.14 (.22)
Average Lack of Premeditation
.42* (.21)
Deviations in Lack of Premeditation
.41* (.11)
Random Parameters
Intercept
1.80* (.54)
1.73* (.52)
Deviations in Lack of Premeditation
Residual
.68* (.09)
.63* (.08)
-2 Restricted Log Pseudo-likelihood
481.04
476.74†
Dependent Variable: Borderline Symptom Checklist—23 (BSL-23)
Fixed Effects
Intercept
2.05 (.16)
2.01* (.16)
Average Lack of Premeditation
.25* (.12)
Deviations in Lack of Premeditation
.43* (.08)
Random Parameters
Intercept
1.06* (.29)
1.08* (.29)
Deviations in Lack of Premeditation
Residual
2.34* (.31)
1.94* (.26)

-1.06* (.09)
.32* (.09)
.41* (.18)
.25* (.10)
.22 (.30)
.16* (.02)
398.67
.10 (.22)
.42 (.22)
.45* (.18)
1.83* (.55)
.30 (.26)
.57* (.09)
483.59
1.98* (.17)
.24* (.12)
.43* (.14)
1.17* (.31)
.26 (.15)
1.48* (.22)

-2 Restricted Log Pseudo-likelihood
379.72
364.74†
364.70
Note. Standard errors are in parentheses.
*p < .05.
†Change in -2 Restricted Log Pseudo-likelihood over the previous model is significant at p < .05.
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Table 22
Multilevel Poisson Regression Models Predicting Weekly BPD Symptoms from Average
Levels of Weekly UPPS-P Lack of Perseverance and Weekly Deviations in UPPS-P Lack
of Perseverance
Parameter

Model 1
(null)

Model 2
(fixed deviation slope)

Model 3
(random
deviation slope)

Dependent Variable: PAI-BOR Total Score
Intercept
Average Lack of Perseverance
Deviations in Lack of Perseverance

-.50 (.10)

Intercept
Deviations in Lack of Perseverance
Residual

.39* (.09)

Fixed Effects
-.51* (.09)
.28* (.09)
.26* (.06)
Random Parameters
.32* (.08)

.08* (.01)

.07* (.009)

.32* (.08)
.04 (.04)
.06* (.009)

226.66†

225.66

-2 Restricted Log Pseudo-likelihood
240.55
Dependent Variable: PAI-BOR Affective Instability Subscale
Intercept
Average Lack of Perseverance
Deviations in Lack of Perseverance

-.60 (.15)

Intercept
Deviations in Lack of Perseverance
Residual

.83* (.23)

Fixed Effects
-.63* (.13)
.44* (.13)
.43* (.09)
Random Parameters
.69* (.19)

.16* (.02)

-2 Restricted Log Pseudo-likelihood
370.17
Dependent Variable: PAI-BOR Identity Disturbance Subscale

-.51* (.09)
.28* (.09)
.25* (.08)

-.64* (.14)
.45* (.14)
.43* (.12)

.14* (.01)

.72* (.20)
.11 (.09)
.13* (.01)

353.09†

354.71

Fixed Effects
-.31* (.10)
.20* (.10)
.28* (.07)
Random Parameters
.42* (.10)

Intercept
Average Lack of Perseverance
Deviations in Lack of Perseverance

-.30 (.11)

-.31* (.10)
.20* (.10)
.28* (.07)

Intercept
Deviations in Lack of Perseverance
Residual

.45* (.11)
.12* (.01)

.11* (.01)

.42* (.10)
.0001 (.03)
.11* (.01)

-2 Restricted Log Pseudo-likelihood

274.93

267.37†

267.30

Dependent Variable: PAI-BOR Negative Relationships Subscale
Fixed Effects
-.42* (.11)
.23* (.11)
.21* (.10)
Random Parameters
.49* (.13)

Intercept
Average Lack of Perseverance
Deviations in Lack of Perseverance

-.41* (.12)

Intercept
Deviations in Lack of Perseverance
Residual

.53* (.14)
.16* (.02)

.16* (.02)

.49* (.14)
.03 (.07)
.15* (.02)

-2 Restricted Log Pseudo-likelihood
Table Continued on Next Page

332.16

322.42†

330.69
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Dependent Variable: PAI-BOR Self-Harm Subscale
Intercept
Average Lack of Perseverance
Deviations in Lack of Perseverance

-1.03* (.11)

Intercept
Deviations in Lack of Perseverance
Residual

.35* (.12)
.18* (.02)

Fixed Effects
-1.03* (.09)
.32* (.09)
.06 (.13)
Random Parameters
.24* (.09)
.18* (.02)

-2 Restricted Log Pseudo-likelihood
407.23
400.24†
Dependent Variable: McLean Screening Instrument for BPD (MSI-BPD)
Fixed Effects
Intercept
.17 (.22)
.13 (.21)
Average Lack of Perseverance
.50* (.21)
Deviations in Lack of Perseverance
.49* (.12)
Random Parameters
Intercept
1.80* (.54)
1.69* (.51)
Deviations in Lack of Perseverance
Residual
.68* (.09)
.64* (.08)
-2 Restricted Log Pseudo-likelihood
481.04
478.44†
Dependent Variable: Borderline Symptom Checklist—23 (BSL-23)
Fixed Effects
Intercept
2.05 (.16)
1.98* (.17)
Average Lack of Perseverance
.40* (.17)
Deviations in Lack of Perseverance
.59* (.08)
Random Parameters
Intercept
1.06* (.29)
1.09* (.29)
Deviations in Lack of Perseverance
Residual
2.34* (.31)
1.58* (.21)

-1.06* (.09)
.32* (.09)
-.03 (.21)
.27* (.10)
.52 (.36)
.15* (.02)
403.53
.13 (.21)
.51* (.21)
.46* (.14)
1.71* (.51)
.06 (.11)
.62* (.08)
479.57
1.98* (.17)
.41* (.17)
.53* (.11)
1.10* (.29)
.09 (.08)
1.45* (.21)

-2 Restricted Log Pseudo-likelihood
379.72
345.95†
345.14
Note. Standard errors are in parentheses. CP = Daily Conception Probability.
*p < .05.
†Change in -2 Restricted Log Pseudo-likelihood over the previous model is significant at p < .05.
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Table 23
Multilevel Poisson Regression Models Predicting Weekly BPD Symptoms from Average
Levels of Weekly UPPS-P Sensation Seeking and Weekly Deviations in UPPS-P
Sensation Seeking
Parameter

Model 1
(null)

Model 2
(fixed deviation slope)

Model 3
(random
deviation slope)

Dependent Variable: PAI-BOR Total Score
Intercept
Average Sensation Seeking
Deviations in Sensation Seeking

-.50 (.10)

Intercept
Deviations in Sensation Seeking
Residual

.39* (.09)

Fixed Effects
-.50* (.10)
.11 (.10)
-.03 (.06)
Random Parameters
.39* (.09)

.08* (.01)

-2 Restricted Log Pseudo-likelihood
240.55
Dependent Variable: PAI-BOR Affective Instability Subscale
Intercept
Average Sensation Seeking
Deviations in Sensation Seeking

-.60 (.15)

Intercept
Deviations in Sensation Seeking
Residual

.83* (.23)

-2 Restricted Log Pseudo-likelihood
370.17
Dependent Variable: PAI-BOR Identity Disturbance Subscale
Intercept
Average Sensation Seeking
Deviations in Sensation Seeking

-.30 (.11)

Intercept
Deviations in Sensation Seeking
Residual

.45* (.11)

-2 Restricted Log Pseudo-likelihood
274.93
Dependent Variable: PAI-BOR Negative Relationships Subscale
-.41* (.12)

Intercept
Deviations in Sensation Seeking
Residual

.53* (.14)

-2 Restricted Log Pseudo-likelihood
Table Continued on Next Page

239.37

240.15
-.62* (.15)
.06 (.15)
-.02 (.12)

.16* (.02)

.88* (.24)
.13 (.11)
.14* (.01)

369.08

370.03

Fixed Effects
-.30* (.10)
.15 (.10)
-.10 (.07)
Random Parameters
.44* (.11)

.12* (.01)

Intercept
Average Sensation Seeking
Deviations in Sensation Seeking

.08* (.01)

.39* (.09)
.04 (.04)
.07* (.01)

Fixed Effects
-.61* (.15)
.06 (.15)
-.007 (.09)
Random Parameters
.85* (.24)

.16* (.02)

-.51* (.10)
.11 (.10)
-.03 (.08)

-.31* (.10)
.15 (.10)
-.10 (.08)

.12* (.01)

.44* (.11)
.02 (.04)
.11* (.01)

274.29

273.24

Fixed Effects
-.42* (.12)
.14 (.11)
.01 (.09)
Random Parameters
.52* (.14)

-.42* (.12)
.14 (.12)
.006 (.10)

.16* (.02)

.16* (.02)

.53* (.14)
.04 (.07)
.16 (.02)

332.16

329.15

331.99

105

	
  
Dependent Variable: PAI-BOR Self-Harm Subscale
Intercept
Average Sensation Seeking
Deviations in Sensation Seeking

-1.03* (.11)

Intercept
Deviations in Sensation Seeking
Residual

.35* (.12)
.18* (.02)

Fixed Effects
-1.03* (.11)
.04 (.11)
-.01 (.14)
Random Parameters
.36* (.12)
.18* (.02)

-2 Restricted Log Pseudo-likelihood
407.23
406.88
Dependent Variable: McLean Screening Instrument for BPD (MSI-BPD)
Fixed Effects
Intercept
.17 (.22)
.14 (.21)
Average Sensation Seeking
.47* (.21)
Deviations in Sensation Seeking
-.04 (.11)
Random Parameters
Intercept
1.80* (.54)
1.67* (.50)
Deviations in Sensation Seeking
Residual
.68* (.09)
.68* (.09)
-2 Restricted Log Pseudo-likelihood
481.04
479.09†
Dependent Variable: Borderline Symptom Checklist—23 (BSL-23)
Fixed Effects
Intercept
2.05 (.16)
2.03* (.16)
Average Sensation Seeking
.25* (.12)
Deviations in Sensation Seeking
.07 (.09)
Random Parameters
Intercept
1.06* (.29)
1.03* (.28)
Deviations in Sensation Seeking
Residual
2.34* (.31)
2.32* (.32)

-1.06* (.11)
.04 (.11)
.08 (.19)
.39* (.13)
.34 (.27)
.16* (.02)
412.39
.12 (.22)
.48* (.21)
.02 (.14)
1.72* (.52)
.12 (.12)
.64* (.09)
480.16
1.99* (.17)
.27* (.12)
.10 (.14)
1.12* (.30)
.25* (.12)
1.70* (.25)

-2 Restricted Log Pseudo-likelihood
379.72
371.19†
378.42
Note. Standard errors are in parentheses.
*p < .05.
†Change in -2 Restricted Log Pseudo-likelihood over the previous model is significant at p < .05.
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fixed effects of average Negative Urgency and deviations in Negative Urgency. Further,
in the case of models predicting the PAI-BOR total score, the PAI-BOR Identity
Disturbance subscale, and the BSL-23, model fit improved further with the addition of
random effects of deviations in Negative Urgency, indicating that the impact of changes
in impulsivity on BPD symptoms may differ across individuals. In each case, both higher
average levels of Negative Urgency and higher-than-usual Negative Urgency were
associated with increased expression of BPD symptoms.
Positive Urgency. In models predicting BPD symptoms from average levels of
and weekly deviations in Positive Urgency, model fit improved significantly with the
inclusion of fixed effects of average and weekly deviations in Positive Urgency. They
were not further improved by the addition of random effects of deviations in Positive
Urgency, suggesting that the impact of fluctuations in Positive Urgency on BPD
symptoms are similar across individuals. In the models predicting the PAI-BOR total
score, the Negative Relationships subscale of the PAI-BOR, the MSI-BPD, and the BSL23, both average levels of Positive Urgency and deviations in Positive Urgency were
associated with higher expression of BPD symptoms. In the models predicting the PAIBOR Self-Harm subscale, the PAI-BOR Identity Disturbance subscale, and the PAI-BOR
Affective Instability subscale, only higher average levels of Positive Urgency were
associated with higher BPD symptom expression.
Lack of Premeditation. In models predicting BPD symptoms from average and
weekly deviations in Lack of Premeditation, model fit was improved significantly by the
inclusion of fixed effects of average and weekly deviations in Lack of Premeditation, but
was not further improved by the inclusion of the random effect of weekly deviations in
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Lack of Premeditation, indicating that the impact of changes in lack of premeditation on
BPD symptoms was similar across individuals. In each model, both higher average levels
of Lack of Premeditation and higher-than-usual Lack of Premeditation were associated
with greater BPD symptom expression.
Lack of Perseverance. In models predicting BPD symptoms from average and
weekly deviations in Lack of Perseverance, model fit was improved significantly by the
inclusion of the fixed effects of average and weekly deviations in Lack of Perseverance,
but was not further improved by the inclusion of random effects of deviations in Lack of
Perseverance, indicating that the impact of changes in Lack of Perseverance on BPD
symptoms were similar across individuals. In each case except the model predicting the
PAI-BOR Self-Harm subscale, both higher average levels of Lack of Perseverance and
higher-than-usual Lack of Perseverance were associated with greater expression of BPD
symptoms. In the model predicting the PAI-BOR Self-Harm subscale, only average
levels of Lack of Perseverance were associated with higher BPD symptom expression.
Sensation Seeking. In models predicting BPD symptoms from average and weekly
deviations in Sensation Seeking, model fit was only improved by the inclusion of fixed
effects of average Sensation Seeking and weekly deviations in Sensation Seeking in the
case of the MSI-BPD and the BSL-23, and was never further improved by the inclusion
of random effects of deviations in sensation seeking, suggesting that the impact of
changes in Sensation Seeking on BPD symptoms was similar (i.e., null) across
individuals. In both of those models, there was a significant effect of average Sensation
Seeking on BPD symptoms. There were no significant effects of weekly deviations in
Sensation Seeking on BPD symptom expression.
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Tests of Indirect Effects. Next, I once again used the RMediation program
(Tofighi & MacKinnon, 2011), to create a 95% confidence intervals for the indirect
effects of the interaction of trait BPD and deviations in estradiol on weekly BPD
symptoms through all weekly self-control and impulsivity variables that: (1) were
significantly predicted by the interaction between Trait BPD and deviations in estradiol
(e.g., Trait BPD X Deviations in estradiol predict self-control), and (2) significantly
predicted BPD symptoms (e.g., deviations in self-control predict weekly scores on the
PAI-BOR).
Self-Control. Figures 21-24 depict mediation models with self-control as the
mediator. The 95% confidence intervals did not include zero for the indirect effects of
Trait BPD x Deviations in Estradiol via self-control on the PAI-BOR total scale (95% CI:
-.01 to -.10), the Affective Instability subscale of the PAI-BOR (95% CI: -.02 to -.13), the
Identity Disturbance subscale of the PAI-BOR (95% CI: -.01 to -.09), or the BSL-23
(95% CI: -.03 to -.14) via weekly self-control. Furthermore, when average and weekly
deviations in self-control were included in the model predicting BPD from the interaction
of Trait BPD with estradiol, the interactive effects of Trait BPD X Deviations in Estradiol
were no longer significant (Predicting the PAI-BOR total score:
γTRAITBPD*ESTRADIOLDEVIATION = -.04, SE = .05, t(117) = -.86, p = .39; Predicting the PAIBOR Affective Instability subscale: γTRAITBPD*ESTRADIOLDEVIATION = -.06, SE = .08, t(117)
= -.79, p = .43; Predicting the PAI-BOR Identity Disturbance subscale:
γTRAITBPD*ESTRADIOLDEVIATION = -.07, SE = .05, t(117) = -1.33, p = .18; Predicting the BSL23: γTRAITBPD*ESTRADIOLDEVIATION = -.05, SE = .07, t(117) = -.76, p = .45). These results
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Weekly Self-Control

γ = .18*, SE = .06

Trait BPD
X
Weekly Deviation in
Estradiol

γ = -.30*, SE = .06

γ = -.10*, SE = .05
Weekly PAI-BOR Total

(γ = -.04, SE = .05)
95% CI for Indirect Effect: -.01 to -.10

Figure 21. A depiction of the indirect effect of the interactive effect of trait BPD and
weekly deviation in estradiol on weekly PAI-BOR total score via weekly self-control.
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Weekly Self-Control

γ = .18*, SE = .06

Trait BPD
X
Weekly Deviation in
Estradiol

γ = -.36*, SE = .09

γ = -.13*, SE = .03
Weekly PAI-BOR
Affective Instability

(γ = -.06, SE = .08)
95% CI for Indirect Effect: -.02 to -.13

Figure 22. A depiction of the indirect effect of the interactive effect of trait BPD and
weekly deviation in estradiol on weekly PAI-BOR Affective Instability score via weekly
self-control.

111

	
  

Weekly Self-Control

γ = .18*, SE = .06

Trait BPD
X
Weekly Deviation in
Estradiol

γ = -.27*, SE = .07

γ = -.13*, SE = .05
Weekly PAI-BOR Identity
Disturbance

(γ = -.07, SE = .05)
95% CI for Indirect Effect: -.01 to -.09

Figure 23. A depiction of the indirect effect of the interactive effect of trait BPD and
weekly deviation in estradiol on weekly PAI-BOR Identity Disturbance score via weekly
self-control.
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Weekly Self-Control

γ = .18*, SE = .06

Trait BPD
X
Weekly Deviation in
Estradiol

γ = -.41*, SE = .08

γ = -.13*, SE = .05
Weekly BSL-23

(γ = -.05, SE = .07)
95% CI for Indirect Effect: -.03 to -.14

Figure 24. A depiction of the indirect effect of the interactive effect of trait BPD and
weekly deviation in estradiol on weekly BSL-23 score via weekly self-control.
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indicate that the interactive effect of trait BPD and deviations estradiol on BPD symptom
expression is partially attributable to changes in self-control.
Negative Urgency. Figures 25-28 depict mediation models with Negative Urgency.
The 95% confidence intervals did not include zero for the indirect effects of Trait BPD x
Deviations in Estradiol via Negative Urgency on the PAI-BOR total scale (95% CI: -.01
to -.04), the Affective Instability subscale (95% CI: -.001 to -.06), the Identity
Disturbance subscale (95% CI: -.01 to -.09), or the BSL-23 (95% CI: -.004 to -.06) via
Negative Urgency. When average and weekly deviations in Negative Urgency were
included in the model predicting BPD from the interaction of Trait BPD with estradiol,
the interactive effects of Trait BPD X Deviations in Estradiol were no longer significant
(Predicting PAI-BOR total: γTRAITBPD*ESTRADIOLDEVIATION = -.03, SE = .05, t(117) = -.71, p
= .47; Predicting Affective Instability subscale: γTRAITBPD*ESTRADIOLDEVIATION = -.03, SE
= .07, t(117) = -.42, p = .67; Predicting Identity Disturbance subscale:
γTRAITBPD*ESTRADIOLDEVIATION = -.06, SE = .05, t(117) = -1.13, p = .26; Predicting BSL-23:
γTRAITBPD*ESTRADIOLDEVIATION = -.02, SE = .07, t(117) = -.42, p = .67). Thereore, the
interactive effect of trait BPD and deviations estradiol on BPD symptoms is partially
attributable to changes in Negative Urgency.
Positive Urgency. Figure 29 depicts the significant mediation model with Positive
Urgency. The 95% confidence interval did not include zero for the indirect effect of Trait
BPD x Deviation in Estradiol via Positive Urgency on BSL-23 (-.01 to -.06). When
average and weekly deviation in Positive Urgency were included in the model predicting
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Weekly Negative
Urgency

γ = -.06*, SE = .03

Trait BPD
X
Weekly Deviation in
Estradiol

γ = .40*, SE = .08

γ = -.10*, SE = .05
Weekly PAI-BOR Total

(γ = -.03, SE = .05)
95% CI for Indirect Effect: -.01 to -.04

Figure 25. A depiction of the indirect effect of the interactive effect of trait BPD and
weekly deviation in estradiol on weekly PAI-BOR total score via weekly UPPS-P
Negative Urgency.
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Weekly Negative
Urgency

γ = -.06*, SE = .03

γ = .58*, SE = .12

γ = -.13*, SE = .03

Trait BPD
X

Weekly PAI-BOR
Affective Instability

Weekly Deviation in
Estradiol

(γ = -.03, SE = .07)
95% CI for Indirect Effect: -.001 to -.06

Figure 26. A depiction of the indirect effect of the interactive effect of trait BPD and
weekly deviation in estradiol on weekly PAI-BOR Affective Instability score via weekly
UPPS-P Negative Urgency.
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Weekly Negative
Urgency

γ = -.06*, SE = .03

γ = .39*, SE = .08

γ = -.13*, SE = .05

Trait BPD
X

Weekly PAI-BOR Identity
Disturbance

Weekly Deviation in
Estradiol

(γ = -.06, SE = .07)
95% CI for Indirect Effect: -.01 to -.09

Figure 27. A depiction of the indirect effect of the interactive effect of trait BPD and
weekly deviation in estradiol on weekly PAI-BOR Identity Disturbance score via weekly
UPPS-P Negative Urgency.

117

	
  

Weekly Negative
Urgency

γ = -.06*, SE = .03

Trait BPD
X
Weekly Deviation in
Estradiol

γ = .53*, SE = .11

γ = -.13*, SE = .05
Weekly BSL-23

(γ = -.02, SE = .07)
95% CI for Indirect Effect: -.004 to -.06

Figure 28. A depiction of the indirect effect of the interactive effect of trait BPD and
weekly deviation in estradiol on weekly BSL-23 score via weekly UPPS-P Negative
Urgency.
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Weekly Positive Urgency

γ = -.11*, SE = .04

Trait BPD
X
Weekly Deviation in
Estradiol

γ = .23*, SE = .17

γ = -.13*, SE = .05
Weekly BSL-23

(γ = -.11, SE = .07)
95% CI for Indirect Effect: -.01 to -.06

Figure 29. A depiction of the indirect effect of the interactive effect of trait BPD and
weekly deviation in estradiol on weekly BSL-23 score via weekly UPPS-P Positive
Urgency.
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symptoms from the interaction of Trait BPD with estradiol, the interactive effects of Trait
BPD X Deviations in Estradiol were no longer significant for the BSL-23 only
(Predicting the BSL-23: γTRAITBPD*ESTRADIOLDEVIATION = -.11, SE = .07, t(117) = -1.53, p
= .12). These results indicate that the interactive effect of trait BPD and deviations
estradiol on expression of more extreme BPD symptoms are partially attributable to
changes in Positive Urgency.
Lack of Perseverance. Figures 30-33 depict mediation models with Lack of
Perseverance as the mediator. The 95% confidence intervals did not include zero for the
indirect effects of Trait BPD x Deviations in Estradiol via Lack of Perseverance on the
PAI-BOR total scale (95% CI: -.04 to -.10), the Affective Instability subscale of the PAIBOR (95% CI: -.04 to -.16), the Identity Disturbance subscale of the PAI-BOR (95% CI:
-.02 to -.11), or the BSL-23 (95% CI: -.07 to -.20) via Lack of Perseverance. Furthermore,
when average and weekly deviations in Lack of Perseverance were included in the model
predicting BPD from the interaction of Trait BPD with estradiol, the interactive effects of
Trait BPD X Deviations in Estradiol were no longer significant (Predicting the PAI-BOR
total score: γTRAITBPD*ESTRADIOLDEVIATION = -.03 SE = .05, t(117) = -.74, p = .45; Predicting
the PAI-BOR Affective Instability subscale: γTRAITBPD*ESTRADIOLDEVIATION = -.03, SE = .07,
t(117) = -.50, p = .61; Predicting the PAI-BOR Identity Disturbance subscale:
γTRAITBPD*ESTRADIOLDEVIATION = -.06, SE = .06, t(117) = -1.05, p = .29; Predicting the BSL23: γTRAITBPD*ESTRADIOLDEVIATION = -.01, SE = .06, t(117) = -.23, p = .82). These results
indicate that the interactive effect of trait BPD and deviations estradiol on BPD symptom
expression is partially attributable to changes in Lack of Perseverance.
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Weekly Lack of
Perseverance

γ = -.22*, SE = .05

Trait BPD
X
Weekly Deviation in
Estradiol

γ = .25*, SE = .08

γ = -.10*, SE = .05
Weekly PAI-BOR Total

(γ = -.03, SE = .05)
95% CI for Indirect Effect: -.04 to -.10

Figure 30. A depiction of the indirect effect of the interactive effect of trait BPD and
weekly deviation in estradiol on weekly PAI-BOR total score via weekly UPPS-P Lack
of Perseverance.
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Weekly Lack of
Perseverance

γ = -.22*, SE = .05

γ = .43*, SE = .12

γ = -.13*, SE = .03

Trait BPD
X

Weekly PAI-BOR
Affective Instability

Weekly Deviation in
Estradiol

(γ = -.03, SE = .07)
95% CI for Indirect Effect: -.04 to -.13

Figure 31. A depiction of the indirect effect of the interactive effect of trait BPD and
weekly deviation in estradiol on weekly PAI-BOR Affective Instability score via weekly
UPPS-P Lack of Perseverance.
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Weekly Lack of
Perseverance

γ = -.22*, SE = .05

γ = .28*, SE = .07

γ = -.13*, SE = .05

Trait BPD
X

Weekly PAI-BOR Identity
Disturbance

Weekly Deviation in
Estradiol

(γ = -.06, SE = .06)
95% CI for Indirect Effect: -.02 to -.16

Figure 32. A depiction of the indirect effect of the interactive effect of trait BPD and
weekly deviation in estradiol on weekly PAI-BOR Identity Disturbance score via weekly
UPPS-P Lack of Perseverance.
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Weekly Lack of
Perseverance

γ = -.22*, SE = .05

Trait BPD
X
Weekly Deviation in
Estradiol

γ = .53*, SE = .11

γ = -.13*, SE = .05
Weekly BSL-23

(γ = -.01, SE = .06)
95% CI for Indirect Effect: -.07 to -.20

Figure 33. A depiction of the indirect effect of the interactive effect of trait BPD and
weekly deviation in estradiol on weekly BSL-23 score via weekly UPPS-P Lack of
Perseverance.
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Lack of Premeditation. Figures 34-37 depict mediation models with Lack of
Premeditation as the mediator. The 95% confidence intervals did not include zero for the
indirect effects of Trait BPD x Deviations in Estradiol via Lack of Premeditation on the
PAI-BOR total scale (95% CI: -.004 to -.06), the Affective Instability subscale of the
PAI-BOR (95% CI: -.001 to -.06), the Identity Disturbance subscale of the PAI-BOR
(95% CI: -.01 to -.07), or the BSL-23 (95% CI: -.01 to -.07) via Lack of Premeditation.
Furthermore, when average and weekly deviations in Lack of Premeditation were
included in the model predicting BPD from the interaction of Trait BPD with estradiol,
the interactive effects of Trait BPD X Deviations in Estradiol were no longer significant
(Predicting the PAI-BOR total score: γTRAITBPD*ESTRADIOLDEVIATION = -.04, SE = .05, t(117)
= -.91, p = .36; Predicting the PAI-BOR Affective Instability subscale:
γTRAITBPD*ESTRADIOLDEVIATION = -.04, SE = .07, t(117) = -.52, p = .60; Predicting the PAIBOR Identity Disturbance subscale: γTRAITBPD*ESTRADIOLDEVIATION = -.09, SE = .05, t(117)
= -1.54, p = .12; Predicting the BSL-23: γTRAITBPD*ESTRADIOLDEVIATION = -.05, SE = .07,
t(117) = -.76, p = .44). These results indicate that the interactive effect of trait BPD and
deviations estradiol on BPD symptom expression is partially attributable to changes in
Lack of Premeditation.
Testing Alternative Moderators: Dismantling Trait BPD Moderation Effects Using
FFM Personality and Childhood Maltreatment
A final set of analyses sought to further explore the finding that “trait BPD” (as
measured using average scores on a heterogeneous measure of BPD symptoms)
moderates the effect of within-person changes in estradiol on BPD symptom expression. I
wanted to determine whether extreme levels of FFM personality domain scores (in
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Weekly Lack of
Premeditation

γ = -.09*, SE = .04

Trait BPD
X
Weekly Deviation in
Estradiol

γ = .35*, SE = .07

γ = -.10*, SE = .05
Weekly PAI-BOR Total

(γ = -.04, SE = .05)
95% CI for Indirect Effect: -.004 to -.06

Figure 34. A depiction of the indirect effect of the interactive effect of trait BPD and
weekly deviation in estradiol on weekly PAI-BOR total score via weekly UPPS-P Lack
of Premeditation.
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Weekly Lack of
Premeditation

γ = -.09*, SE = .04

γ = .54*, SE = .13

γ = -.13*, SE = .03

Trait BPD
X

Weekly PAI-BOR
Affective Instability

Weekly Deviation in
Estradiol

(γ = -.04, SE = .07)
95% CI for Indirect Effect: -.001 to -.06

Figure 35. A depiction of the indirect effect of the interactive effect of trait BPD and
weekly deviation in estradiol on weekly PAI-BOR Affective Instability score via weekly
UPPS-P Lack of Premeditation.
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Weekly Lack of
Premeditation

γ = -.09*, SE = .04

γ = .26*, SE = .08

γ = -.13*, SE = .05

Trait BPD
X

Weekly PAI-BOR Identity
Disturbance

Weekly Deviation in
Estradiol

(γ = -.09, SE = .05)
95% CI for Indirect Effect: -.01 to -.07

Figure 36. A depiction of the indirect effect of the interactive effect of trait BPD and
weekly deviation in estradiol on weekly PAI-BOR Identity Disturbance score via weekly
UPPS-P Lack of Premeditation.
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Weekly Lack of
Premeditation

γ = -.09*, SE = .04

Trait BPD
X
Weekly Deviation in
Estradiol

γ = .43*, SE = .14

γ = -.13*, SE = .05
Weekly BSL-23

(γ = -.05, SE = .07)
95% CI for Indirect Effect: -.01 to -.07

Figure 37. A depiction of the indirect effect of the interactive effect of trait BPD and
weekly deviation in estradiol on weekly BSL-23 score via weekly UPPS-P Lack of
Premeditation.
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accordance with the FFM theory of BPD) or different types of childhood maltreatment
(in accordance with the biosocial theory of BPD) would perform similarly to “trait BPD”
as moderators of the effects of weekly deviations in estradiol on BPD symptom
expression.
FFM Personality Domains as Alternative Moderators. First, I substituted each
of the domain scores (Neuroticism, Extraversion, Openness, Agreeableness, and
Conscientiousness) for Trait BPD (for original model, see Table 7). Results of these
models are presented in Tables 24-28. The null models have been transposed from Table
3 for ease of model comparison. Consistent with a FFM personality model of BPD in
which extremely high Neuroticism is a key underlying aspect of BPD, Neuroticism
exerted main effects and interacted significantly with estradiol variables to predict BPD
symptom expression. In each case except the Self-Harm subscale of the PAI-BOR, higher
levels of Neuroticism were associated with greater BPD symptoms. Additionally, there
were significant interactions between Neuroticism and average estradiol in three models.
Among women lower in Neuroticism, higher average levels of estradiol were associated
with lower levels of Affective Instability (γLOWNEUROTICISM*AVGESTRADIOL = -.31, SE = .15,
t(37) = -1.99, p = .04), Identity Disturbance (γLOWNEUROTICISM *AVGESTRADIOL = -.16, SE
= .07, t(37) = -2.28, p = .02), and the BSL-23 (γLOWNEUROTICISM *AVGESTRADIOL = -.27, SE
= .10, t(37) = -2.70, p = .01). Among women higher in Neuroticism, higher average
levels of estradiol were not significantly associated with Affective Instability
(γHIGHNEUROTICISM*AVGESTRADIOL = .08, SE = .19, t(37) = .46, p = .64) or Identity
Disturbance (γHIGHNEUROTICISM*AVGESTRADIOL = .12, SE = .14, t(37) = .85, p = .40), but
were associated with higher scores on the BSL-23 (γHIGHNEUROTICISM*AVGESTRADIOL = .29,
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Table 24
Multilevel Poisson Regression Models Predicting Weekly BPD Symptoms from the
Interaction of Neuroticism with Average Estradiol and Weekly Deviations in Estradiol
Parameter

Model 1
(null)

Model 4
(with moderator)

Dependent Variable: PAI-BOR Total Score
Fixed Effects
Intercept
Avg Estradiol
Weekly Deviation in Estradiol
Neuroticism
Neuroticism*Avg Estradiol
Neuroticism*Estradiol Deviation

-.50* (.10)

-.51* (.09)
-.02 *.09)
.01 (.05)
.31* (.09)
.06 (.08)
-.03 (.04)
Random Parameters
.39* (.09)
.29* (.08)

Intercept
Weekly Deviation in Estradiol
Residual

.08* (.01)

.08* (.01)

-2 Restricted Log Pseudo-likelihood
240.55
Dependent Variable: PAI-BOR Affective Instability Subscale

239.20
Fixed Effects

Intercept
Avg Estradiol
Weekly Deviation in Estradiol
Neuroticism
Neuroticism*Avg Estradiol
Neuroticism*Estradiol Deviation

-.60* (.15)

-.64* (.12)
-.11 (.13)
-.02 (.07)
.50* (.13)
.20* (.08)
-.05 (.07)
Random Parameters
.83* (.23)
.83* (.22)

Intercept
Weekly Deviation in Estradiol
Residual

.16* (.02)

.16* (.02)

-2 Restricted Log Pseudo-likelihood
370.17
Dependent Variable: PAI-BOR Identity Disturbance Subscale

362.00†
Fixed Effects

Intercept
Avg Estradiol
Weekly Deviation in Estradiol
Neuroticism
Neuroticism*Avg Estradiol
Neuroticism*Estradiol Deviation

-.30* (.11)

-.32* (.09)
-.02 (.10)
.04 (.05)
.32* (.10)
.14* (.04)
-.10 (.09)
Random Parameters
.45* (.11)
.32* (.08)

Intercept
Weekly Deviation in Estradiol
Residual
-2 Restricted Log Pseudo-likelihood
Table Continued on Next Page
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.12* (.01)

.12* (.01)

274.93

264.30†

	
  
Dependent Variable: PAI-BOR Negative Relationships Subscale
Fixed Effects
Intercept
Avg Estradiol
Weekly Deviation in Estradiol
Neuroticism
Neuroticism*Avg Estradiol
Neuroticism*Estradiol Deviation

-.41* (.12)

-.41* (.11)
-.04 (.11)
.006 (.06)
.38* (.11)
-.04 (.09)
.08 (.06)
Random Parameters
.53* (.14)
.42* (.12)

Intercept
Weekly Deviation in Estradiol
Residual
-2 Restricted Log Pseudo-likelihood
Dependent Variable: PAI-BOR Self-Harm Subscale

.16* (.02)

.16* (.02)

332.16

324.17†

Fixed Effects
-1.03* (.11)
-1.04* (.11)
.01 (.12)
.03 (.09)
.05 (.11)
.008 (.10)
-.05 (.09)
Random Parameters
.35* (.12)
.39* (.14)

Intercept
Avg Estradiol
Weekly Deviation in Estradiol
Neuroticism
Neuroticism*Avg Estradiol
Neuroticism*Estradiol Deviation
Intercept
Weekly Deviation in Estradiol
Residual

.18* (.02)

.18* (.03)

-2 Restricted Log Pseudo-likelihood
407.23
Dependent Variable: Borderline Symptom Checklist—23 (BSL-23)

406.69
Fixed Effects

Intercept
Avg Estradiol
Weekly Deviation in Estradiol
Neuroticism
Neuroticism*Avg Estradiol
Neuroticism*Estradiol Deviation

2.05* (.16)

2.00* (.13)
.001 (.14)
-.12 (.07)
.60* (.14)
.27* (.12)
.006 (.92)
Random Parameters
1.06* (.29)
.65* (.19)

Intercept
Weekly Deviation in Estradiol
Residual
-2 Restricted Log Pseudo-likelihood
Table Continued on Next Page
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2.34* (.31)

2.24* (.30)

379.72

369.59†

	
  
Dependent Variable: McLean Screening Instrument for BPD (MSI-BPD)
Fixed Effects
Intercept
.17 (.22)
.15 (.21)
Avg Estradiol
-.07 (.22)
Weekly Deviation in Estradiol
-.11 (.09)
Neuroticism
.61* (.22)
Neuroticism*Avg Estradiol
.05 (.18)
Neuroticism*Estradiol Deviation
.06 (.08)
Random Parameters
Intercept
1.80* (.54)
1.58* (.50)
Weekly Deviation in Estradiol
Residual
.68* (.09)
.69* (.09)
-2 Restricted Log Pseudo-likelihood
481.04
480.08
Note. Standard errors are in parentheses.
*p < .05.
†Change in -2 Restricted Log Pseudo-likelihood over the previous model is significant at p < .05.
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Table 25
Multilevel Poisson Regression Models Predicting Weekly BPD Symptoms from the
Interaction of Extraversion with Average Estradiol and Weekly Deviations in Estradiol
Parameter

Model 1
(null)

Model 4
(with moderator)

Dependent Variable: PAI-BOR Total Score
Fixed Effects
Intercept
Avg Estradiol
Weekly Deviation in Estradiol
Extraversion
Extraversion*Avg Estradiol
Extraversion*Estradiol Deviation

-.50* (.10)

-.53* (.11)
-.07 (.11)
.02 (.05)
-.06 (.11)
-.01 (.10)
.05 (.04)
Random Parameters
.39* (.09)
.40* (.10)

Intercept
Weekly Deviation in Estradiol
Residual

.08* (.01)

.08 (.01)

-2 Restricted Log Pseudo-likelihood
240.55
Dependent Variable: PAI-BOR Affective Instability Subscale

238.77
Fixed Effects

Intercept
Avg Estradiol
Weekly Deviation in Estradiol
Extraversion
Extraversion*Avg Estradiol
Extraversion*Estradiol Deviation

-.60* (.15)

-.70* (.16)
-.17 (.17)
-.01 (.07)
-.19 (.16)
-.15 (.16)
.07 (.06)
Random Parameters
.83* (.23)
.84* (.24)

Intercept
Weekly Deviation in Estradiol
Residual

.16* (.02)

.16* (.02)

-2 Restricted Log Pseudo-likelihood
370.17
Dependent Variable: PAI-BOR Identity Disturbance Subscale

368.72
Fixed Effects

Intercept
Avg Estradiol
Weekly Deviation in Estradiol
Extraversion
Extraversion*Avg Estradiol
Extraversion*Estradiol Deviation

-.30* (.11)

-.34* (.11)
-.07 (.12)
.01 (.05)
.003 (.12)
-.01 (.11)
.04 (.05)
Random Parameters
.45* (.11)
.46* (.12)

Intercept
Weekly Deviation in Estradiol
Residual
-2 Restricted Log Pseudo-likelihood
Table Continued on Next Page
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.12* (.01)

.12* (.01)

274.93

273.75

	
  
Dependent Variable: PAI-BOR Negative Relationships Subscale
Fixed Effects
Intercept
Avg Estradiol
Weekly Deviation in Estradiol
Extraversion
Extraversion*Avg Estradiol
Extraversion*Estradiol Deviation

-.41* (.12)

-.45* (.13)
-.07 (.13)
.05 (.06)
-.06 (.13)
-.01 (.13)
.04 (.06)
Random Parameters
.53* (.14)
.55* (.15)

Intercept
Weekly Deviation in Estradiol
Residual
-2 Restricted Log Pseudo-likelihood
Dependent Variable: PAI-BOR Self-Harm Subscale

.16* (.02)

.16* (.02)

332.16

331.99

Fixed Effects
-1.03* (.11)
-1.00* (.11)
-.04 (.12)
.05 (.10)
-.11 (.11)
.10 (.11)
.07 (.08)
Random Parameters
.35* (.12)
.37* (.13)

Intercept
Avg Estradiol
Weekly Deviation in Estradiol
Extraversion
Extraversion*Avg Estradiol
Extraversion*Estradiol Deviation
Intercept
Weekly Deviation in Estradiol
Residual

.18* (.02)

.18* (.02)

-2 Restricted Log Pseudo-likelihood
407.23
Dependent Variable: Borderline Symptom Checklist—23 (BSL-23)

331.11
Fixed Effects

Intercept
Avg Estradiol
Weekly Deviation in Estradiol
Extraversion
Extraversion*Avg Estradiol
Extraversion*Estradiol Deviation

2.05* (.16)

1.96* (.18)
-.04 (.19)
-.10 (.06)
-.10 (.19)
-.10 (.18)
.05 (.06)
Random Parameters
1.06* (.29)
1.15* (.32)

Intercept
Weekly Deviation in Estradiol
Residual
-2 Restricted Log Pseudo-likelihood
Table Continued on Next Page
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2.34* (.31)

2.26* (.30)

379.72

377.15

	
  
Dependent Variable: McLean Screening Instrument for BPD (MSI-BPD)
Fixed Effects
Intercept
.17 (.22)
.11 (.25)
Avg Estradiol
-.08 (.27)
Weekly Deviation in Estradiol
-.11 (.08)
Extraversion
.03 (.25)
Extraversion*Avg Estradiol
-.01 (.24)
Extraversion*Estradiol Deviation
-.07 (.07)
Random Parameters
Intercept
1.80* (.54)
2.02* (.63)
Weekly Deviation in Estradiol
Residual
.68* (.09)
.69* (.09)
-2 Restricted Log Pseudo-likelihood
481.04
480.26
Note. Standard errors are in parentheses.
*p < .05.
†Change in -2 Restricted Log Pseudo-likelihood over the previous model is significant at p < .05.
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Table 26
Multilevel Poisson Regression Models Predicting Weekly BPD Symptoms from the Interaction of
Openness to Experience with Average Estradiol and Weekly Deviations in Estradiol
Parameter

Model 1
(null)

Model 4
(with moderator)

Dependent Variable: PAI-BOR Total Score
Fixed Effects
Intercept
Avg Estradiol
Weekly Deviation in Estradiol
Openness
Openness*Avg Estradiol
Openness*Estradiol Deviation

-.50* (.10)

-.52* (.09)
-.01 (.09)
-.001 (.04)
.21* (.09)
-.23* (.10)
.04 (.04)
Random Parameters
.39* (.09)
.32* (.08)

Intercept
Weekly Deviation in Estradiol
Residual

.08* (.01)

.08* (.01)

-2 Restricted Log Pseudo-likelihood
240.55
Dependent Variable: PAI-BOR Affective Instability Subscale

236.98†
Fixed Effects

Intercept
Avg Estradiol
Weekly Deviation in Estradiol
Openness
Openness*Avg Estradiol
Openness*Estradiol Deviation

-.60* (.15)

-.64* (.14)
-.07 (.14)
-.05 (.06)
.28 (.16)
-.42* (.16)
.03 (.06)
Random Parameters
.83* (.23)
.70* (.20)

Intercept
Weekly Deviation in Estradiol
Residual

.16* (.02)

.16* (.02)

-2 Restricted Log Pseudo-likelihood
370.17
Dependent Variable: PAI-BOR Identity Disturbance Subscale

362.07†
Fixed Effects

Intercept
Avg Estradiol
Weekly Deviation in Estradiol
Openness
Openness*Avg Estradiol
Openness*Estradiol Deviation

-.30* (.11)

-.33* (.10)
-.03 (.11)
-.01 (.05)
.17 (.11)
-.21* (.11)
.02 (.04)
Random Parameters
.45* (.11)
.40* (.10)

Intercept
Weekly Deviation in Estradiol
Residual
-2 Restricted Log Pseudo-likelihood
Table Continued on Next Page
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.12* (.01)

.12* (.01)

274.93

272.63†

	
  

Dependent Variable: PAI-BOR Negative Relationships Subscale
Fixed Effects
Intercept
Avg Estradiol
Weekly Deviation in Estradiol
Openness
Openness*Avg Estradiol
Openness*Estradiol Deviation

-.41* (.12)

-.44* (.11)
-.01 (.12)
.03 (.06)
.17 (.12)
-.20 (.13)
.03 (.04)
Random Parameters
.53* (.14)
.49* (.14)

Intercept
Weekly Deviation in Estradiol
Residual
-2 Restricted Log Pseudo-likelihood
Dependent Variable: PAI-BOR Self-Harm Subscale

.16* (.02)

.17* (.02)

332.16

330.48

Fixed Effects
-1.03* (.11)
-1.04* (.11)
.06 (.12)
.01 (.09)
.18 (.12)
-.19 (.12)
.13 (.08)
Random Parameters
.35* (.12)
.38 * (.13)

Intercept
Avg Estradiol
Weekly Deviation in Estradiol
Openness
Openness*Avg Estradiol
Openness*Estradiol Deviation
Intercept
Weekly Deviation in Estradiol
Residual

.18* (.02)

.18* (.02)

-2 Restricted Log Pseudo-likelihood
407.23
Dependent Variable: Borderline Symptom Checklist—23 (BSL-23)

405.97
Fixed Effects

Intercept
Avg Estradiol
Weekly Deviation in Estradiol
Openness
Openness*Avg Estradiol
Openness*Estradiol Deviation

2.05* (.16)

2.00* (.16)
.06 (.16)
-.12 (.06)
.29 (.16)
-.53* (.18)
.03 (.05)
Random Parameters
1.06* (.29)
.90* (.25)

Intercept
Weekly Deviation in Estradiol
Residual
-2 Restricted Log Pseudo-likelihood
Table Continued on Next Page
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2.34* (.31)

2.27* (.30)

379.72

375.44†

	
  
Dependent Variable: McLean Screening Instrument for BPD (MSI-BPD)
Fixed Effects
Intercept
.17 (.22)
.12 (.21)
Avg Estradiol
.03 (.22)
Weekly Deviation in Estradiol
-.09 (.07)
Openness
.60* (.22)
Openness*Avg Estradiol
-.53* (.23)
Openness*Estradiol Deviation
.06 (.06)
Random Parameters
Intercept
1.80* (.54)
1.49* (.47)
Weekly Deviation in Estradiol
Residual
.68* (.09)
.70* (.09)
-2 Restricted Log Pseudo-likelihood
481.04
473.55†
Note. Standard errors are in parentheses.
*p < .05.
†Change in -2 Restricted Log Pseudo-likelihood over the previous model is significant at p < .05.
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Table 27
Multilevel Poisson Regression Models Predicting Weekly BPD Symptoms from the
Interaction of Agreeableness with Average Estradiol and Weekly Deviations in Estradiol
Parameter

Model 1
(null)

Model 4
(with moderator)

Dependent Variable: PAI-BOR Total Score
Fixed Effects
Intercept
Avg Estradiol
Weekly Deviation in Estradiol
Agreeableness
Agreeableness*Avg Estradiol
Agreeableness*Estradiol Deviation

-.50* (.10)

-.54* (.09)
-.05 (.09)
.02 (.05)
-.16 (.10)
-.15 (.10)
.04 (.04)
Random Parameters
.39* (.09)
.33* (.08)

Intercept
Weekly Deviation in Estradiol
Residual

.08* (.01)

.08* (.01)

-2 Restricted Log Pseudo-likelihood
240.55
Dependent Variable: PAI-BOR Affective Instability Subscale

238.22
Fixed Effects

Intercept
Avg Estradiol
Weekly Deviation in Estradiol
Agreeableness
Agreeableness*Avg Estradiol
Agreeableness*Estradiol Deviation

-.60* (.15)

-.66* (.14)
-.16 (.14)
-.02 (.07)
-.27 (.14)
-.22 (.15)
.06 (.06)
Random Parameters
.83* (.23)
.72* (.21)

Intercept
Weekly Deviation in Estradiol
Residual

.16* (.02)

.16* (.02)

-2 Restricted Log Pseudo-likelihood
370.17
Dependent Variable: PAI-BOR Identity Disturbance Subscale

368.41
Fixed Effects

Intercept
Avg Estradiol
Weekly Deviation in Estradiol
Agreeableness
Agreeableness*Avg Estradiol
Agreeableness*Estradiol Deviation

-.30* (.11)

-.34* (.10)
-.08 (.10)
.01 (.05)
-.16 (.11)
-.12 (.11)
.02 (.04)
Random Parameters
.45* (.11)
.41* (.10)

Intercept
Weekly Deviation in Estradiol
Residual
-2 Restricted Log Pseudo-likelihood
Table Continued on Next Page

140

.12* (.01)

.12* (.01)

274.93

273.36

	
  
Dependent Variable: PAI-BOR Negative Relationships Subscale
Fixed Effects
Intercept
Avg Estradiol
Weekly Deviation in Estradiol
Agreeableness
Agreeableness*Avg Estradiol
Agreeableness*Estradiol Deviation

-.41* (.12)

-.45* (.10)
-.06 (.10)
.03 (.07)
-.30* (.11)
-.16 (.11)
-.001 (.05)
Random Parameters
.53* (.14)
.39* (.11)

Intercept
Weekly Deviation in Estradiol
Residual
-2 Restricted Log Pseudo-likelihood
Dependent Variable: PAI-BOR Self-Harm Subscale

.16* (.02)

.17* (.02)

332.16

332.05

Fixed Effects
-1.03* (.11)
-1.05* (.11)
.04 (.12)
.05 (.09)
.12 (.12)
-.13 (.12)
.13 (.08)
Random Parameters
.35* (.12)
.41* (.14)

Intercept
Avg Estradiol
Weekly Deviation in Estradiol
Agreeableness
Agreeableness*Avg Estradiol
Agreeableness*Estradiol Deviation
Intercept
Weekly Deviation in Estradiol
Residual

.18* (.02)

.18* (.02)

-2 Restricted Log Pseudo-likelihood
407.23
Dependent Variable: Borderline Symptom Checklist—23 (BSL-23)

406.07
Fixed Effects

Intercept
Avg Estradiol
Weekly Deviation in Estradiol
Agreeableness
Agreeableness*Avg Estradiol
Agreeableness*Estradiol Deviation

2.05* (.16)

1.98* (.16)
-.04 (.16)
-.12 (.06)
-.27 (.16)
-.35 (.18)
-.01 (.05)
Random Parameters
1.06* (.29)
.92* (.26)

Intercept
Weekly Deviation in Estradiol
Residual
-2 Restricted Log Pseudo-likelihood
Table Continued on Next Page

141

2.34* (.31)

2.26* (.30)

379.72

378.34

	
  
Dependent Variable: McLean Screening Instrument for BPD (MSI-BPD)
Fixed Effects
Intercept
.17 (.22)
.11 (.22)
Avg Estradiol
-.10 (.22)
Weekly Deviation in Estradiol
-.09 (.08)
Agreeableness
-.29 (.22)
Agreeableness*Avg Estradiol
-.33 (.23)
Agreeableness*Estradiol Deviation
-.01 (.07)
Random Parameters
Intercept
1.80* (.54)
1.70* (.54)
Weekly Deviation in Estradiol
Residual
.68* (.09)
.70* (.09)
-2 Restricted Log Pseudo-likelihood
481.04
480.81
Note. Standard errors are in parentheses.
*p < .05.
†Change in -2 Restricted Log Pseudo-likelihood over the previous model is significant at p < .05.
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Table 28
Multilevel Poisson Regression Models Predicting Weekly BPD Symptoms from the
Interaction of Conscientiousness with Average Estradiol and Weekly Deviations in Estradiol
Parameter

Model 1
(null)

Model 4
(with moderator)

Dependent Variable: PAI-BOR Total Score
Fixed Effects
Intercept
Avg Estradiol
Weekly Deviation in Estradiol
Conscientiousness
Conscientiousness*Avg Estradiol
Conscientiousness*Estradiol Deviation

-.50* (.10)

-.53* (.10)
-.05 (.10)
.01 (.10)
-.13 (.10)
.02 (.10)
-.02 (.04)
Random Parameters
.39* (.09)
.38* (.10)

Intercept
Weekly Deviation in Estradiol
Residual

.08* (.01)

.08* (.01)

-2 Restricted Log Pseudo-likelihood
240.55
Dependent Variable: PAI-BOR Affective Instability Subscale

238.71
Fixed Effects

Intercept
Avg Estradiol
Weekly Deviation in Estradiol
Conscientiousness
Conscientiousness*Avg Estradiol
Conscientiousness*Estradiol Deviation

-.60* (.15)

-.65* (.15)
-.14 (.15)
-.05 (.06)
-.18 (.15)
.05 (.16)
-.01 (.05)
Random Parameters
.83* (.23)
.83* (.24)

Intercept
Weekly Deviation in Estradiol
Residual

.16* (.02)

.16* (.02)

-2 Restricted Log Pseudo-likelihood
370.17
Dependent Variable: PAI-BOR Identity Disturbance Subscale

368.84
Fixed Effects

Intercept
Avg Estradiol
Weekly Deviation in Estradiol
Conscientiousness
Conscientiousness*Avg Estradiol
Conscientiousness*Estradiol Deviation

-.30* (.11)

-33* (.11)
-.07 (.11)
-.01 (.05)
-.11 (.11)
.01 (.11)
.01 (.04)
Random Parameters
.45* (.11)
.44* (.11)

Intercept
Weekly Deviation in Estradiol
Residual
-2 Restricted Log Pseudo-likelihood
Table Continued on Next Page
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.12* (.01)

.12* (.01)

274.93

272.18

	
  
Dependent Variable: PAI-BOR Negative Relationships Subscale
Fixed Effects
Intercept
Avg Estradiol
Weekly Deviation in Estradiol
Conscientiousness
Conscientiousness*Avg Estradiol
Conscientiousness*Estradiol Deviation

-.41* (.12)

-.45* (.12)
-.04 (.12)
.03 (.06)
-.13 (.12)
-.01 (.12)
-.05 (.05)
Random Parameters
.53* (.14)
.53* (.15)

Intercept
Weekly Deviation in Estradiol
Residual
-2 Restricted Log Pseudo-likelihood
Dependent Variable: PAI-BOR Self-Harm Subscale

.16* (.02)

.16* (.02)

332.16

330.85

Fixed Effects
-1.03* (.11)
-1.04* (.11)
.02 (.11)
.01 (.09)
-.13 (.11)
.08 (.11)
-.10 (.08)
Random Parameters
.35* (.12)
.37* (.13)

Intercept
Avg Estradiol
Weekly Deviation in Estradiol
Conscientiousness
Conscientiousness*Avg Estradiol
Conscientiousness*Estradiol Deviation
Intercept
Weekly Deviation in Estradiol
Residual

.18* (.02)

.18* (.02)

-2 Restricted Log Pseudo-likelihood
407.23
Dependent Variable: Borderline Symptom Checklist—23 (BSL-23)

405.01
Fixed Effects

Intercept
Avg Estradiol
Weekly Deviation in Estradiol
Conscientiousness
Conscientiousness*Avg Estradiol
Conscientiousness*Estradiol Deviation

2.05* (.16)

1.98* (.33)
2.27* (.30)
-.11 (.07)
-.09 (.18)
.08 (.18)
.02 (.04)
Random Parameters
1.06* (.29)
1.15* (.33)

Intercept
Weekly Deviation in Estradiol
Residual
-2 Restricted Log Pseudo-likelihood
Table Continued on Next Page
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2.34* (.31)

2.27* (.30)

379.72

378.77

	
  
Dependent Variable: McLean Screening Instrument for BPD (MSI-BPD)
Fixed Effects
Intercept
.17 (.22)
.08 (.24)
Avg Estradiol
-.12 (.24)
Weekly Deviation in Estradiol
-.08 (.07)
Conscientiousness
-.07 (.24)
Conscientiousness*Avg Estradiol
.18 (.24)
Conscientiousness*Estradiol Deviation
-.03 (.05)
Random Parameters
Intercept
1.80* (.54)
1.98* (.62)
Weekly Deviation in Estradiol
Residual
.68* (.09)
.69* (.09)
-2 Restricted Log Pseudo-likelihood
481.04
480.64
Note. Standard errors are in parentheses.
*p < .05.
†Change in -2 Restricted Log Pseudo-likelihood over the previous model is significant at p < .05.
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SE = .10, t(37) = 2.90, p = .006). See Figures 38-40 for depictions of these interactions.
There were no significant interactions of Neuroticism with deviations in estradiol.
Also consistent with dimensional models of BPD in which high Openness to
Experience (specifically, high scores on the facets of Openness to Actions and Openness
to Feelings) are associated with higher levels of BPD, there were significant interactions
of Openness to Experience with average levels of estradiol to predicting weekly PAIBOR total score, PAI-BOR Affective Instability, PAI-BOR Identity Disturbance, the
BSL-23, and the MSI-BPD. In the model predicting the PAI-BOR Total score, among
women lower in Openness, higher average levels of estradiol were associated with higher
scores (γLOWOPENNESS *AVGESTRADIOL = .22, SE = .10, t(37) = 2.20, p = .03); among women
higher in Openness, higher average levels of estradiol were associated with lower scores
(γHIGHOPENNESS *AVGESTRADIOL = -.25, SE = .12, t(37) = -1.98, p = .05). See Figure 41 for a
graph of this interaction. In model predicting the Affective Instability subscale, among
women lower in Openness, higher average levels of estradiol were associated with higher
scores (γLOWOPENNESS *AVGESTRADIOL = .35, SE = .14, t(37) = 2.50, p = .01); among women
higher in Openness, higher average levels of estradiol were associated with lower scores
(γHIGHOPENNESS *AVGESTRADIOL = -.50, SE = .20, t(37) = -2.50, p = .01). See Figure 42 for a
graph of the interaction. In the model predicting Identity Disturbance, among women
lower in Openness, higher average levels of estradiol were not significantly associated
with higher scores (γLOWOPENNESS *AVGESTRADIOL = .17, SE = .18, t(37) = .33, p = .33);
among women higher in Openness, higher average levels of estradiol were associated
with lower scores (γHIGHOPENNESS *AVGESTRADIOL = -.25, SE = .11, t(37) = -2.10, p = .04).
This interaction is depicted in Figure 43. In the model predicting the BSL-23, among
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Weekly PAI-BOR Affective Instability

0.9
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Low Neuroticism (-1 SD)
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Figure 38. A graph of the interaction between Neuroticism and average estradiol
predicting weekly PAI-BOR Affective Instability subscale score.
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Weekly PAI-BOR Identity Disturbance
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Low Neuroticism (-1 SD)
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High Neuroticism (+1 SD)
0
Low Average Estradiol

High Average Estradiol

Figure 39. A graph of the interaction between Neuroticism and average estradiol
predicting weekly PAI-BOR Identity Disturbance subscale score.
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Weekly Borderline Symptom Checklist-23

1
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High Neuroticism (+1 SD)
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Low Average Estradiol
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Figure 40. A graph of the interaction between Neuroticism and average estradiol
predicting weekly BSL-23 score.

149

	
  
1
0.9

Weekly PAI-BOR Total
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Low Average Estradiol
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Figure 41. A graph of the interaction between Openness to Experience and average
estradiol predicting weekly PAI-BOR total score.
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Weekly PAI-BOR Affective Instability
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Figure 42. A graph of the interaction between Openness to Experience and average
estradiol predicting weekly PAI-BOR Affective Instability subscale score.
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Weekly PAI-BOR Identity Disturbance
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Figure 43. A graph of the interaction between Openness to Experience and average
estradiol predicting weekly PAI-BOR Identity Disturbance subscale score.
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women lower in Openness, higher average levels of estradiol were associated with higher
scores (γLOWOPENNESS *AVGESTRADIOL = .59, SE = .27, t(37) = 2.21, p = .03); among women
higher in Openness, higher average levels of estradiol were associated with lower scores
(γHIGHOPENNESS *AVGESTRADIOL = -.47, SE = .22, t(37) = -2.14, p = .03). See Figure 44 for a
graph of this interaction. Finally, in the model predicting number of symptoms endorsed
on the MSI-BPD, among women lower in Openness, higher average levels of estradiol
were associated with a higher number of symptoms endorsed on the MSI-BPD
(γLOWOPENNESS *AVGESTRADIOL = .51, SE = .24, t(37) = 2.12, p = .04); among women higher
in Openness, higher average levels of estradiol were associated with fewer symptoms
endorsed on the MSI-BPD (γHIGHOPENNESS *AVGESTRADIOL = -.50, SE = .21, t(37) = -2.42, p
= .02). See Figure 45 for a graph of this interaction. There were no interactions of
Openness to Experience with weekly deviations in estradiol predicting BPD symptom
expression.
In general, there were not significant main effects of or interactions of estradiol
variables with Agreeableness or Conscientiousness, the other two FFM variables
hypothesized to be abnormal in BPD. There was one exception: higher levels of
Agreeableness were associated with lower scores on the PAI-BOR Negative
Relationships subscale.
Types of Childhood Maltreatment as Alternative Moderators. Next, I substituted
each scale of the CTQ for the Trait BPD variable (again, for original model, see Table 7).
Results of models testing interactions of estradiol variables with the subscales of the CTQ
are presented in Tables 29-33. Consistent with the biosocial theory, which posits that
invalidation of a child’s desires and emotions is associated with risk for BPD, both the
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Weekly Borderline Symptom Checklist-23
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Figure 44. A graph of the interaction between Openness to Experience and average
estradiol predicting weekly PAI-BOR Affective Instability subscale score.
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Weekly Number of Items Endorsed on the
MSI-BPD
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Low Openness (-1 SD)
High Openness (+1 SD)
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Low Average Estradiol
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Figure 45. A graph of the interaction between Openness to Experience and average
estradiol predicting weekly number of items endorsed on the MSI-BPD.
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Table 29
Multilevel Poisson Regression Models Predicting Weekly BPD Symptoms from the Interaction of
the Emotional Abuse scale of the CTQ with Average Estradiol and Weekly Deviations in
Estradiol
Parameter

Model 1
(null)

Model 4
(with moderator)

Dependent Variable: PAI-BOR Total Score
Fixed Effects
Intercept
Avg Estradiol
Weekly Deviation in Estradiol
Emotional Abuse
Emotional Abuse*Avg Estradiol
Emotional Abuse*Estradiol Deviation

-.50* (.10)

-.53* (.10)
-.14 (.10)
.01 (.04)
.30* (.13)
-.05 (.12)
-.01 (.05)
Random Parameters
.39* (.09)
.33* (.08)

Intercept
Weekly Deviation in Estradiol
Residual

.08* (.01)

.08* (.01)

-2 Restricted Log Pseudo-likelihood
240.55
Dependent Variable: PAI-BOR Affective Instability Subscale

237.91
Fixed Effects

Intercept
Avg Estradiol
Weekly Deviation in Estradiol
Emotional Abuse
Emotional Abuse*Avg Estradiol
Emotional Abuse*Estradiol Deviation

-.60* (.15)

-.66* (.15)
-.28 (.15)
.04 (.06)
.44* (.19)
-.07 (.18)
.01 (.07)
Random Parameters
.83* (.23)
.69* (.20)

Intercept
Weekly Deviation in Estradiol
Residual

.16* (.02)

.17* (.02)

-2 Restricted Log Pseudo-likelihood
370.17
Dependent Variable: PAI-BOR Identity Disturbance Subscale

368.08
Fixed Effects

Intercept
Avg Estradiol
Weekly Deviation in Estradiol
Emotional Abuse
Emotional Abuse*Avg Estradiol
Emotional Abuse*Estradiol Deviation

-.30* (.11)

-.33* (.11)
-.15 (.11)
.01 (.05)
.28* (.13)
.01 (.13)
-.06 (.05)
Random Parameters
.45* (.11)
.39* (.10)

Intercept
Weekly Deviation in Estradiol
Residual
-2 Restricted Log Pseudo-likelihood
Table Continued on Next Page
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.12* (.01)

-.15 (.11)

274.93

272.34

	
  
Dependent Variable: PAI-BOR Negative Relationships Subscale
Fixed Effects
Intercept
Avg Estradiol
Weekly Deviation in Estradiol
Emotional Abuse
Emotional Abuse*Avg Estradiol
Emotional Abuse*Estradiol Deviation

-.41* (.12)

-.46* (.12)
-.15 (.12)
.03 (.06)
.30* (.14)
-.01 (.15)
-.01 (.06)
Random Parameters
.53* (.14)
.47* (.13)

Intercept
Weekly Deviation in Estradiol
Residual
-2 Restricted Log Pseudo-likelihood
Dependent Variable: PAI-BOR Self-Harm Subscale

.16* (.02)

.17* (.02)

332.16

331.30

Fixed Effects
-1.03* (.11)
-1.01* (.12)
.01 (.12)
.01 (.09)
.14 (.16)
-.10 (.15)
.03 (.11)
Random Parameters
.35* (.12)
.41* (.14)

Intercept
Avg Estradiol
Weekly Deviation in Estradiol
Emotional Abuse
Emotional Abuse*Avg Estradiol
Emotional Abuse*Estradiol Deviation
Intercept
Weekly Deviation in Estradiol
Residual

.18* (.02)

.18* (.02)

-2 Restricted Log Pseudo-likelihood
407.23
Dependent Variable: Borderline Symptom Checklist—23 (BSL-23)

406.69
Fixed Effects

Intercept
Avg Estradiol
Weekly Deviation in Estradiol
Emotional Abuse
Emotional Abuse*Avg Estradiol
Emotional Abuse*Estradiol Deviation

2.05* (.16)

1.99* (.17)
-.18 (.17)
-.12 (.06)
.54* (.21)
-.07 (.20)
-.01 (.05)
Random Parameters
1.06* (.29)
.91* (.27)

Intercept
Weekly Deviation in Estradiol
Residual
-2 Restricted Log Pseudo-likelihood
Table Continued on Next Page
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2.34* (.31)

2.27* (.30)

379.72

369.74†

	
  
Dependent Variable: McLean Screening Instrument for BPD (MSI-BPD)
Fixed Effects
Intercept
.17 (.22)
.08 (.24)
Avg Estradiol
-.26 (.24)
Weekly Deviation in Estradiol
-.06 (.07)
Emotional Abuse
.51 (.30)
Emotional Abuse*Avg Estradiol
-.02 (.29)
Emotional Abuse*Estradiol Deviation
-.07 (.08)
Random Parameters
Intercept
1.80* (.54)
1.81* (.57)
Weekly Deviation in Estradiol
Residual
.68* (.09)
.70* (.09)
-2 Restricted Log Pseudo-likelihood
481.04
478.96
Note. Standard errors are in parentheses.
*p < .05.
†Change in -2 Restricted Log Pseudo-likelihood over the previous model is significant at p < .05.
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Table 30
Multilevel Poisson Regression Models Predicting Weekly BPD Symptoms from the Interaction of
the Emotional Neglect scale of the CTQ with Average Estradiol and Weekly Deviations in
Estradiol
Parameter

Model 1
(null)

Model 4
(with moderator)

Dependent Variable: PAI-BOR Total Score
Fixed Effects
Intercept
Avg Estradiol
Weekly Deviation in Estradiol
Emotional Neglect
Emotional Neglect*Avg Estradiol
Emotional Neglect*Estradiol Deviation

-.50* (.10)

-.54* (.09)
-.07 (.09)
.01 (.04)
.25* (.09)
-.02 (.09)
-.02 (.03)
Random Parameters
.39* (.09)
.33* (.09)

Intercept
Weekly Deviation in Estradiol
Residual

.08* (.01)

.08* (.01)

-2 Restricted Log Pseudo-likelihood
240.55
Dependent Variable: PAI-BOR Affective Instability Subscale

237.74
Fixed Effects

Intercept
Avg Estradiol
Weekly Deviation in Estradiol
Emotional Neglect
Emotional Neglect*Avg Estradiol
Emotional Neglect*Estradiol Deviation

-.60* (.15)

-.67* (.14)
-.19 (.14)
-.03 (.07)
.38* (.13)
-.01 (.13)
-.01 (.05)
Random Parameters
.83* (.23)
.68* (.20)

Intercept
Weekly Deviation in Estradiol
Residual

.16* (.02)

.17* (.02)

-2 Restricted Log Pseudo-likelihood
370.17
Dependent Variable: PAI-BOR Identity Disturbance Subscale

369.20
Fixed Effects

Intercept
Avg Estradiol
Weekly Deviation in Estradiol
Emotional Neglect
Emotional Neglect*Avg Estradiol
Emotional Neglect*Estradiol Deviation

-.30* (.11)

-.33* (.10)
-.08 (.10)
.01 (.05)
.26* (.10)
-.001 (.09)
-.05 (.04)
Random Parameters
.45* (.11)
.40* (.10)

Intercept
Weekly Deviation in Estradiol
Residual
-2 Restricted Log Pseudo-likelihood
Table Continued on Next Page
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.12* (.01)

.12* (.01)

274.93

274.03

	
  
Dependent Variable: PAI-BOR Negative Relationships Subscale
Fixed Effects
Intercept
Avg Estradiol
Weekly Deviation in Estradiol
Emotional Neglect
Emotional Neglect*Avg Estradiol
Emotional Neglect*Estradiol Deviation

-.41* (.12)

-.47* (.12)
-.08 (.12)
.02 (.06)
.24* (.11)
.01 (.11)
.001 (.05)
Random Parameters
.53* (.14)
.49* (.14)

Intercept
Weekly Deviation in Estradiol
Residual
-2 Restricted Log Pseudo-likelihood
Dependent Variable: PAI-BOR Self-Harm Subscale

.16* (.02)

.17* (.02)

332.16

330.01

Fixed Effects
-1.03* (.11)
-1.03* (.11)
.03 (.12)
.01 (.09)
.12 (.11)
-.11 (.10)
-.003 (.08)
Random Parameters
.35* (.12)
.40* (.14)

Intercept
Avg Estradiol
Weekly Deviation in Estradiol
Emotional Neglect
Emotional Neglect*Avg Estradiol
Emotional Neglect*Estradiol Deviation
Intercept
Weekly Deviation in Estradiol
Residual

.18* (.02)

.18* (.02)

-2 Restricted Log Pseudo-likelihood
407.23
Dependent Variable: Borderline Symptom Checklist—23 (BSL-23)

407.13
Fixed Effects

Intercept
Avg Estradiol
Weekly Deviation in Estradiol
Emotional Neglect
Emotional Neglect*Avg Estradiol
Emotional Neglect*Estradiol Deviation

2.05* (.16)

1.98* (.26)
-.08 (.16)
-.13* (.06)
.49* (.15)
.03 (.14)
.01 (.04)
Random Parameters
1.06* (.29)
.87* (.26)

Intercept
Weekly Deviation in Estradiol
Residual
-2 Restricted Log Pseudo-likelihood
Table Continued on Next Page
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2.34* (.31)

2.27* (.31)

379.72

369.90†

	
  
Dependent Variable: McLean Screening Instrument for BPD (MSI-BPD)
Fixed Effects
Intercept
.17 (.22)
.09 (.22)
Avg Estradiol
-.13 (.23)
Weekly Deviation in Estradiol
-.08 (.08)
Emotional Neglect
.52* (.21)
Emotional Neglect*Avg Estradiol
-.05 (.20)
Emotional Neglect*Estradiol Deviation
-.003 (.05)
Random Parameters
Intercept
1.80* (.54)
1.71* (.55)
Weekly Deviation in Estradiol
Residual
.68* (.09)
.71* (.09)
-2 Restricted Log Pseudo-likelihood
481.04
478.93
Note. Standard errors are in parentheses.
*p < .05.
†Change in -2 Restricted Log Pseudo-likelihood over the previous model is significant at p < .05.
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Table 31
Multilevel Poisson Regression Models Predicting Weekly BPD Symptoms from the Interaction of
the Physical Abuse scale of the CTQ with Average Estradiol and Weekly Deviations in Estradiol
Parameter

Model 1
(null)

Model 4
(with moderator)

Dependent Variable: PAI-BOR Total Score
Fixed Effects
Intercept
Avg Estradiol
Weekly Deviation in Estradiol
Physical Abuse
Physical Abuse*Avg Estradiol
Physical Abuse*Estradiol Deviation

-.50* (.10)

-.52* (.11)
-.14 (.12)
-.001 (.04)
.26 (.24)
-.08 (.21)
.01 (.05)
Random Parameters
.39* (.09)
.38* (.10)

Intercept
Weekly Deviation in Estradiol
Residual

.08* (.01)

.08* (.01)

-2 Restricted Log Pseudo-likelihood
240.55
Dependent Variable: PAI-BOR Affective Instability Subscale

238.75
Fixed Effects

Intercept
Avg Estradiol
Weekly Deviation in Estradiol
Physical Abuse
Physical Abuse*Avg Estradiol
Physical Abuse*Estradiol Deviation

-.60* (.15)

-.62* (.16)
-.32 (.17)
-.04 (.06)
.51 (.34)
-.23 (.31)
.01 (.08)
Random Parameters
.83* (.23)
.77* (.23)

Intercept
Weekly Deviation in Estradiol
Residual

.16* (.02)

.17* (.02)

-2 Restricted Log Pseudo-likelihood
370.17
Dependent Variable: PAI-BOR Identity Disturbance Subscale

370.04
Fixed Effects

Intercept
Avg Estradiol
Weekly Deviation in Estradiol
Physical Abuse
Physical Abuse*Avg Estradiol
Physical Abuse*Estradiol Deviation

-.30* (.11)

-.36* (.12)
-.10 (.12)
.01 (.05)
.08 (.26)
.11 (.23)
-.01 (.06)
Random Parameters
.45* (.11)
.43 (11)

Intercept
Weekly Deviation in Estradiol
Residual
-2 Restricted Log Pseudo-likelihood
Table Continued on Next Page
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.12* (.01)

.12* (.01)

274.93

273.48

	
  
Dependent Variable: PAI-BOR Negative Relationships Subscale
Fixed Effects
Intercept
Avg Estradiol
Weekly Deviation in Estradiol
Physical Abuse
Physical Abuse*Avg Estradiol
Physical Abuse*Estradiol Deviation

-.41* (.12)

-.45* (.14)
-.13 (.14)
.02 (.06)
.22 (.29)
-.05 (.26)
.04 (.07)
Random Parameters
.53* (.14)
.53* (.15)

Intercept
Weekly Deviation in Estradiol
Residual
-2 Restricted Log Pseudo-likelihood
Dependent Variable: PAI-BOR Self-Harm Subscale

.16* (.02)

.17* (.02)

332.16

331.24

Fixed Effects
-1.03* (.11)

Intercept
Avg Estradiol
Weekly Deviation in Estradiol
Physical Abuse
Physical Abuse*Avg Estradiol
Physical Abuse*Estradiol Deviation

-.97* (.13)
-.04 (.13)
.01 (.09)
.30 (.27)
-.27 (.24)
-.01 (.13)
Random Parameters
.35* (.12)
.40* (.14)

Intercept
Weekly Deviation in Estradiol
Residual

.18* (.02)

.18* (.02)

-2 Restricted Log Pseudo-likelihood
407.23
Dependent Variable: Borderline Symptom Checklist—23 (BSL-23)

405.73
Fixed Effects

Intercept
Avg Estradiol
Weekly Deviation in Estradiol
Physical Abuse
Physical Abuse*Avg Estradiol
Physical Abuse*Estradiol Deviation

2.05* (.16)

1.97* (.19)
-.18 (.19)
-.14 (.06)
.41 (.40)
-.01 (.35)
.04 (.06)
Random Parameters
1.06* (.29)
1.03* (.30)

Intercept
Weekly Deviation in Estradiol
Residual
-2 Restricted Log Pseudo-likelihood
Table Continued on Next Page
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2.34* (.31)

2.26* (.30)

379.72

376.69

	
  
Dependent Variable: McLean Screening Instrument for BPD (MSI-BPD)
Fixed Effects
Intercept
.17 (.22)
.17 (.26)
Avg Estradiol
-.32 (.27)
Weekly Deviation in Estradiol
-.07 (.07)
Physical Abuse
.77 (.54)
Physical Abuse*Avg Estradiol
-.39 (.48)
Physical Abuse*Estradiol Deviation
-.02 (.09)
Random Parameters
Intercept
1.80* (.54)
1.89* (.60)
Weekly Deviation in Estradiol
Residual
.68* (.09)
.71* (.09)
-2 Restricted Log Pseudo-likelihood
481.04
479.47
Note. Standard errors are in parentheses.
*p < .05.
†Change in -2 Restricted Log Pseudo-likelihood over the previous model is significant at p < .05.
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Table 32
Multilevel Poisson Regression Models Predicting Weekly BPD Symptoms from the Interaction of
the Physical Neglect scale of the CTQ with Average Estradiol and Weekly Deviations in Estradiol
Parameter

Model 1
(null)

Model 4
(with moderator)

Dependent Variable: PAI-BOR Total Score
Fixed Effects
Intercept
Avg Estradiol
Weekly Deviation in Estradiol
Physical Neglect
Physical Neglect*Avg Estradiol
Physical Neglect*Estradiol Deviation

-.50* (.10)

-.54* (.10)
-.10 (.10)
.01 (.04)
.19 (.13)
.001 (.13)
-.04 (.04)
Random Parameters
.39* (.09)
.37* (.09)

Intercept
Weekly Deviation in Estradiol
Residual

.08* (.01)

.08* (.01)

-2 Restricted Log Pseudo-likelihood
240.55
Dependent Variable: PAI-BOR Affective Instability Subscale

237.25
Fixed Effects

Intercept
Avg Estradiol
Weekly Deviation in Estradiol
Physical Neglect
Physical Neglect*Avg Estradiol
Physical Neglect*Estradiol Deviation

-.60* (.15)

-.67* (.15)
-.24 (.15)
-.02 (.07)
.34 (.19)
-.05 (.19)
-.06 (.06)
Random Parameters
.83* (.23)
.75* (.22)

Intercept
Weekly Deviation in Estradiol
Residual

.16* (.02)

.16* (.02)

-2 Restricted Log Pseudo-likelihood
370.17
Dependent Variable: PAI-BOR Identity Disturbance Subscale

370.10
Fixed Effects

Intercept
Avg Estradiol
Weekly Deviation in Estradiol
Physical Neglect
Physical Neglect*Avg Estradiol
Physical Neglect*Estradiol Deviation

-.30* (.11)

-.34* (.11)
-.10 (.11)
.01 (.05)
.17 (.14)
.07 (.14)
-.09 (.05)
Random Parameters
.45* (.11)
.42* (.11)

Intercept
Weekly Deviation in Estradiol
Residual
-2 Restricted Log Pseudo-likelihood
Table Continued on Next Page
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.12* (.01)

.12* (.01)

274.93

272.54

	
  
Dependent Variable: PAI-BOR Negative Relationships Subscale
Fixed Effects
Intercept
Avg Estradiol
Weekly Deviation in Estradiol
Physical Neglect
Physical Neglect*Avg Estradiol
Physical Neglect*Estradiol Deviation

-.41* (.12)

-.47* (.12)
-.10 (.12)
.02 (.06)
.20 (.16)
-.01 (.16)
.03 (.05)
Random Parameters
.53* (.14)
.52* (.15)

Intercept
Weekly Deviation in Estradiol
Residual
-2 Restricted Log Pseudo-likelihood
Dependent Variable: PAI-BOR Self-Harm Subscale

.16* (.02)

.17* (.02)

332.16

331.18

Fixed Effects
-1.03* (.11)
-1.04* (.12)
.01 (.12)
.01 (.09)
.04 (.16)
-.01 (.16)
-.001 (.10)
Random Parameters
.35* (.12)
.42* (.15)

Intercept
Avg Estradiol
Weekly Deviation in Estradiol
Physical Neglect
Physical Neglect*Avg Estradiol
Physical Neglect*Estradiol Deviation
Intercept
Weekly Deviation in Estradiol
Residual

.18* (.02)

.18* (.02)

-2 Restricted Log Pseudo-likelihood
407.23
Dependent Variable: Borderline Symptom Checklist—23 (BSL-23)

406.48
Fixed Effects

Intercept
Avg Estradiol
Weekly Deviation in Estradiol
Physical Neglect
Physical Neglect*Avg Estradiol
Physical Neglect*Estradiol Deviation

2.05* (.16)

1.97* (.17)
-.12 (.17)
-.12 (.07)
.37 (.22)
.03 (.22)
-.01 (.04)
Random Parameters
1.06* (.29)
1.01* (.17)

Intercept
Weekly Deviation in Estradiol
Residual
-2 Restricted Log Pseudo-likelihood
Table Continued on Next Page
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2.34* (.31)

2.26* (.30)

379.72

377.11

	
  
Dependent Variable: McLean Screening Instrument for BPD (MSI-BPD)
Fixed Effects
Intercept
.17 (.22)
.09 (.23)
Avg Estradiol
-.19 (.24)
Weekly Deviation in Estradiol
-.08 (.08)
Physical Neglect
.45 (.31)
Physical Neglect*Avg Estradiol
-.10 (.31)
Physical Neglect*Estradiol Deviation
.002 (.06)
Random Parameters
Intercept
1.80* (.54)
1.87* (.60)
Weekly Deviation in Estradiol
Residual
.68* (.09)
.71* (.09)
-2 Restricted Log Pseudo-likelihood
481.04
480.60
Note. Standard errors are in parentheses.
*p < .05.
†Change in -2 Restricted Log Pseudo-likelihood over the previous model is significant at p < .05.
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Table 33
Multilevel Poisson Regression Models Predicting Weekly BPD Symptoms from the Interaction of
the Sexual Abuse scale of the CTQ with Average Estradiol and Weekly Deviations in Estradiol
Parameter

Model 1
(null)

Model 4
(with moderator)

Dependent Variable: PAI-BOR Total Score
Fixed Effects
Intercept
Avg Estradiol
Weekly Deviation in Estradiol
Sexual Abuse
Sexual Abuse*Avg Estradiol
Sexual Abuse*Estradiol Deviation

-.50* (.10)

-.55* (.10)
-.09(.10)
-.01 (.04)
.09 (.10)
.12 (.08)
-.15* (.06)
Random Parameters
.39* (.09)
.37* (.10)

Intercept
Weekly Deviation in Estradiol
Residual

.08* (.01)

.08* (.01)

-2 Restricted Log Pseudo-likelihood
240.55
Dependent Variable: PAI-BOR Affective Instability Subscale

234.20†
Fixed Effects

Intercept
Avg Estradiol
Weekly Deviation in Estradiol
Sexual Abuse
Sexual Abuse*Avg Estradiol
Sexual Abuse*Estradiol Deviation

-.60* (.15)

-.69* (.15)
-.21 (.15)
-.07 (.06)
.16 (.15)
.12 (.12)
-.21* (.09)
Random Parameters
.83* (.23)
.83* (.23

Intercept
Weekly Deviation in Estradiol
Residual

.16* (.02)

.16* (.02)

-2 Restricted Log Pseudo-likelihood
370.17
Dependent Variable: PAI-BOR Identity Disturbance Subscale

360.97†
Fixed Effects

Intercept
Avg Estradiol
Weekly Deviation in Estradiol
Sexual Abuse
Sexual Abuse*Avg Estradiol
Sexual Abuse*Estradiol Deviation

-.30* (.11)

-.34* (.10)
-.10 (.11)
-.02 (.05)
.11 (.10)
.16 (.09)
-.24* (.07)
Random Parameters
.45* (.11)
.41* (.11)

Intercept
Weekly Deviation in Estradiol
Residual
-2 Restricted Log Pseudo-likelihood
Table Continued on Next Page
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.12* (.01)

.11* (.01)

274.93

267.30†

	
  
Dependent Variable: PAI-BOR Negative Relationships Subscale
Fixed Effects
Intercept
Avg Estradiol
Weekly Deviation in Estradiol
Sexual Abuse
Sexual Abuse*Avg Estradiol
Sexual Abuse*Estradiol Deviation

-.41* (.12)

-.47* (.12)
-.09 (.12)
.02 (.06)
.13 (.12)
.10 (.10)
-.01 (.09)
Random Parameters
.53* (.14)
.52* (.15)

Intercept
Weekly Deviation in Estradiol
Residual
-2 Restricted Log Pseudo-likelihood
Dependent Variable: PAI-BOR Self-Harm Subscale

.16* (.02)

.17* (.02)

332.16

327.22†
Fixed Effects

Intercept
Avg Estradiol
Weekly Deviation in Estradiol
Sexual Abuse
Sexual Abuse*Avg Estradiol
Sexual Abuse*Estradiol Deviation

-1.03* (.11)

-1.06* (.11)
.04 (.11)
-.004 (.10)
-.21 (.15)
.25* (.10)
-.09 (.17)
Random Parameters
.35* (.12)
.35* (.12)

Intercept
Weekly Deviation in Estradiol
Residual

.18* (.02)

.18* (.02)

-2 Restricted Log Pseudo-likelihood
407.23
Dependent Variable: Borderline Symptom Checklist—23 (BSL-23)

404.35†
Fixed Effects

Intercept
Avg Estradiol
Weekly Deviation in Estradiol
Sexual Abuse
Sexual Abuse*Avg Estradiol
Sexual Abuse*Estradiol Deviation

2.05* (.16)

1.96* (.17)
-.10 (.17)
-.14 (.06)
.14 (.17)
.29* (.14)
-.15* (.07)
Random Parameters
1.06* (.29)
.65* (.19)

Intercept
Weekly Deviation in Estradiol
Residual
-2 Restricted Log Pseudo-likelihood
Table Continued on Next Page
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2.34* (.31)

2.24* (.30)

379.72

369.64†

	
  
Dependent Variable: McLean Screening Instrument for BPD (MSI-BPD)
Fixed Effects
Intercept
Avg Estradiol
Weekly Deviation in Estradiol
Sexual Abuse
Sexual Abuse*Avg Estradiol
Sexual Abuse*Estradiol Deviation

.17 (.22)

.07 (.23)
-.15 (.23)
-.10 (.07)
.03 (.23)
.33 (.20)
-.13 (.12)
Random Parameters
1.80* (.54)
1.81* (.59)

Intercept
Weekly Deviation in Estradiol
Residual

.68* (.09)

.71* (.09)

-2 Restricted Log Pseudo-likelihood
481.04
478.51†
Note. Standard errors are in parentheses.
*p < .05.
†Change in -2 Restricted Log Pseudo-likelihood over the previous model is significant at p < .05.
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emotional abuse and emotional neglect subscales of the CTQ predicted higher BPD
scores in all cases except in the prediction of the Self-Harm subscale. However, these
subscales did not interact significantly with estradiol variables to predict BPD symptoms.
The Sexual Abuse subscale, however, significantly interacted with estradiol variables to
predict BPD symptom expression.
There were significant interactions between Sexual Abuse and higher average
levels of estradiol predicting both the PAI-BOR Self-Harm subscale and the BSL-23,
following a similar pattern as the interactions of Neuroticism and average estradiol in the
previous section. In the model predicting the PAI-BOR Self-Harm subscale, among
women reporting higher levels of Sexual Abuse, higher average levels of estradiol were
associated with higher Self-Harm (γHIGHSEXABUSE*AVGESTRADIOL = .30, SE = .09, t(37) =
3.33, p = .001), whereas among women reporting lower levels of Sexual Abuse, higher
average levels of estradiol were associated with lower Self-Harm
(γLOWSEXABUSE*AVGESTRADIOL = -.21, SE = .04, t(37) = -5.25, p < .0001). See Figure 46 for
a graph of this interaction. In the model predicting the BSL-23, among women reporting
higher levels of Sexual Abuse, higher levels of average estradiol were associated with
higher scores (γHIGHSEXABUSE*AVGESTRADIOL = .21, SE = .08, t(37) = 2.62, p = .01), whereas
among women reporting lower levels of Sexual Abuse, higher levels of estradiol were
associated with lower scores (γLOWSEXABUSE*AVGESTRADIOL = -.40, SE = .14, t(37) = -2.85,
p = .007). See Figure 47 for a graph of this interaction.
There were also significant interactions between levels of Sexual Abuse and
weekly deviations in estradiol predicting the PAI-BOR total scale, the PAI-BOR
Affective Instability subscale, the PAI-BOR Identity Disturbance subscale, and the BSL-
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Figure 46. A graph of the interaction between self-reported levels of childhood sexual
abuse and average estradiol predicting weekly PAI-BOR Self-Harm subscale score.

172

	
  

Weekly Borderline Symptom Checklist-23

1

Low Sexual Abuse (-1 SD)

0.9
High Sexual Abuse (+1 SD)

0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0
Low Average Estradiol

High Average Estradiol

Figure 47. A graph of the interaction between self-reported levels of childhood sexual
abuse and average estradiol predicting weekly BSL-23 score.
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23, though they indicated that the impact of higher-than-usual estradiol was opposite
from high average levels estradiol. In the model predicting the PAI-BOR total scale,
among women reporting higher levels of Sexual Abuse, higher-than-usual levels of
estradiol were associated with lower BPD symptom expression
(γHIGHSEXABUSE*ESTRADIOLDEVIATION = -.17, SE = .09, t(37) = -1.95, p = .05) whereas among
women reporting lower levels of Sexual Abuse, higher-than-usual levels of estradiol were
associated with higher BPD symptom expression (γLOWSEXABUSE* ESTRADIOLDEVIATION = .13,
SE = .02, t(37) = 6.50, p < .0001). A graph of this interaction can be found in Figure 48.
In the model predicting the PAI-BOR Affective Instability subscale, among women
reporting higher levels of Sexual Abuse, higher-than-usual levels of estradiol were
associated with lower levels of Affective Instability (γHIGHSEXABUSE*ESTRADIOLDEVIATION = .28, SE = .12, t(37) = -2.21, p = .02), whereas among women reporting lower levels of
Sexual Abuse, higher-than-usual levels of estradiol were not associated with lower
Affective Instability (γLOWSEXABUSE*ESTRADIOLDEVIATION = .14, SE = .10, t(37) = 1.32, p
= .19). See Figure 49 for a graph of this interaction. In the model predicting the PAIBOR Identity Disturbance scale, among women reporting higher levels of Sexual Abuse,
higher-than-usual levels of estradiol were associated with lower Identity Disturbance
(γHIGHSEXABUSE*ESTRADIOLDEVIATION = -.26, SE = .09, t(37) = -2.82, p = .005), whereas
among women reporting lower levels of Sexual Abuse, higher-than-usual levels of
estradiol were associated with higher Identity Disturbance
(γLOWSEXABUSE*ESTRADIOLDEVIATION = .21, SE = .08, t(37) = 2.66, p = .008). See Figure 50
for a graph of this interaction. In the model predicting the BSL-23, among women
reporting higher levels of Sexual Abuse, higher-than-usual levels of estradiol were
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Figure 48. A graph of the interaction between self-reported levels of childhood sexual
abuse and deviation in estradiol predicting weekly PAI-BOR total score.
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Figure 49. A graph of the interaction between self-reported levels of childhood sexual
abuse and deviation in estradiol predicting weekly PAI-BOR Affective Instability
subscale score.
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Weekly PAI-BOR Identity Disturbance
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Figure 50. A graph of the interaction between self-reported levels of childhood sexual
abuse and deviation in estradiol predicting weekly PAI-BOR Identity Disturbance
subscale score.
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associated with lower levels of BPD symptoms (γHIGHSEXABUSE*ESTRADIOLDEVIATION = -.30,
SE = .11, t(37) = -2.84, p = .005), whereas among women reporting lower levels of
Sexual Abuse, higher-than-usual levels of estradiol were not associated with BPD
symptom expression (γLOWSEXABUSE*ESTRADIOLDEVIATION = .01, SE = .09, t(37) = .16, p
= .87). A graph of this interaction can be found in Figure 51.
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Figure 51. A graph of the interaction between self-reported levels of childhood sexual
abuse and deviation in estradiol predicting weekly BSL-23 score.
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Chapter Four: Discussion
Despite recent advancements in the understanding and treatment of individuals
with Borderline Personality Disorder, very little work has addressed the physiological
underpinnings of day-to-day and week-to-week variability in BPD symptom expression.
Given the higher rates of diagnosis and impairment in women diagnosed with BPD
(Grant et al., 2008), it has been suggested that the monthly reproductive cycle—and
particularly changes in estradiol, a hormone that peaks naturally at ovulation—may play
a role in modulating symptoms. The present study builds upon previous evidence that
ovulation-related increases in estradiol are associated with greater emotional and
behavioral symptoms of BPD, especially among women high in trait levels of BPD
symptoms. The purpose of this project was to test a new cyclical vulnerability theory of
BPD, which posits that women at risk for BPD experience exaggerated reductions in felt
social acceptance at ovulation and consequent increases in BPD symptom expression at
that time.
The cyclical vulnerability theory and its associated hypotheses were generally
unsupported by the data. In fact, results of hypothesis tests actually support the opposite
the pattern of ovulatory effects on BPD symptoms, in which individuals with high trait
levels of affective and behavioral dysregulation report slightly lower levels of BPD
symptoms when fertility and estradiol are higher, whereas women with low trait levels of
these problems report slight increases in BPD symptoms when fertility and estradiol are
higher. However, this pattern was not entirely consistent, and requires further exploration
in subsequent studies. The results of specific hypothesis tests carried out for the present
project are reviewed and discussed below, followed by discussions of potential
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alternative theoretical explanations for these effects, how these effects compare to
previously-established findings, and the ways in which the present study can be used to
improve future work in this area.
Do Ovulation or Increases in Estradiol Predict Greater BPD Symptoms?
Hypothesis 1 predicted that all women would experience increases in symptoms
of BPD at ovulation and when estradiol was relatively higher for them. Contrary to this
prediction, there were no significant effects of conception probability on BPD symptoms
at the daily level. At the weekly level, there was only one significant effect of withinperson changes in estradiol, and it was in the opposite of the predicted direction; when
women had higher-than-usual estradiol—likely at visits that were relatively closer to
ovulation—they had lower scores on the Borderline Symptom Checklist (BSL-23), a
measure of BPD symptoms based on the DSM-IV criteria for BPD. Zero-order
correlations and significance tests suggested that the BSL-23 was more significantly
related to a measure of actual diagnosis of BPD than the PAI-BOR or the MSI-BPD. In
the present study, then, it appears that more extreme, clinically-relevant symptoms were
more likely to lessen under conditions of higher-than-usual levels of estradiol.
Hypothesis 2 predicted that the effects of daily fertility and weekly fluctuations in
estradiol would be moderated by trait levels of BPD such that women with higher levels
of trait BPD would show exaggerated increases in BPD symptoms at higher levels of
conception probability and higher-than-usual estradiol. Contrary to this prediction, there
was no evidence for exaggerated symptom expression at higher fertility or higher-thanusual estradiol among women higher in trait BPD. Rather, there was some evidence for
the opposite pattern. Women with low trait levels of BPD reported higher BPD symptoms
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at higher levels of fertility and at higher-than-usual levels of estradiol, including higher
scores on the daily and weekly total scales of the PAI-BOR. Women with high trait levels
of BPD, on the other hand, reported symptom reduction at higher levels of fertility and
higher-than-usual estradiol: lower scores on the weekly PAI-BOR total scale, the
Affective Instability subscale, the Identity Disturbance subscale, and the BSL-23.
It would appear that, rather than becoming vulnerable at ovulation and during
periods of increased estradiol, women higher in trait BPD actually experience periods of
reduced symptoms and enhanced well-being. This also indicates, however, that women
high in trait BPD may experience higher symptom expression at lower levels of fertility
and estradiol—a different sort of cyclical vulnerability. Though the computation of
effect sizes in multilevel Poisson regression is not straightforward, it is possible to
discuss the practical implications of the estimates presented here in a couple of more
practical ways. First, estimates in Poisson regression may be exponentiated to determine
the percent change in the dependent variable that would be achieved with a one-unit
increase in the predictor. In the present study, the average unstandardized estimate for
the effect of deviations in estradiol on weekly BPD symptoms among women with high
levels of trait BPD symptoms was -.15, which means that a one unit (i.e., 100%) increase
above an individual’s mean level of estradiol was associated with a 13.9% reduction in
BPD symptoms among women high in trait BPD symptoms. Second, results can also be
more clearly understood by discussing them in terms of change on the response scale. For
example, an estimate of -.15 corresponds to a change in symptoms that is only about onetenth the distance between “Sometimes True” and “False, Not True at All” on the
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response scale for the PAI-BOR. So, although there does appear to be a cyclical effect on
symptoms, the effects found here are relatively small.
Although clearly post-hoc, an evolutionary psychological interpretation of the
present findings should be considered. Evolutionary psychologists have established that
ovulation can have a profound effect on numerous psychological and behavioral
processes of relevance to BPD symptoms. The effects found here appear to lend further
support to the notion that affective and behavioral symptoms do change, however
modestly, at the higher levels of fertility and higher-than-usual levels of estradiol that
generally accompany ovulation. As mentioned earlier, higher fertility has been associated
with increased implicit motivation to seek out social contact, and may be associated with
an increased tendency toward agreeableness at that time so as to improve the chances of
finding a mate (Schultheiss, Dargel, & Rhode, 2003). However, effects here seem to
point toward a normalizing effect of ovulation on emotions and behavior, with women
with high trait BPD and women with low trait BPD reporting slightly more “normal”
(more average) levels of symptoms at ovulation and higher-than-usual estradiol. It is
possible that these opposite effects indicate that higher fertility represents a cue for
women to appear more emotionally and behaviorally stable (in the case of high-BPD
women) or to appear more emotionally and behaviorally provocative and risk-taking (in
the case of low-BPD women). Women who are better able to up- or down-regulate
abnormally high or low levels of BPD-related traits at ovulation may appear healthier,
more balanced, and hence more attractive to potential mates.
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Do Ovulation or Increases in Estradiol Predict Lower Felt Acceptance?
Hypothesis 3a predicted that changes in felt acceptance would mediate the effect
of fertility and higher-than-usual estradiol on BPD symptoms. Contrary to prediction,
rather than feeling exaggerated decreases in felt acceptance at higher levels of fertility
and higher-than-usual estradiol, women with higher levels of trait BPD showed increases
in felt acceptance under these conditions. On the other hand, women with lower trait BPD
symptoms reported feeling less social acceptance at ovulation, a finding that is consistent
with previous work in this area demonstrating that normal women show decreases in selfesteem (Hill & Durante, 2009)—a construct intimately connected to feelings of social
acceptance (Leary et al., 1998)—at ovulation. Overall, these findings suggest that, unlike
normal women, women high in trait BPD may actually experience a boost in feelings of
social acceptance at higher-than-usual levels of estradiol. Further, there was evidence that
these differing effects of estradiol deviations on felt acceptance mediated the interactive
effects of trait BPD and estradiol deviations on BPD features. That is, there is some
evidence that women with higher levels of trait BPD evidenced fewer BPD symptoms at
higher levels of estradiol because that higher estradiol was associated with feeling more
socially accepted, which, in turn, was associated with lower BPD symptoms. It should
also be noted that the effects of daily and weekly deviations in felt acceptance were, in
every case, significant above and beyond mean levels of felt acceptance, highlighting the
importance of within-person changes in feelings of belongingness and social wellbeing—
especially for individuals with BPD.
It is possible that this effect can also be explained from an evolutionary
perspective. These divergent effects of changes in estradiol on felt acceptance may be a 	
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further example of a “normalizing” ovulatory effect that confers a reproductive benefit on
both low-BPD and high-BPD women. In theory, it should be most reproductively
beneficial to experience whatever social emotions at ovulation encourage socializing and
mating. Individuals with BPD experience the world as an unsafe place in which people,
including potential mates, cannot be trusted and in which social rejection is inevitable
(Baer, Peters, Eisenlohr-Moul, Geiger, & Sauer, 2012). In order to increase social
motivation at ovulation among these women, adjustments to the usual ovulatory pattern
(of decreased felt acceptance and increased social motivation) may be necessary.
Although normal women may, in some sense, require feelings of lower social acceptance
at ovulation in order to be motivated to seek out greater social contact and potential mates,
women with high trait BPD may require feelings of higher social acceptance at ovulation
in order to feel safe enough to engage in the same social, mate-seeking behaviors.
Alternative, Proximal Mediators: Are Changes in Self-Control or Impulsivity
Responsible for Cycle Effects?
Hypotheses 3b and 3c predicted that, among women higher in trait BPD, higherthan-usual levels of estradiol would be associated with decreased self-control and
increased impulsivity, and that these changes would mediate the impact of changes in
estradiol on BPD symptom expression. This hypothesis was also unsupported, and once
again, significant effects were observed in the opposite of the predicted direction. Among
women higher in trait BPD, higher-than-usual estradiol was associated with better selfcontrol, lower Positive and Negative Urgency, lower Lack of Perseverance, and lower
Lack of Premeditation. Among women low in trait BPD symptoms, none of these
associations were significant. Insofar as poor self-control and elevated levels of these
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types of impulsivity are consistent with BPD (de Ridder, Lensvelt-Mulders, Finkenauer,
Stok, & Baumeister, 2012; Tragesser & Robinson, 2009), these findings are entirely
consistent with the results presented above.
Further, both average levels of and relative changes in self-control and
impulsivity significantly predicted BPD symptoms in expected directions in the full
sample. This finding provides further validation of the presence and importance of selfcontrol and impulsivity effects on BPD symptom expression, especially at the withinperson level. Although average levels of self-control and impulsivity were associated
with BPD symptoms, day-to-day fluctuations in these processes often had an equal or
greater impact on daily symptoms. Further, meditational hypotheses confirmed that each
of these variables at least partially mediated the interactive effect of Trait BPD and
deviations in estradiol on BPD symptom expression.
Partially consistent with the existing evidence suggesting that Negative Urgency,
Positive Urgency, and Lack of Premeditation are associated with BPD features (Tragesser
& Robinson, 2009), the strongest and most consistent indirect effects were found for
Negative Urgency, Lack of Premeditation, and Lack of Perseverance. Therefore, in the
present study, ovulatory reductions in the tendency to respond to negative emotion with
impulsive action, the tendency to act without thinking though the consequences of one’s
actions, and the tendency to have difficulty persisting in the face of difficulty were
primarily responsible for estradiol-related changes in BPD symptom expression. It is
possible that shifts in estradiol underlie changes in aspects of impulsivity or the capacity
to regulate them, and such changes may account for the impact of the cycle on BPD
symptoms.
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Investigating Alternative Moderators of Cyclical and Hormonal Effects: Roles of FFM
Personality and Childhood Maltreatment
Because BPD is a heterogeneous disorder, it may be questionable to rely on trait
levels of BPD as a moderator of ovulatory or hormonal effects. It would be more
preferable to identify moderators that capture central underlying traits or risk factors for
BPD. Therefore, using two theoretical models of BPD (Five Factor Models of BPD and
Linehan’s biosocial theory) as my guide, I tested additional models in which five factor
model domain scores and types of childhood maltreatment were substituted for Trait BPD
in moderation models. These models provided some new insights into the reasons for
differential effects of changes in estradiol on BPD symptom expression among women
high and low in trait BPD symptoms.
Neuroticism, Estradiol, and BPD Symptoms. From the FFM perspective on
personality disorders, the central characteristic of BPD is a high level of all aspects of
Neuroticism (Widiger & Mullins-Sweatt, 2009). Therefore, I expected that Neuroticism
would function as a moderator in similar ways to trait BPD. However, there were no
significant interactions between Neuroticism and deviations in estradiol, suggesting that
the moderating effect of trait BPD on deviations in estradiol is not due to extreme levels
of Neuroticism, as might be expected. It is possible that some other, more specific
characteristic of all or some of those with higher trait BPD—such as reactivity to
sensations (Rosenthal, Ahn, & Geiger, 2011), rejection sensitivity (Ayduk et al., 2008),
or a chronically elevated physiological stress response (e.g., Jogems-Kosterman, de
Knijff, Kusters, & van Hoof, 2007)—is responsible.
Rather than modulating the effect of estradiol fluctuations, Neuroticism
significantly altered the association between trait (or average) levels of estradiol and
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BPD symptoms. Among women low in Neuroticism, higher average levels of estradiol
buffered against BPD symptoms, predicting lower levels of affective instability, identity
disturbance, and more extreme symptoms of BPD as measured on the BSL-23. Among
women high in Neuroticism, however, higher average levels of estradiol were associated
with higher levels of more extreme symptoms on the BSL-23. Therefore, it appears that
Neuroticism may serve as a risk factor for negative reactions to chronically elevated
estradiol, and low Neuroticism may allow women to benefit—at least in psychological
terms—from chronically elevated estradiol. Notably, these between-person effects were
generally about twice as large as the within-person effects found in the interactions
between trait BPD and deviations in estradiol discussed earlier.
Openness to Experience, Estradiol, and BPD Symptoms. The FFM personality
perspective also provides evidence that certain aspects of Openness to Experience—
specifically, a tendency to be open to emotions and to actions—are high among
individuals diagnosed with BPD. Like Neuroticism, Openness to Experience did not
interact with deviations in estradiol to predict BPD symptoms, but did moderate the
impact of trait levels of estradiol on BPD symptoms. Among women with higher
Openness to Experience, higher trait levels of estradiol were associated with lower scores
on the PAI-BOR total, the Affective Instability subscale, the Identity Disturbance
subscale, the BSL-23, and the MSI-BPD. Among women low in Openness to Experience,
there were smaller but significant effects of higher trait levels of estradiol predicting
higher scores on each of these scales. When one inspects the graphs in Figures 20-24, it
appears that high Openness to Experience actually serves as a risk factor for BPD
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symptoms at low trait levels of estradiol—note that this in in contrast to Neuroticism,
which served as a risk factor at high levels of average estradiol.
Therefore, chronically low estradiol was associated with more symptoms among
women with higher levels of Openness to Experience, though further work will be needed
to elucidate the mechanisms of this effect. In one small cross-sectional study that tested
all participants during menses, lower levels of estradiol were associated with higher selfreported risk taking (Balada, Torrubia, & Arqué, 1993). If this association is replicable,
it is possible that higher Openness to Experience—and especially openness to actions—
serves to disinhibit this tendency toward risk taking among women low in average
estradiol. In any case, higher Openness to Experience has been established apart from
Neuroticism as a fundamental FFM personality abnormality in BPD, and may therefore
confer risk for BPD through much different pathways than Neuroticism.
Other FFM Personality Variables, Estradiol, and BPD Symptoms. Other aspects
of FFM personality thought to be abnormal in BPD—including Agreeableness and
Conscientiousness—did not interact with estradiol variables to predict symptoms in the
present study. However, consistent with the FFM conceptualization, both Agreeableness
and Conscientiousness showed negative zero-order correlations with average levels of
BPD symptoms.
Sexual Abuse, Estradiol, and BPD Symptoms. Only one subscale of the
Childhood Trauma Questionnaire, Sexual Abuse, moderated any effects of estradiol on
BPD symptoms. The pattern in which Sexual Abuse moderated average levels of
estradiol was similar to Neuroticism. Among women who reported greater experiences of
having been sexually violated as a child, higher average levels of estradiol were
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associated with higher scores on the PAI-BOR Self-Harm subscale as well as higher
scores on the BSL-23. Each of these measures represents relatively extreme BPD
symptoms, indicating that Sexual Abuse may prime women in some way to experience
greater negative behavioral (i.e., externalizing) effects of chronically-elevated estradiol. It
has been suggested (e.g., Figueroa & Silk, 1997) and demonstrated (Jogems-Kosterman,
de Knijff, Kusters, & van Hoof, 2007) that sexual abuse and other childhood
maltreatment is responsible for a chronically-activated physiological stress response (e.g.,
chronically elevated cortisol) in BPD. Such physiological changes secondary to
childhood maltreatment may play a role in modulating the effects of average estradiol on
BPD symptoms, and future studies should include measures of a chronic physiological
stress activation. Crucially, these results are consistent with Linehan’s discussion of the
biosocial model of BPD; Linehan (1993) asserts that childhood Sexual Abuse, insofar as
it blatantly ignores the wishes of the child, can be conceptualized as the most extreme
form of the childhood invalidating environment theorized to play a central role in the
development of BPD.
Several smaller interactions were found between greater reports of childhood
sexual abuse and deviations in estradiol, though these within-person effects followed the
opposite pattern. Among women reporting higher levels of childhood sexual abuse,
higher-than-usual estradiol was associated with reductions in Affective Instability,
Identity Disturbance, and the BSL-23, whereas women reporting low or no childhood
sexual abuse had increases in symptoms at higher levels of estradiol. These effects are
consistent with the interactive effects of trait BPD and deviations in estradiol, and may at
least partially explain the moderating impact of trait BPD.
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Having experienced sexual abuse in childhood may cause women to be more
vigilant and use greater caution at times when high fertility primes sexuality. Such
greater caution may, in some cases, translate into less BPD-related interpersonal and
behavioral symptoms. However, these effects were smaller than the effects of average
estradiol, indicating that the interaction of childhood sexual abuse and average levels of
estradiol may have greater consequence for BPD symptom expression. These findings
once again highlight that between-person effects (effects of average estradiol) and withinperson effects (effects of estradiol deviations) may be quite different.
Contextualizing the Present Findings in the Extant Literature on the Cycle and BPD
In previous studies, ovulation-related variability and changes in estradiol were
associated with both higher levels of and increases in BPD symptom expression (DeSoto
et al., 2003). In the present study, I found evidence for such effects only inconsistently
among those low in trait levels of BPD. There may be several reasons for these
inconsistent findings.
First, unlike the DeSoto et al. (2003) study, the present was not designed to track
women across specific points in the ovulatory cycle. Rather, it was designed to
investigate the unique impact of naturally-occurring changes in estradiol on the
expression of BPD symptoms across one ovulatory cycle. Only one of the DeSoto et al.
(2003) studies examined the association of naturally-occurring variability in endogenous
estradiol with BPD symptom expression, but it focused on between-person associations
of such overall variability with trait levels of symptoms rather than within-person effects
of week-to-week changes in estradiol. However, post-hoc correlations in the present
study between an individual’s overall variability in estradiol and measures of BPD
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revealed no significant associations (all r’s less than .05, all p’s > .45). Therefore, not
only were there no within-person effects consistent with those reported by DeSoto et al.
(2003); the data from the present study also failed to replicate their primary reported
effect.
Second, the present study focused on endogenous (naturally-occurring) rather
than exogenous (synthetic) estrogen, whereas two of the three studies reported in DeSoto
et al. (2003) reported a negative impact of hormonal contraceptives containing synthetic
estrogen. This may be due to the fact that hormonal birth control and other exogenous
forms of estrogen do differ in some ways from endogenous estradiol in their biochemical
activity. Chronically elevated levels of estrogen due to taking hormonal contraceptives
may have negative effects in some women similar to those found above, at least among
women sensitive to higher levels of estrogen (see Kiesner, 2011).
There are a variety of physiological pathways through which chronically-elevated
synthetic estrogen could exert negative effects in select women; however, one
particularly plausible pathway is via elevated levels of C-reactive protein (CRP), a
marker of inflammation, among women taking sustained doses of synthetic estrogens in
the form of hormonal birth control (van Rooijen et al., 2006) and hormone replacement
therapy (Eilertsen, Sandvik, Steinsvik, & Sandset, 2008). Several studies have provided
evidence of a causal link between elevated levels of C-Reactive Protein to later
depression and other symptoms of affective dysregulation (Gimeno et al., 2009;
Matthews et al., 2010; Howren, Lamkin, & Suls, 2009). Given the centrality of poor
affect regulation in BPD, it is possible that even mild increases in levels of inflammation
mediate the negative affective consequences of chronically elevated synthetic estrogen
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found in some women. While normal women may not experience negative effects of
artificially elevated synthetic hormone, women with higher trait levels of BPD may
experience negative effects such as those found by DeSoto et al. (2003) due to a
chronically-activated stress response system that is unable to effectively downregulate
inflammation via vagal inhibition (Thayer, 2009) or some other physiological pathway
that is compromised during chronic stress.
Using Biosocial and Evolutionary Theories to Understand the Effects of the Cycle on
BPD Symptoms
Though the original “estradiol peak” cyclical vulnerability model was not
supported, an inverse “estradiol trough” cyclical vulnerability model was supported.
Women higher in trait BPD reported greater symptoms when estradiol was lower-thanusual for them; these effects were mediated by a reduction in felt acceptance, and, more
proximally, by changes in self-control and impulsivity. In an attempt to better understand
the role of trait BPD in this model, alternative moderators were tested. Only Sexual
Abuse mirrored the moderating role of trait BPD. Sexual Abuse, a social risk factor,
interacted with cyclical changes to predict BPD symptom expression: among those
reporting high levels of Sexual Abuse, lower-than-usual levels of estradiol (such as those
found at menses or the premenstrual week) were associated with higher BPD symptom
expression. This finding provides support for the idea that Linehan’s (1993) biosocial
model may operate not only at a trait level, but at a state level, as well.
There are several potential physiological mechanisms through which state
physiological predisposition to emotion dysregulation may occur at lower-than-usual
levels of estradiol. First, recent evidence indicates that natural fluctuations (higher-than-
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usual levels) of estradiol are associated with improvements in working memory (Segal,
2012), which may play a role in the ability to modulate negative emotion, feelings of
rejection, or related urges (Schmeichel, Volokhov, & Demaree, 2008), premeditate the
consequences of behavior (Bechara & Martin, 2004), or persist on goal-relevant tasks
(McVay & Kane, 2009). This interpretation may be particularly relevant to the mediation
of cyclical vulnerability effects by self-control and impulsivity. Second, despite evidence
that long-term administration of exogenous estrogen elevates CRP (a marker of
inflammation; see above), there is evidence that fluctuations in endogenous estrogen
follow the opposite pattern, with higher-than-usual levels of estradiol predicting
reductions in CRP (Blum et al., 2005). As noted previously, such inflammatory markers
prospectively predict depressive symptoms, which may explain greater symptoms at
lower-than-usual estradiol (Gimeno et al., 2009; Matthews et al., 2010; Howren, Lamkin,
& Suls, 2009). However, it has yet to be established whether these quicker day-to-day
and week-to-week changes in inflammation map onto changes in psychological
symptoms.
Finally, within-person effects of estradiol may actually be due to the parallel
variation of estradiol and oxytocin across the cycle. Oxytocin, a hormone involved in
social cognition, affiliative behavior, and attachment, is estradiol-dependent throughout
the cycle, and peaks naturally the day after ovulation (i.e., the day after luteinizing
hormone surge; Shukovski, Healy, & Findlay, 1989). Furthermore, there is some
evidence that trait oxytocin levels are abnormally low among women with BPD and
women with a history of childhood maltreatment or trauma (Bertsch, Schmidinger,
Neumann, & Herpertz, 2013), and that administration of oxytocin attenuates emotional
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reactivity in BPD (Simeon et al., 2011; although cf. Bartz et al., 2011). It is possible, then,
that the cyclical effect of estradiol on BPD symptoms may exist only due to oxytocin’s
potentially ameliorative effects on BPD symptoms.
From an evolutionary perspective, it would be reasonable to expect that such
physiological changes that confer cyclical vulnerability to BPD symptoms among at-risk
women would occur at points in the cycle when signaling reproductive fitness to potential
mates and selecting a reproductively fit mate was less important. During the periods of
low estradiol associated with the premenstrual and menstrual weeks, fertility is also low,
so it may be less important for women at risk for BPD symptoms to (1) present
themselves as normal and psychologically healthy and (2) have optimized cognitive
capacity so as to inhibit impulses to mate with less-than-ideal mates and to seek out ideal
mates. During periods of high fertility, however, increased estradiol may modulate the
ability of at-risk women to accurately perceive social acceptance, to respond in helpful
ways to emotion, think through behavior, and to persist in goal-related action. In addition
to improving the experience of at-risk women, these positive ovulatory changes may
serve to signal reproductive fitness to potential mates and to increase a woman’s ability
to carefully select a mate that is higher in reproductive fitness.
Using FFM and Biosocial Theories of BPD to Understand the Effects of Average
Levels of Estradiol on BPD Symptoms
Unlike the effects of estradiol fluctuations, the effects of a woman’s average
levels of estradiol were moderated by all factors associated with risk for higher BPD
symptoms, and the effects followed a pattern that was different from the within-person
effects. Between women, higher average levels of estradiol was associated with greater
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risk among those who reported risk factors for BPD such as Neuroticism or childhood
sexual abuse, and low average estradiol was associated with greater risk among those
high in Openness to Experience.
In the modified biosocial model presented and supported above, trait risk
variables such as trait BPD or Sexual Abuse interact with state physiological variables to
predict fluctuations in symptoms. However, in Linehan’s (1993) classic biosocial model
of BPD, childhood maltreatment such as Sexual Abuse interacts with trait physiological
variables (those conferring risk for emotional dysregulation) to predict trait BPD
symptoms. The findings that average levels of estradiol interacts with such risk factors as
trait BPD, Sexual Abuse, and even FFM Neuroticism and Openness are probably best
understood using Linehan’s classic, trait-level biosocial framework in which
psychosocial and personality factors interact with physiological dysregulation to produce
trait BPD symptoms. In the case of three out of four of these risk-related moderators,
higher scores on a measure of risk (trait BPD, Sexual Abuse, or Neuroticism) interacted
synergistically with higher average estradiol to predict higher trait BPD symptoms.
In order to provide further illustration of the association between average levels of
estradiol and BPD symptoms at any given assessment, two additional figures are
provided. Figure 52 is a descriptive scatterplot of the (nonsignificant) association
between average levels of estradiol and weekly BPD scores in the full sample. Figure 53
is a descriptive scatterplot of the association between average levels of estradiol and
weekly BPD scores graphed according to the individual’s self-reported trait BPD
symptoms (as measured by the original trait version of the PAI-BOR) at recruitment.
Upon inspection of the these figures, it seems clear that women in this sample with high
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levels of trait BPD symptoms show a stronger, positive association between average
levels of estradiol and BPD symptoms on any given week than women with low levels of
trait BPD symptoms. Indeed, among women with moderate-to-low trait BPD symptoms,
it would appear that the association between average levels of estradiol and weekly BPD
symptoms is either nonsignificant or negative. While descriptive only, this apparent
pattern should motivate additional research on the role of average levels of estradiol in
BPD.
In what way might high levels of average estradiol represent a trait physiological
risk factor for emotion dysregulation consistent with the biosocial model? There are
several possibilities. First, in the present study, higher trait levels of estradiol were
strongly associated with lower FFM Extraversion—particularly low warmth and low
positive emotions (r’s ranging from -.30 to -.36). Although low Extraversion is not
hypothesized to be central to BPD in the FFM dimensional model of BPD, low positive
emotion and low warmth are nevertheless consistent with the dysregulated emotion and
low Agreeableness found in BPD. Assuming these associations are replicable, high
average levels of estradiol may serve as a physiological risk factor for low warmth and
positive emotion that interacts with other BPD risk factors to predict trait BPD symptoms.
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Figure 52. Descriptive scatterplot of the (nonsignificant) association between an
individual’s average levels of estradiol across four weeks and their weekly PAI-BOR
scores in the full sample.
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Figure 53. Descriptive scatterplot of the association between an individual’s average
levels of estradiol across four weeks and weekly PAI-BOR scores graphed by quartiles of
average PAI-BOR total score.
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Other studies have found higher trait levels of estradiol among women high in
alexithymia (a condition related to emotional awareness and expression) vs. controls
(Ushiroyama, Ueki, Orino, & Ikeda, 1994), and higher trait levels of estradiol were
associated with greater self-reported loneliness among a group of adolescent girls
(Fujisawa, Nishitani, Obara, & Shinohara, 2012). These findings provide further
evidence that average estradiol may be associated with other psychosocial risk factors for
BPD-related symptoms (i.e., low Extraversion, high loneliness or alexithymia) that, in
turn, interact with trait BPD, Neuroticism, or Sexual Abuse to predict higher trait
symptoms. Notably, these effects are consistent with the evidence that chronic
administration of exogenous estrogen in the context of hormonal contraceptives confer
risk for BPD among women high in trait BPD (De Soto et al., 2003). The physiological
mechanisms of these effects have not been studied; however, they may be similar to the
physiological mechanisms through which chronic exogenous estrogen administration
increases BPD symptom risk.
In the case of high Openness to Experience (which, from the FFM perspective,
serves as a risk factor for BPD), it was low levels of average estradiol that were
associated with higher BPD symptoms. Due to the divergent effects from other riskrelated moderators, one can only assume that high levels of Openness to Experience exert
moderating effects on BPD symptoms through different physiological pathways than trait
BPD, Neuroticism, or Sexual Abuse. As mentioned previously, there is one study
suggesting that risk taking is higher among women with low trait levels of estradiol
(Balada, Torrubia, & Arqué, 1993). It is possible that high Openness to Experience—and
especially Openness to Actions, which is known to be high in BPD—serve to unmask

200

	
  
higher levels of risk-taking behavior among women low in estradiol. However, this is but
one of many potential explanations for this finding, and a clear understanding of these
results awaits further research.
Limitations and General Recommendations for Future Work in this Area
The project presented here is not without flaws, and the insights gained here may
be used to refine the methodology of future projects on this topic. Perhaps most
importantly, it is likely that the non-clinical sample used here created a floor effect in
which the range of daily and weekly BPD symptoms was restricted (i.e., to the lower
range). Although the sample was selected to create a flat distribution of BPD symptoms,
the distributions for trait BPD were still relatively positively skewed, and only four of the
individuals in the study met SCID-II criteria for BPD. Future studies will include a larger
number of women overall, with a greater number of women meeting diagnostic criteria
for BPD.
Another limitation concerns the definition and measurement of the ovulatory
cycle. In the present study, the focus was relatively limited to ovulatory and estradiol
effects. In the future, it would be appropriate to examine other hormones (e.g.,
progesterone) that can provide more information about hormonal changes in symptoms
occurring at other points in the cycle (e.g., the luteal phase). Although the reliability of
luteal-phase effects on mood-related issues (i.e., Premenstrual Syndrome or PMS) has
recently been seriously questioned (Romans et al., 2012), it is possible that such effects
are more robust among individuals with BPD, and that non-ovulatory cycle effects are
important for understanding cycle-related variability in BPD symptom expression. A
related point, mentioned previously, is that higher-than-usual levels of estradiol in the
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current study may covary with some third hormonal variable (e.g., luteinizing hormone or
oxytocin) that exerts more powerful ovulatory effects on BPD symptoms. In future
studies, alternative ways of defining and measuring the cycle should be explored.
It is also possible that low statistical power played a role in the failure to identify
significant small interactive effects at the weekly level. Therefore, the failure of some
small effects presented in the current study to reach significance should not necessarily
be interpreted as evidence for nonsignificance; larger sample sizes may be necessary to
detect small interactive effects of trait variables with deviations in estradiol on BPD
symptoms. On the other hand, several small interactive effects were detected, suggesting
that these effects are reasonably robust and that low statistical power may not be
responsible for the failure of some small interactive effects to reach significance.
Finally, the present study could have benefitted from the inclusion of more
concrete measures of basic underlying traits and processes. The study failed to include
measures of some core trait constructs that may have served as clearer, more powerful
moderators of the effects of estradiol. Chronic physiological stress activation such as that
found in post-traumatic stress, sensitivity to rejection or sensations, or some other risk
variable that is associated with trait BPD may be truly responsible for the interactive
effects seen here. Future studies should seek to pinpoint and measure such key constructs.
The study also relied on daily and weekly self-report measures of BPD symptoms using
heterogeneous symptom inventories; in the future, studies may be strengthened by the
inclusion of more concrete measures of behavior, such as substance use, aggression, or
observer reports of interpersonal functioning.
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Clinical Implications and Directions for Future Clinical Research
The small effect sizes found here may indicate that cyclical vulnerability does not
exert clinically meaningful effects on BPD. However, future studies should explore the
possibility that the synergistic effects of the cycle with other daily and weekly variables
may be more significant in the lives of women who suffer from diagnosable levels of
BPD. Small cycle-related changes symptoms may become more significant in the face of
the more serious stressors that often plague the lives of women with BPD. In the context
of ongoing BPD-related stressors such as unemployment, physical disability, substance
use or abuse, or even simply ongoing interpersonal stress, small cyclical changes in
emotional or behavioral vulnerability (i.e., at low levels of estradiol and fertility) may
have larger, more serious implications. Further, trait levels of estradiol may also interact
with either acute or chronic stressors in the lives of women with BPD to predict
symptoms. As mentioned previously, the present study used a sample of generally
healthy undergraduate women, and though they were sampled to achieve higher sample
levels of BPD than would be found in the general population, only four of the participants
met SCID-II criteria for BPD. Therefore, it is crucial that future studies examine whether
the effects found here generalize to clinical populations.
The most appropriate next step in this line of research would be another, larger
prospective study aimed at replicating and extending the present findings to women with
a diagnosis of BPD. Ideally, such a study would recruit groups of women clinically
diagnosed with BPD, clinically diagnosed with an Axis I disorder such as Major
Depressive Disorder, and women with no diagnosis. Inclusion of the Axis I group would
allow for a determination of whether increases in fertility and estradiol benefit women
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with risk for psychopathology in general or only women with a pattern of symptoms
consistent with BPD. This study should also include progesterone, oxytocin, and other
ways of measuring the cycle, and should aim to determine whether it is truly low fertility
and estradiol that are the key cycle variables responsible for the effects observed here. A
study that included more information about the individual’s trait and weekly hormonal
levels as well as a sample that provides a less restricted range of symptoms may prove
elucidating.
If the effects observed here were found to be clinically significant in a larger
study, the eventual goal of this program of research would be to conduct a randomized
controlled trial of an adjunctive intervention (i.e., an addition to a broader empiricallysupported treatment such as Dialectical Behavior Therapy) for women with BPD. Such
an intervention would be carried out in the context of individual therapy. Daily symptom
tracking sheets, which are already a standard part of Dialectical Behavior Therapy, would
be modified to include information about cycle day and menses. After the individual had
tracked emotional and behavioral symptoms across two cycles, the therapist would
aggregate the data and determine whether a cycle or phase-related pattern had emerged. If
so, the therapist would explain the results of this assessment to the client, and would
encourage the client to focus the use of skills such as those learned in DBT on the
problematic times of the month. Several different types of skills may be relevant to
compensating for symptom vulnerability at certain times of the month, including the
ability to exercise nonjudgmental present-centered awareness of physical symptoms or
emotional lability (i.e., DBT mindfulness skills), the ability to label, understand, and
respond effectively to emotions as they arise (i.e., DBT emotion regulation skills), the
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ability to tolerate distress without acting on impulses (i.e., DBT distress tolerance skills),
and the ability to interact with others in useful ways even in the presence of strong
emotion (i.e., DBT interpersonal effectiveness skills). Such a study would seek to
determine whether focusing the use of skills on times of the month that are generally
problematic for the client might boost the effectiveness of the intervention.
Conclusions
The present study provides some interesting preliminary evidence about the role
of fertility and estradiol in predicting BPD symptom expression. A great deal of
additional work is needed to clarify the role of the cycle and related hormones in BPD
symptom expression, to tease apart between-person and within-person effects of
hormones, to clarify the key BPD-related traits responsible for moderated cycle effects,
and to better understand the physiological and psychological mechanisms through which
the cycle exerts its influence. If clear mechanisms of naturalistic change across the cycle
can be established, medical, psychiatric, and psychotherapeutic attempts to improve
functioning in BPD can become more timely, focused, and effective, reducing the
considerable burden of this debilitating disorder.
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